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Abstract 
The recent success of companion diagnostics along with the increasing regulatory pressure 
for better identification of the target population has created an unprecedented incentive for 
the drug discovery companies to invest into novel strategies for stratified biomarker 
discovery. Catching with this trend, trials with stratified biomarker in drug development have 
quadrupled in the last decade but represent a small part of all Interventional trials reflecting 
multiple co-developmental challenges of therapeutic compounds and companion diagnostics. 
To overcome the challenge, varied knowledge management and system biology approaches 
are adopted in the clinics to analyze/interpret an ever increasing collection of OMICS data. 
By semi-automatic screening of more than 150,000 trials, we filtered trials with stratified 
biomarker to analyse their therapeutic focus, major drivers and elucidated the impact of 
stratified biomarker programs on trial duration and completion. The analysis clearly shows 
that cancer is the major focus for trials with stratified biomarker. But targeted therapies in 
cancer require more accurate stratification of patient population. This can be augmented by a 
fresh approach of selecting a new class of biomolecules i.e. miRNA as candidate 
stratification biomarker. miRNA plays an important role in tumorgenesis in regulating 
expression of oncogenes and tumor suppressors; thus affecting cell proliferation, 
differentiation, apoptosis, invasion, angiogenesis. miRNAs are potential biomarkers in 
different cancer. However, the relationship between response of cancer patients towards 
targeted therapy and resulting modifications of the miRNA transcriptome in pathway 
regulation is poorly understood. With ever-increasing pathways and miRNA-mRNA 
interaction databases, freely available mRNA and miRNA expression data in multiple cancer 
therapy have created an unprecedented opportunity to decipher the role of miRNAs in early 
prediction of therapeutic efficacy in diseases. We present a novel SMARTmiR algorithm to 
predict the role of miRNA as therapeutic biomarker for an anti-EGFR monoclonal antibody 
i.e. cetuximab treatment in colorectal cancer. The application of an optimised and fully 
automated version of the algorithm has the potential to be used as clinical decision support 
tool. Moreover this research will also provide a comprehensive and valuable knowledge map 
demonstrating functional bimolecular interactions in colorectal cancer to scientific 
community. This research also detected seven miRNA i.e. hsa-miR-145, has-miR-27a, has-
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miR-155, hsa-miR-182, hsa-miR-15a, hsa-miR-96 and hsa-miR-106a as top stratified 
biomarker candidate for cetuximab therapy in CRC which were not reported previously.  
Finally a prospective plan on future scenario of biomarker research in cancer drug 
development has been drawn focusing to reduce the risk of most expensive phase III drug 
failures.  
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Introduction 
1. Cancer 
Cancer is not a single disease but a combination of many diseases. Cumulatively, we call 
them cancer as they share a fundamental commonality: abnormal, uncontrolled growth of 
cells spreading throughout the body. Different forms of cancer are highly heterogeneous in 
terms of histology and clinical outcome as well as at the molecular level (Majewski & 
Bernards 2011).  
1.1. Modern theories of cancer 
During the last century tremendous amount of research was undertaken in the field of cancer. 
These researches demonstrated that cancer is the outcome of several genetic alterations 
occurring and accumulating inside the cell. These alterations disrupt the balance between cell 
proliferation and programmed cell death. Multiple factors are associated with the oncogenic 
processes i.e. carcinogenic exposure, infectious agents, genomic alterations and pathway 
modification impacting normal cellular processes.  
1.1.1. Genomics 
In 1962, the discovery of DNA double helix by Watson and Crick spurred a series of 
discoveries on gene function and the malfunction leading to mutations. This new 
understanding showed the disease cause dynamic changes in the genome (Hanahan & Robert 
A Weinberg 2011). Two types of mutations play a crucial role in initiating cancer; one that 
induces oncogenes from proto-oncogene with dominant gain of function while the other in 
tumor suppressor genes resulting in recessive loss of function.  
1.1.1.1. Proto-oncogene 
 Proto-oncogene is a normal cellular gene that encodes a protein belonging to functional 
categories of growth factor, growth factor receptor, intracellular transducers, intracellular 
receptors and transcription factors. It can be mutated into a cancer promoting oncogene, 
either by changing the protein coding segment or by altering its expression (Harvey Lodish et 
al, 2000). Transformation of proto-oncogene to oncogene is summarized in Figure 1. 
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Figure 1: Transformation of proto-oncogene to oncogene and cellular fate (Harvey 
Lodish et al, 2000) 
Normal cell can lead to be cancerous cell due to the activation of oncogenes in the presence of a carcinogen. 
There are three genomic events that can trigger such a change  
 Point mutation in proto-oncogene. 
 Localized amplification of a chromosomal part that incorporates a proto-oncogene 
resulting in over expression. 
 Chromosomal translocation that drives the integration of another promoter with 
proto-oncogene resulting in over expression.      
1.1.1.2. Tumor suppressor genes 
Tumor suppressor genes, also called anti-oncogene, generally encode a protein which inhibits 
cell proliferation.  The categories of tumor suppressor genes also include cell cycle control 
proteins, DNA repair proteins and anti-apoptotic proteins. Losses of function mutations in 
these genes inhibit the cell to pause the uncontrolled growth. As only one copy of tumor 
suppressor genes have got the ability to control cell proliferation, both alleles of tumor 
suppressor genes must be lost or inactivated to promote tumor (Harvey Lodish, Arnold Berk, 
S Lawrence Zipursky, Paul Matsudaira, David Baltimore 2000). 
1.1.2. Pathway centric understanding of cancer 
Successive research in the last two decades discovered that the formation of cancer in human 
is a multistep process involving multiple proteins for sustainable proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis and activating invasion or metastasis (Figure 2). These hallmarks of cancer 
were proposed by Hanahan and Weinberg in 2000. Later it was again updated in 2011 by the 
same group. In the next section, an overview of the six hallmark of cancer is presented and 
discussed in the lights of recent discoveries.  
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Figure 2: Hallmark of cancer (Hanahan & Robert A. Weinberg 2011) 
The diagram shows six major mechanisms for the induction of cancer from normal cells, its uncontrolled growth and spread 
to other organs. 
1.1.2.1. Sustaining proliferative signalling  
The regulatory process of producing and releasing growth promoting signals are highly 
regulated in normal tissues. Due to this, normal tissue can maintain normal architecture and 
function by homeostasis of cells. Cancer cells deregulate these signals by the following 
means;  
a. Over expression of growth factors, that binds cell surface receptors with intracellular 
tyrosine kinase domains.     
b. By increasing surface receptors displayed at the cancer cell surface, the cell becomes 
hyper-responsive to the limited amount of available ligands.     
c. Point mutation in the receptors results in structural alteration facilitating ligand 
independent firing. 
d. Somatic mutations activating alternative downstream pathways lead to cell 
proliferation in normal cells triggered by activated growth factor receptors. The 
mutation in the catalytic domain of PIP3 results in hyperactive PIP3 kinase signalling 
including activation of Akt/PKB signal transducer (the hallmark of cancers, next 
generation).   
e. Somatic mutations to enhance cellular proliferation by disrupting a negative feedback 
loop e.g. oncogenic mutations in Ras protein inhibit its GTPase activity inhibiting 
negative feedback loop for cellular proliferation (Hanahan & Robert A Weinberg 
2011; Evan & Vousden 2001)    
19 
 
1.1.2.2. Evading growth suppressors 
In addition to maintaining growth stimulation signal, cancer cell must also nullify the 
powerful negative regulation of cell proliferation by the action of tumor suppressor genes. 
Among a large network of molecules, two most prominent tumor suppressors are 
retinoblastoma-associated (RB) and TP53 proteins. They govern the decisions of cells to 
proliferate or activate apoptosis.   
a. RB proteins integrate signals both from intracellular and extracellular sources and 
dictate whether a cell should proceed through its growth and division cycle. The 
defects in the RB pathway promote persistent cell proliferation in cancer cells. Loss of 
RB function is akin to the removal of a gatekeeper of cell cycle progression, hence 
triggering uncontrolled cellular proliferation.  
b. TP53 acts within the intracellular environment to assess the degree of genome 
damage, the levels of nucleotide pools, growth promoting signals, level of oxygen and 
glucose. It permits the cell cycle to progress only if those parameters are at normal 
level. On the contrary, if there is irreparable damage to those subcellular components, 
TP53 can trigger apoptosis. A loss of function mutation in TP53 can trigger 
uncontrolled growth as well (Hanahan & Robert A Weinberg 2011)   
1.1.2.3. Resisting cell death  
Programmed cell death by apoptosis is a natural cellular mechanism to destroy the cancerous 
growth.  Several upstream regulators and downstream effectors are the building blocks of 
apoptotic mechanisms. Some of the most important mechanisms of apoptosis and its blocking 
are listed below.   
a. The regulators are divided into two network modules leading to the activation of 
effector proteases (caspase 8 and caspase 9). One network module processes 
extracellular death inducing signals i.e. Fas ligand/Fas receptors signalling. Tumor 
necrosis factor/TNF receptor signalling. The other one sense and integrate 
intracellular signals. Next the resulting activated caspases execute disassembly of cell 
followed by phagocytosis. 
b. The Bcl-2 family of proteins has got both pro or anti apoptotic function. Bcl-2 inhibits 
apoptosis by inhibiting Bax and Bak. This inhibition blocks mitochondrial membrane 
disruption and release of cytochrome c in the cellular environment thus the cascade of 
proteolytic caspase is inhibited.    
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c. DNA damage sensors which act through TP53 tumor suppressors are the most notable 
one. Sensing the genomic damage, TP53 induces the apoptosis by up regulating 
expression of Noxa and Puma.  
d. Hyperactive signalling by MYC also triggers apoptosis.  
e. Insufficient IL3 signalling for the survival of lymphocytes also starts apoptosis.   
f. Different cancer cell evolved mechanisms to resists apoptosis by loss of function 
mutation of TP53, over expression of Bcl-2 (anti-apoptotic regulator), IL-3 (survival 
factor) and under expression of Bax, Bak (pro-apoptotic regulators) (Hanahan & 
Robert A Weinberg 2011; Evan & Vousden 2001).   
1.1.2.4. Enabling replicative immortality 
The scientific perception was that the cancer cells must have unlimited replicative potential to 
generate microscopic tumors. Successive research deciphers that the length of telomere of a 
chromosome determines the number of cell division. Normal cell can pass through a limited 
number of cycles for cell division and growth. As telomeres progressively shorten with each 
cycle of cell division/growth resulting end to end chromosomal fusion which triggers 
apoptosis. However cancer cell enable replicative immortality by continuously regenerating 
the telomeric region of chromosome with over expression of telomerase (Hanahan & Robert 
A Weinberg 2011; Harley 2008) 
1.1.2.5. Inducing angiogenesis 
Tumor grows rapidly due to uncontrolled cell division and proliferation of cancer cell. The 
growth of tumors has to be supported with continuous flow of nutrients, oxygen and the 
resulting metabolic waste has to be excreted out. Angiogenesis synthesizes neo-vascular 
structure in and around the tumor to meet that needs.  The cellular process of angiogenesis is 
controlled by the fine counter balance between inducing and inhibiting factors of 
angiogenesis. Some of the well-known angiogenesis inducers and inhibitors are vascular 
endothelial growth factor-A (VEGF-A) and thrombospondin-1(TSP-1).  
a. The binding of VEGF-A to three receptor tyrosine kinase (VEGFR 1-3) trigger VEGF 
signalling which orchestrates the formation of new blood vessels. 
b. Chronic up regulation of FGF (Fibroblast Growth Factor) enables cells to sustain 
angiogenesis.    
c. TSP-1 binds to the trans-membrane receptors of endothelial cells and inhibits the 
angiogenesis.  
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d. Angiostatin and endostatin endogenously inhibit angiogenesis.  
Tumors continuously induce angiogenesis by sustaining VEGF-VEGFR signalling by up 
regulation of VEGF in response to hypoxia or RAS and Myc signalling. Increased expression 
of pro-angiogenic molecules i.e. FGF also induce angiogenesis. Macrophages, neutrophils 
and mast cells can also activate angiogenesis by infiltrating pre-malignant/malignant lesions 
(Hanahan & Robert A Weinberg 2011; Carmeliet & Jain 2011). 
1.1.2.6. Activating invasion or metastasis 
Metastasis or invasion means the spread of cancer from one part of body to another. During 
tumor development the shape of its cells, the adhesion to other cells and to extracellular 
matrix degrades. The resulting tumor cells reach other parts of the body through the blood 
stream or lymph system. Cancer cells develop those properties by following mechanisms:  
a. E-cadherin is a cell adhesive protein, helping to maintain epithelial cell sheets and 
quiescence of the cells to it. Down regulation or loss of function mutation in E-
cadherin is a mechanism frequently used for the tumor tissues to metastasize to other 
body parts.  
b. N-cadherin is adhesive protein helping in cell migration. The up-regulation of N-
cadherin also drives the tumor cells to invade other body parts. 
c. Epithelial to mesenchymal transition (EMT) is one prominent mechanism to 
transform the epithelial cells to invade and to resist apoptosis. A set of transcription 
factors namely Snail, Slug, Twist and Zeb1/2 are the key driver of EMT pathway. 
Some of these transcription factors down regulate E-cadherin expression to help in 
metastasis.  
d. The interactions between cancer cells and nearby stromal cells play a crucial role for 
invasive growth and metastasis. Mesenchymal stem cells receive the signal from the 
cancer cells and in response produce CCL5. CCL5 stimulates cancer cells to invade 
other organs.  
e. In order to facilitate invasion the tumor matrix has to be degraded. Cancer cells secret 
IL4 which activate macrophages. Activated macrophages disrupt the tumor matrix to 
support invasion (Hanahan & Robert A Weinberg 2011; Tracey A. Martin, Lin Ye, 
Andrew J. Sanders, Jane Lane 2013). 
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Other than these 6 hallmarks of cancer there are other emerging hallmarks of the disease i.e. 
deregulating cellular energetics and avoiding immune destruction. The hallmarks of cancer 
and their interconnectivities are illustrated in Figure 3.     
 
Figure 3: Intracellular signaling networks regulate the operations of cancer cells 
(Hanahan & Robert A. Weinberg 2011). 
The figure demonstrates an elaborate integrated circuit operates within normal cells and is reprogrammed to regulate 
hallmark capabilities within cancer cells. Separate sub-circuits, depicted here in differently colored fields, are specialized to 
orchestrate the various capabilities. There is considerable crosstalk between such sub-circuits and major molecular players of 
each sub circuits are also visible. Each cancer cell is exposed to a complex mixture of signals from its microenvironment; 
each of these sub-circuits is connected with signals originating from other cells in the tumor microenvironment.  
 
Unlike other diseases, cancer has represented one of the unvanquishable challenges to human 
ingenuity, resilience and perseverance. However, thanks to enormous amount of research in 
oncology, today millions of cancer patients extend their life span with early identification of 
the disease followed by treatment. Nevertheless complete cure of cancers remain elusive. In 
the next section, an evaluation of the most advanced cancer treatment i.e. targeted therapies is 
presented. 
1.2. Targeted cancer treatment 
Over the last three decades the scientific community has witnessed a remarkable shift in 
understanding the mechanisms of cancer pathogenesis. Our current understanding on that 
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matter has paved the way for mechanism based targeted therapy in cancer. The growing 
number of current targeted therapies in cancer can be categorized by their effects on one or 
more hallmarks of cancer as illustrated in Figure 4. The observed efficacy of each of these 
drugs represents a validation, whether a particular hallmark is important for tumor biology. A 
minute observation on the mode of action of current targeted therapy in cancer demonstrates 
that most of them are directed towards specific molecular targets. These targets directly or 
indirectly enable particular capabilities. This type of mode of action is rewarding as it 
represents inhibitory activity against a target while having less nonspecific toxicity (Hanahan 
& Robert A. Weinberg 2011).  
 
Figure 4: Recent targeted therapies of cancer and their mode of action (Hanahan & 
Robert A. Weinberg 2011). 
Emerging or existing cancer treatments those shows promise to control with each of the acquired capabilities necessary for 
tumor growth and progression have been developed and are in clinical trials or in some cases approved for clinical use in 
treating certain forms of human cancer. Additionally, the investigational drugs are being developed to target each of the 
enabling characteristics and emerging hallmarks which also hold promise as cancer therapeutics.  
 
However, in the last decade all drug companies were affected by the crisis fuelled by 
increased expenditure, augmented pipeline attrition rate and patent expiry of major 
blockbusters. The success rate of late stage clinical trials fell by 10% for phase II studies in 
recent years. Additionally, the number of phase III terminations doubled in the last five years 
(Arrowsmith 2011a; Elias 2006). Most of the phase III failed drugs target cancer. Many of 
these failures were supposed to be related to the clinical explorations of life extension 
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strategies, particularly in cancer where compounds are successful in one tumor type produces 
a poor outcome in another tumor type (Arrowsmith 2011b; Khanna 2012).  Heterogeneity of 
cancer is one of the root causes of cancer drug failures.  To eliminate less promising 
candidate drugs early in the clinical trials, selection of biomarker indicating any “off target” 
effects in preclinical screens will be crucial. In addressing most alarming cause of drug 
failures i.e. efficacy, clinical study design should consider patient stratification strategies, 
biomarkers, scoring systems and computational models (Khanna 2012).    
So the drug discovery and development processes are in search for new models that would 
reduce the time taken by a drug to reach the market and increase the clinical success rate, thus 
satisfying regulatory authorities and patients’ needs. 
1.3. Recent trend in drug discovery 
One of the major causes of expensive drug failure is the marginal disease improvement 
compared to the current standard of care when analysed in a large population of late stage 
trials (Frank & Hargreaves 2003a). This has propelled one of the paradigm shifts of 
pharmaceutical drug discovery from blockbusters to niche busters i.e. therapies targeted 
towards specific target molecules of specific patient populations termed as targeted therapy. 
The success of targeted therapy depends on identifying stratified biomarker i.e. molecular 
signature that will stratify the patients prior to treatment (Trusheim et al. 2007a). Companion 
diagnostics (CDx) (diagnosis for identifying patients benefit from a therapy based on 
stratified biomarker) holds great promise to improve the predictability of therapeutics 
interventions (Jørgensen 2013).  
Currently about 10% of drug labels approved by the FDA contain pharmacogenomic 
information reflecting a clear trend towards targeted therapy (Frueh et al. 2008). Biomarker 
driven approach is being actively pursued by pharmaceutical companies as one of the next 
major reinventions in the field. The impact is evident through the FDA release of 
“Pharmacogenomic Biomarkers in Drug Labels” summarizing 136 approved drugs with 155 
associated biomarkers as of 01.03.2014 (Ptolemy & Rifai 2010) (US Food and Drug 
Administration n.d.).  
1.4. Biomarker 
Biomarker is a characteristic measured and evaluated as an indicator of normal biological 
processes or pharmacologic responses to a therapeutic intervention (Frank & Hargreaves 
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2003a). The biomarker is either produced by the diseased organ (tumor) or by the body in 
response to a disease or therapeutic intervention. It can be applied along the whole spectrum 
of disease management. It can be used for risk assessment of the disease as well. During early 
diagnosis, biomarker can be applied for staging, grading and selection of initial therapy while 
in the late stages, they can be used for therapeutic dosage, monitoring, selection of additional 
therapy and diseases recurrence (Biomarkers Definitions Working Group, 2001). FDA in its 
critical path initiative emphasized on applying biomarkers as an essential tool to combat the 
current situation of pharmaceutical industries suffering from late stage failures and lack of 
successful pipeline portfolios. Recent publications suggested that a more efficient model of 
pharmaceutical pipeline can be designed by applying biomarkers in all stages of drug 
discovery and development i.e. emphasizing biomarker usage from target identification to 
drug marketing (Bakhtiar n.d.; Colburn 2003; Deyati et al. 2013). Figure 5 summarizes a 
model pipeline for the drug discovery and development applying biomarker in all stages. 
Based on the application in drug discovery and development, there can be five types of 
biomarker. The definitions of each of them are listed below:  
 
1.7.1. Disease biomarker: a biomarker that depicts prodromal signs to enable 
earlier diagnosis or allow for the outcome of interest to be determined at a more initial stage 
of a disease.  
 
1.7.2. Efficacy biomarker: a biomarker used to assess whether a drug will have 
clinically significant positive outcome before the treatment. 
 
1.7.3. Safety biomarker: a biomarker which can determine dose response for 
toxicity.  
 
1.7.4. Pharmacodynamic biomarker: a biomarker that indicates selection 
of an optimal dose of a drug for a patient. 
 
1.7.5. Patient Stratification biomarker: a biomarker that can predict the 
probable drug response on a selected subpopulation of patients.  
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Figure 5: Model pipeline of biomarker driven drug discovery and development. 
The emerging trend of applying biomarker in all five major stages of drug discovery (i.e. identifying the targets, discovery of 
lead molecule) and development (i.e. preclinical testing to filing the drug candidate to regulatory authorities). Each stage of 
drug discovery and development with its prospective biomarker are colour coded.    
 
However, till now the use of patient stratification biomarker in late stage clinical trials stands 
out among other biomarker applications to cope with the most alarming issue of expensive 
late stage failures. 
1.5. Biomarker in current clinical practice: 
focus on oncology (Deyati et al. 2013) 
Cancer being a highly heterogeneous disease is among the first indications in moving towards 
targeted therapies.  Different tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib, 
crizotinib, dasatinib, vemurafenib) and monoclonal antibodies (cetuximab, panitumumab, 
trastuzumab, pertuzumab, tositumumab) have been at the forefront of targeted therapies in 
cancer (Deyati et al. 2013; Majewski & Bernards 2011). 
The success stories of targeted therapy in cancer started with commercialization of 
trastuzumab, cetuximab, imatinib, gefitinib. The trend has been on the rising with recent 
examples of Zelboraf (Vemurafenib) approved with the companion genetic test for BRAF 
mutation for late stage melanoma and Xalkori (Crizotinib) approved in combination with the 
companion genetic test for the ALK gene for late stage lung cancer (Dean & Lorigan 2012; 
Sai-Hong Ignatius Ou et al. 2012; Ruzzo et al. 2010a; Trusheim et al. 2007a). EGFR, 
Her2/neu, ALK, BRAF, Bcr-Abl, PIK3CA, JAK2, MEK, Kit, and PML-RARα are targets of 
recently approved targeted therapies in cancer. These target molecules and their downstream 
effectors are often subject to various changes on genomic, transcriptomic, proteomics and 
epigenetic levels. Therefore, status of those molecules (biomarker) underlies diversified 
patient-specific clinical responses to targeted therapies (Majewski & Bernards 2011).  
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As cancer is one of the prime areas of targeted therapies, we present here Table 1 
summarizing stratification biomarkers currently in clinical practice in oncology along with 
their approved treatment. As shown in the Table 1, with few exceptions such as KRAS, most 
of the biomarkers are direct drug targets of the respective therapies. The majority of 
stratification biomarkers have been approved after the therapy went to the market (i.e. 
derived from the retrospective analysis of late-stage clinical trials or post-marketing surveys). 
It is obvious that the biology of the target and its changes under pathological conditions was 
not apparent during clinical development. Even in the stratified patient population, 
therapeutic response do not meet with equal success (Sawyers 2004; Paez et al. 2004; 
Kreitman 2006) suggesting that clear understanding of downstream pathways and molecular 
interaction networks are necessary for biomarker-driven stratified medicine. Efforts to 
elucidate such global downstream changes lead to host of technologies for biomarker 
identification reviewed in the next section. 
 
Functional Class Biomarker Therapy 
Kinase EGFR Cetuximab, Erlotinib, 
Gefitinib, 
Panitumumab   
Kinase Her2/neu Lapatinib, 
Trastuzumab, 
Pertuzumab  
Kinase PDGFR Imatinib 
Kinase Estrogen receptor  Fulvestrant,  
Exemestane  
Kinase ALK  Crizotinib 
Kinase KRAS  Cetuximab, 
Panitumumab  
Kinase BRAF  Vemurafenib 
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Immune cell surface 
receptor 
CD20 Tositumumab 
Immune cell surface 
receptor 
CD25 Denileukin difitox 
Immune cell surface 
receptor 
CD30  Brentuximab vedotin 
Immune cell surface 
receptor 
C-Kit Imatinib 
CNV PML-RARα Arsenic trioxide 
CNV BCR-ABL Dasatinib 
Table 1: FDA-approved Stratification Biomarkers for targeted therapy in oncology 
1.6. Biomarker discovery using high 
throughput technology  
The rapid evolution of high throughput technologies designed for screening of biomedical 
samples by whole genome sequencing and microRNA (miRNA) profiling gave birth to 
several biological disciplines devoted to the generation and study of those multiple OMICS 
data. Figure 6 summarizes the latest technologies and diversification of the biomarker types 
based on bio molecular properties and underlying data types depending on changes detected 
by the respective technology.  
1.6.1. Genetic biomarkers 
Genetic biomarkers are biomarkers derived from technologies assessing genomic changes 
such as exome and whole genome sequencing, polymerase chain reaction (PCR) and 
Fluorescence in situ hybridization (FISH). They can accurately identify single nucleotide 
polymorphisms (SNPs), copy number variations (CNVs) and structural variations in the 
genome and delineate their functional significance in the pathophysiology of a defined 
phenotype. These technologies have helped to find stratification biomarkers in oncology and 
some of them are already in clinical practice. For example, KRAS sequencing and PCR were 
used to discover predictive and prognostic role of KRAS mutation in colorectal cancer and 
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lung cancer for anti EGFR-therapy resistance (Mauro Moroni et al. 2005; Lièvre et al. 2006; 
Eberhard et al. 2005; Amado et al. 2008). PCR/FISH analyses were used to show that 
translocation of BCR-ABL and PML-RARα may serve as predictive biomarkers conferring 
sensitivity to Imatinib mesylate and resistance to arsenic oxide in leukemia (Druker et al. 
2001; Niu et al. 1999). The same technologies were used to identify mutation/amplification 
and translocation of ALK gene as biomarkers predicting the efficacy of Crizotinib treatment 
in late stage lung cancer (Kwak et al., 2010).  
1.6.2. Expression biomarkers 
Differing from the traditional single biochemical and histopathological measurements, 
expression biomarkers (transcriptomics biomarker) represent a fingerprint containing 
multiple biomarkers, which collectively indicate particular pathophysiology (Bhattacharya & 
Mariani 2009). Well established high throughput technologies like microarray expression 
profiling can identify differential expression of an entire genome at any specific sample at a 
given time point. There are several reports on using these technologies to identify biomarkers 
in specific cancer subtypes. Two expression biomarker tests are clinically approved for 
patient stratification in breast cancer. MammaPrint, a unique 70 gene expression profile, is a 
prognostic biomarker for distant recurrence of the disease following surgery in breast cancer 
patients (van ’t Veer et al., 2002). Oncotype DX is another gene expression signature-based 
biomarker test containing 16 cancer-related genes and 5 reference genes that predict the 
recurrence of breast cancer in Tamoxifen-treated patients with node negative, estrogen 
positive tumors (Paik et al., 2004).  
1.6.3. Protein biomarkers 
Human plasma holds the largest source of the proteome hence technologies that can measure 
changes in the protein profile are invaluable to identify protein biomarkers in blood. For 
example, mass spectrometry can capture minor changes of the protein levels and 
immunohistochemistry can accurately identify a specific protein in the living system. 
Application of proteomics in discovery of oncology biomarkers can be exhibited by 
immunohistochemistry-derived Her2 which is prognostic, predictive biomarkers for the 
sensitivity to Trastuzumab therapy in breast cancer (Lewis Phillips et al. 2008). EGFR is 
another pharmacodynamic biomarker discovered by immunohistochemical assay in colorectal 
and lung cancer samples conferring sensitivity to Cetuximab, Panitumumab and Gefitinib 
treatment (Saltz et al. 2004; Vanhoefer et al. 2004; Lynch et al. 2004; Freeman et al. 2009a). 
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Clinical acceptance of novel proteomics biomarkers suffers an anemic rate due to the lack of 
PCR-like amplification techniques for the vast number of analytes present in extremely small 
quantities in dynamic plasma (Ptolemy & Rifai 2010). As a potential solution, a novel 
method of immune PCR using conjugations of specific antibodies and nucleic acids is 
suggested  which leads to 100-10000 fold signal amplification thus increasing sensitivity of 
protein biomarker detection (McDermed et al., 2012; Niemeyer et al., 2005). 
1.6.4. Metabolic biomarkers 
Ever since Otto Warburg hypothesized that altered metabolism (converting glucose carbon to 
lactate in oxygen rich condition) is specific to cancer cells due to mitochondrial defects, 
metabolic biomarkers have drawn the attention of researchers to be an effective biomarker for 
early cancer diagnosis and prognosis (Ward & Thompson 2012). Since then, numerous 
efforts have been dedicated to identify metabolic biomarkers in oncology. NMR 
spectroscopy, HPLC, radioimmunoassay, LC-MS, GC-MS, and enzyme immunoassay help to 
analyze the metabolite levels in response to pathophysiological change or treatment. Until 
now, only two metabolic biomarkers have made it to clinical practice. Metanephrine and 
Normetaephrine are two metabolites that are used to predict disease state associated to 
pheochromocytoma (see: http://www.accessdata.fda.gov/cdrh_docs/reviews/K032199.pdf). 
Despite rapid technological advancement in metabolomics, it is still impossible to 
differentiate metabolites derived from different sub-cellular compartments. Current 
fractionation methods often lead to metabolite leakage between different layers making it 
even more difficult for metabolite identification (Ward & Thompson 2012). 
1.6.5. microRNA biomarkers 
The involvement of microRNAs (miRNAs) in key cellular processes such as proliferation, 
cell death and negative regulation of numerous oncoproteins makes them a prime candidate 
as cancer biomarkers. It has been reported that cancer-specific miRNAs are detected in the 
blood from the earlier stages of tumor development and concentration increases as the tumor 
progresses over time, making them an indicator of tumor growth (Krutovskikh & Herceg 
2010). Unlike other types of biomarkers, miRNAs are remarkably stable in the circulation 
and formalin-fixed paraffin embedded tissue, making them potentially robust oncology 
biomarkers. Functional miRNA species have mostly been validated in vitro using luciferase 
reporter activity (Krutovskikh & Herceg 2010). Microarray profiling is a powerful, high 
throughput technology capable of monitoring the expression of thousands of small non-
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coding RNAs at a specific context. Mirage (SAGE), Stem-loop qRT-PCR for mature 
miRNAs, qRT-PCR for precursor miRNAs and bead-based technologies are also frequently 
used for microRNA profiling (Liu et al. 2008). However, no such biomarker exists in cancer 
clinical practice yet. It is noteworthy that genetic biomarkers witnessed a remarkable rise in 
clinical acceptance after the human genome project characterizing all the genes. Similar 
effort is needed to discover and characterize all the miRNAs in human cells to transform the 
potential of miRNAs as cancer biomarker into clinical success. Further understanding on how 
miRNAs compete with proteins to bind and control the expression of mRNA, as well as the 
functional interaction networks through which miRNAs act are needed for future clinical 
translation (Krutovskikh & Herceg 2010).  
 
Figure 6: Data types and technologies for biomarker discovery  
The figure illustrates current technologies and data types used for biomarker discovery in preclinical and clinical research. 
Abbreviations: CNV, copy number variations; FISH, fluorescence in situ hybridization; GCMS, gas chromatography mass 
spectrometry; HPLC, high-performance liquid chromatography; LCMS, liquid chromatography–mass spectrometry; NMR, 
nuclear magnetic resonance; PCR, polymerase chain reaction; SNPs, single nucleotide polymorphisms; SVs, structural 
variations. 
 
Noting this enormous amplification of data points obtained from biomedical samples, the 
question arises whether these technological advances along with ever-increasing availability 
of the screening platforms can lead to clinical breakthroughs? To get a better understanding 
of the technologies contributing to the identification of currently approved stratification 
biomarkers in oncology; we present an OMICS wise overview on data generation platforms 
and types of data resulting from these platforms in Table 2. 
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OMICS Technology Biomarker Associated no 
of drugs 
References 
GenOMICS Fluorescence in situ 
hybridization or 
Polymerase chain 
reaction 
ALK 1 (Janoueix-
Lerosey et al. 
2008) 
GenOMICS Fluorescence in situ 
hybridization 
Her2/neu  1 (Bekaii-Saab 
et al. 2009) 
GenOMICS Polymerase chain 
reaction 
BRAF  1 (Chapman et 
al. 2011) 
GenOMICS Polymerase chain 
reaction 
CD20 1 (Kaminski et 
al. 2005) 
GenOMICS Polymerase chain 
reaction 
PML-RARα  1 (Niu et al. 
1999) 
GenOMICS Polymerase chain 
reaction 
KRAS  1 (Heinrich et 
al. 2003) 
GenOMICS Sequencing EGFR  1 (M. Moroni et 
al. 2005) 
GenOMICS Sequencing KRAS  1 (Lynch et al. 
2004; 
Freeman et al. 
2009b) 
GenOMICS Sequencing C-Kit  1 (Heinrich et 
al. 2003) 
GenOMICS Sequencing BCR-ABL 1 (Takei et al. 
2008) 
GenOMICS Sequencing PDGFR 1 (Takei et al. 
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2008) 
ProteOMICS Immunohistochemistry EGFR  3 (Lewis 
Phillips et al. 
2008; Tsao et 
al. 2005; Addo 
et al. 2002; 
Hochhaus et 
al. 2008) 
ProteOMICS Immunohistochemistry CD25 1 (Dang et al. 
2007) 
ProteOMICS Immunohistochemistry Her2/neu 1 (Slamon et al. 
2001) 
Table 2: OMICS technologies for stratification biomarker discovery in oncology 
 
As evident from Table 2, few stratification biomarkers derived from each technology are 
currently approved and are in clinical use for cancer. This reflects the hard and long process 
of developing sensitive, specific and highly predictive biomarkers for clinical decision 
making from high throughput data. Nevertheless, OMICS technologies have tremendous 
potential to discover future biomarkers and the expectations have been augmented in last 20 
years supporting the huge investments in the development of these technologies (Deyati et al. 
2013).  
To understand the future potential of these high throughput technologies, we compared the 
number of published candidate biomarkers, i.e. those reported in the scientific literature, 
clinical trials registries or scientific conferences with the number of approved biomarkers for 
each technology described above. For this purpose, we retrieved all cancer-related candidate 
biomarkers (including disease, stratification, prognostic and diagnostic biomarkers) from 
GVK Bio Online Biomarker Database (GOBIOM). GOBIOM is independent manually 
curated biomarker related knowledge base that uses the information derived from clinical 
reports, annual meetings and journal articles (Jagarlapudi & Kishan 2009). During the time of 
writing, GOBIOM contained information on 15,732 biomarkers covering 16 therapeutic areas 
supported by 36,681 unique references.  
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Figure 7: Comparative performance of different OMICS technologies in oncology 
biomarker discovery collected through the Gobiom database.  
Red: Total number of candidate biomarkers reported in the public domain. Blue: Number of FDA approved biomarkers. 
Current contribution of OMICs technologies in oncology biomarker discovery extracted from the Gobiom database. In red: 
the total number of candidate biomarkers reported in the public domain. In blue: the number of FDA approved biomarkers in 
current clinical practice for oncology. 
 
As evident in Figure 7, although transcriptomics technology is one of the oldest and widely 
used high throughput technologies, most of the candidate biomarkers are reported to be 
coming from genomic research followed by proteomics. Stability of the signal coming from 
genomic analysis as well as higher stability of the protein versus mRNA might be the reason 
for those biomarkers overweighting the transcriptomics derived biomarkers (Deyati et al. 
2013). Never the less transcription and its regulation is one of the most important 
mechanisms to implement and manifest the genetic information stored in DNA. 
Transcriptomics technologies are also economically less expensive than proteomics 
technologies. State of the art analysis of transcriptomics data as well as accurate functional 
interpretation can potentially improve the situation (Khatri et al. 2012). In the next chapter 
the applied transcriptomic technologies in this thesis i.e. microarray technology along with 
state of the art statistical methods for data analysis are described in detail.  
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2. Computational Methods to 
Analyse Microarray Data for Cancer 
Biomarker Discovery 
Over the years substantial research has been undertaken to identify differentially expressed 
disease biomarker by analyzing microarray data from patient samples. These biomarkers 
serve as diagnostic or prognostic indicators that dictate preferred therapeutics. This chapter is 
focusing on microarray technology and its data analysis in cancer. The focus will be also on 
quality assessment, data combination, feature selection and prediction.  
Microarray technology for measuring expression profiles of genes is an invaluable tool to 
infer the physiological condition of the cell, tissue or an organism. Compared to measuring 
the expression level of proteins, measuring mRNA expression profile is easier and less 
expensive. Thus scientific community often applies gene expression level and its post 
transcription control as a reasonable substitute. A set of probes are attached to the solid 
surface of microarray or chip. The key principle behind the microarray technology is a 
process called hybridization in which a nucleotide strand binds to its unique complementary 
strand. Fluorescence tagged nucleotide sequences are allowed to complementary bind with its 
probes and based on the intensity of the fluorescence, the relative abundance of the 
nucleotide sequence (gene) is determined. The microarray can be categorized into two major 
categories i.e. single channel and two-channel. In two-channel microarray two labeled 
samples are hybridized on the same surface of the chip to determine the relative expression of 
the genes between the two samples. As the name indicates in one-color microarray gene 
expression profile of only one sample can be measured (Lockhart et al. 1996; DeRisi et al. 
1997). 
Over the years, the biomedical community has witnessed an exponential growth in 
publication analyzing gene expression profiles from clinical samples which are largely 
deposited to the Gene Expression Omnibus (GEO) (Edgar et al. 2002). Clinical gene 
expression data that has been analysed in this dissertation are extracted from biopsies of 
tumor samples and healthy tissues taken from GEO and The Cancer Genome Atlas (TCGA). 
In order to control bias, the gene expression profiles are typically measured on the same 
platforms across samples of interest. The data analysis was also followed by common pre-
processing steps including background correction, imputation, and normalization.  
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2.1. Analysis of microarray data 
The data analysis of a microarray experiment is a multi-step process. It starts with sample 
preparation and hybridization in microarray, which produce image files containing probe 
signal intensities. This probe signal intensities require image analysis, signal adjustment and 
data normalization to eliminate all the non-biological variability (or noise) inherent to the 
system. These procedures are often referred to as “data normalization”. Due to the multiple 
microarray platforms with different target preparation and hybridization methods, numerous 
normalization methods have been developed. After pre-processing, the normalized gene 
expression data can be analysed using statistical tools and exploratory methods to extract 
genes or patterns with biological significance. The analysis of one-color and two color 
microarray data is more or less similar, the main difference between these methods lies in the 
normalization of the data. 
2.1.1. Image Analysis 
Microarray image analysis starts with placing a computer-aligned grid over the hybridized 
surface area. Next, software is used to measure the intensity of each spot representing each 
probe on the hybridized array. Each spot on the chip surface is investigated for any 
hybridization biases or poorly hybridized probe to evaluate the hybridization quality. The 
software eliminates these “bad spots” and other spot intensities are stored in a file. The signal 
adjustment is a crucial step to correct the background noise and processing effect, to adjust 
for cross hybridization caused by the binding of non-specific target (DNA or RNA) and 
finally to adjust for expression estimates so that proper scale dimensionality is ensured. The 
intensities of the pixels surrounding the spot are measured to compute the background 
adjustment for spotted arrays. Due to the highly dense nature of Affymetrix GeneChips®, 
only the probe intensities must be used to determine any adjustment. A specialized statistical 
algorithm called Ideal Mismatch procedure is used to calculate the adjusted signal from 
Affymetrix GeneChips® (Freeman et al. 2009a).  
 
2.1.2. Data Normalization 
Data normalization is a method that strives to eliminate experimental variation due to 
differential amount of extracted RNA, dye effects, scanner difference etc. The scientific 
rationale for data normalization is to achieve uniform level of gene expression for most genes 
and make sure the gene expression is following a normal distribution when comparing two or 
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more samples on a genome-wide level. Hence the expected mean intensity ratio between two 
channels (two-color data) or chips (one color data) should be one, otherwise the data is 
numerically processed to adjust this ratio to one. Normalizations include the following steps: 
data transformation to stabilize intensity variance across the datasets and removal of non-
biological variation within a single array or between different arrays. In some normalization 
processes expression of house-keeping genes or spike-in controls (external control sequences 
from other organism) are applied. Replicates from biological and technical point of view are 
also very useful to minimize the effect of outliers and in enhancing data quality 
(Quackenbush 2001). Mean or median probe intensity values of multiple probes (one-color 
arrays) or replicate spots (two-color arrays) are often applied to increase the robustness of the 
data. The choice of normalization method is often based upon prior knowledge of the dataset. 
To maintain normal distribution of log intensity ratios for each slide of two-color 
microarrays, log centering and scaling are applied. However, LOWESS (locally weighted 
linear regression) or dye-swap smoothing are often preferred normalization methods where 
dye biases can depend on spot overall intensity or co-ordinate within the array (Ekstrøm et al. 
2004; Bandyopadhyaya et al. 2002). There are several preferred normalization methods for 
Affymetrix GeneChip®, to name just a few Microarray Suite (MAS) 5.0 statistical algorithm 
from Affymetrix (Gold et al. 2005), robust multichip average (RMA) (Wang et al. 2004), 
model-based expression index (MBEI) (Wu et al. 2005). These normalization methods 
considerably differ from one other leading to different results in data analysis. Popular MAS 
5.0 normalization applies a linear regression algorithm. Adjusted PM values are log 
transformed and a robust mean is calculated on the resulting values. Then the data is scaled 
using a trimmed mean after obtaining a signal for each probe set as the antilog of the 
resulting value (Gold et al. 2005). MBEI normalization is done with median intensity selected 
as a baseline array for normalization. The algorithm uses an invariant set method where 
numerous probes are selected ad-hoc as references for comparison of two samples and a non-
parametric curve (running median) is fitted through the data points (Wu et al. 2005). RMA 
and GCRMA are a modification of MBEI normalization method.  They use quantile 
normalization instead of median method used in MBEI. Nevertheless, apply same empirical 
distribution of probe intensities for each array of an experiment and the maximum 
background corrected; log-transformed PM intensity on each chip is evaluated. Next the 
original intensity values are replaced with average values and the process repeated for all 
intensities in descending order. After that, expression value for each probe on each GeneChip 
is measured by fitting an additive linear model to the normalized data. In addition to RMA 
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method described above, GCRMA takes into account of sequence information to address 
nonspecific background variation (Quackenbush 2001). Quality and comparability of the data 
analysis of microarray experiments has become a major challenge due to the wide range of 
methods for data production and normalization. As a solution Microarray Gene Expression 
Data Society (MGED) created a guideline called Minimum Information about Microarray 
Experiments (MIAME) for microarray data reporting standards. Nowadays many journals 
regarded the MIAME standards to publish microarray data  (Brazma et al. 2001; Verducci et 
al. 2006). 
 
2.1.3. Statistical analysis of microarray data 
The main idea behind statistical analysis of high dimensional microarray data is to 
characterize the structure of the data, reduce the dimensionality and extract statistically 
significant pattern in it. Fold change was among the first methods used to evaluate whether 
genes were differentially expressed. However, nowadays it is considered an inadequate test 
statistic as it does not account for the variance and offers no associated level of confidence. 
Parametric tests are more predominantly used for the analysis of microarray data due to its 
normalized nature. Typical parametric tests used in microarray analysis are student’s t-test or 
analysis of variance (ANOVA). These methods assume the data is normally distributed and 
try to estimate whether the variance in the data comes from the normal distribution. Often 
microarray experiments have a large number of observations but fewer samples which lead to 
test multiple hypotheses.  In a biological experiment, the observed differences are expected to 
happen by chance and as well as due to biological variability. The required correction of the 
statistical tests are often achieved by the Bonferroni method and the false discovery rate 
(FDR) suggested by Benjamin and Hochberg (Benjamini Yoav 1995). There are ample 
commercial and non-commercial statistical analytical tools available for advanced data 
analysis and visualization. Treeview (Eisen et al. 1998), GeneCluster (Tamayo et al. 1999), 
SAM (Tusher et al. 2001a), dCHIP (Li & Wong 2001), Gene data expressionist, GeneSpring 
(Agilent Technologies) and numerous other R and Bioconductor packages provides great 
resources to analyse microarray data. The main purpose of these packages vary from 
normalization, removal of insignificant genes, statistical analysis to identify differentially 
expressed genes or classify genes based on different phenotypes. 
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One of the big challenges of analyzing microarray data with traditional classical statistics is 
the presence of large number of unchanged genes adding high level of noise and uncertainty. 
The power and reliability of the statistical test can be improved by eliminating those genes; 
here arises the application of gene filtering to reduce the dimensionality of the data and 
differentiation approach to screen significant differentially expressed genes. In the next 
section, some of the popular data mining methods to identify differentially expressed genes 
are summarized.  
2.1.3.1. Data mining Algorithms to screen differentially 
expressed genes and feature selection  
 
Significance analysis of Microarray (SAM): SAM identifies a set of statistically significant 
genes in expression analysis by assimilating a set of gene specific t tests.  Each gene is 
assigned a score on the basis of its change in gene expression relative to the standard 
deviation of repeated measurements for that gene. Genes with scores greater than a threshold 
are deemed potentially significant. The algorithm applies permutation of repeated 
measurements to estimate the percentage of genes estimated by chance i.e. the false discovery 
rate. The threshold can be adjusted smaller or larger set of genes. The algorithm incorporates 
the gene specific fluctuation of expression with a statistics based on the ratio of change in 
gene expression to standard deviation in that data for that gene. The “relative distance” d(i) in 
gene expression is calculated as follows.  
d(i) = 
𝑥𝐼(𝑖)−𝑥𝑈(𝑖)
𝑠(𝑖)+𝑠0
  
xI(i) and xU(i) are defined as the average levels of expression for gene (i) within states I and 
U. The “gene-specific scatter” s(i) is the standard deviation of repeated expression 
measurements:  
s(i) = √𝑎{∑ [𝑥𝑚(𝑖) − 𝑥𝐼(𝑖)]2 + ∑ [𝑥𝑛(𝑖) −  𝑥𝑈(𝑖)]2𝑛𝑚 }   
a = (1/n1 + 1/n2)/(n1 + n2 -2). n1 and n2 are the number of measurements in states I and U. The 
statistical distribution d(i) should be independent of the level of gene expression so that d(i) 
across all genes are comparable.  When gene expression level is low the variance in d(i) can 
be high because of small values of s(i). To ensure that the variance of d(i) is independent of 
40 
 
gene expression by a small positive constant S0 added to the denominator to calculate d(i)  
(Tusher et al. 2001a).    
 
Limma: Limma is a package to identify differentially expressed genes in a microarray 
experiment by applying a linear model to the expression data for each gene. To stabilize the 
experimental analysis with a smaller number of array, shrinkage method like empirical bayes 
is used for an expression overview across all the genes in the array. The linear model with 
Limma requires two matrices. The first one is the designed matrix which provides a 
representation of the hybridized RNA targets in the array. The second one is the contrast 
matrix which allows the coefficients defined by the design matrix to be combined into 
contrasts of interest. Limma operates on a matrix of expression values in which each row 
represents a gene or some other relevant genomic feature and each column represent a RNA 
sample. The algorithm fits a linear model to each row of data and it facilitates to handle 
complex experimental design and to test extremely flexible hypothesis. Genomic data is 
highly parallel in nature. So when the sample number is low the model can borrow 
information between gene-wise models allowing different levels of variability between genes 
and between samples thus the statistical inferences get robust. All the features of the 
statistical models can be accessed not just for gene wise expression analysis but also for gene 
expression signature. Mathematically a linear model E[yj] = Xαj is assumed where yj 
symbolizes the expression data the gene j, X is the designed matrix and αj is the vector of 
coefficient. The contrasts of interest are given by βj = C
T
 αj where C is the contrasts matrix 
(Ritchie et al. 2015).  
 
Correlation based feature selection (CFS): CFS algorithm uses a correlation based heuristic 
to evaluate the importance of features. The heuristic takes into account the usefulness of 
individual features for predicting the class label along with the level of correlation among 
them. The underlying hypothesis of CFS is “Good feature subsets contain features highly 
correlated with the class, yet uncorrelated with each other”. The formalism of heuristics is as 
follows: 
Merits = 
𝑘𝑟𝑐𝑓
√𝑘+𝑘(𝑘−1)𝑟𝑓𝑓
 
Where Merits is the heuristic “merit” of a feature subset S containing k features, rcf the 
average feature class correlation and rff the average feature-feature intercorrelation. Equation 
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n can also be viewed as Pearson’s correlation where all the variables have been standardized. 
The numerator indicates how predictive a group of features are whereas the denominator 
implicate how much redundancy there is among them (Hall 2000).  
 
Mann-Whitney-U test: Mann Whitney U test is an unpaired, univariate and non-parametric 
test i.e. two independent random samples A and B can be compared with Mann-Whitney-U 
test. The Mann-Whitney-U statistics is defined as follows:  
U= n1n2 + n2 (n2 + 1)/2 - ∑ Ri
𝑛2
𝑖=𝑛1+1
 
When A and B are randomly collected from population, the samples are independent from 
each other and the measurement scale is ordinal. Sample A of size n1 and B of size n2 was 
pooled and Ri is the rank.  
The aim of the test is to find out if the centrality of a test variable when it differs significantly 
between two groups of interest. The p-value serves as the evaluation measure of 
discrimination. Mann Whitney u test is especially appropriate for two class biological 
problems (Lehmann, E.L, Romano 2006)  
2.1.3.2. Clustering Algorithm 
Clustering is an unsupervised learning algorithm to separate a group of data points into a 
number of clusters. Clustering can be defined as the process of organizing objects into groups 
whose members are similar in some way. Unsupervised clustering can further be split to 
hierarchical clustering method and non-hierarchical clustering methods such as self-
organizing maps (SOM) or K-means clustering. One of the major goals of clustering is to 
determine the intrinsic grouping within an unlabelled data. Clustering is one of the most 
popular methods as the first step in gene expression data analysis. In order to reduce the high 
dimensional gene expression data, clustering algorithm like PCA is applied. Strategically 
microarray data analysis can be applied either at the gene level to find out similarities or 
dissimilarities between different genes across the samples to find out the correlation between 
two genes or comparing the samples to find out differentially expressed genes in different 
experimental conditions (Korol, A.B., 2003).  
Principal component analysis: Principal component analysis (PCA) is an unsupervised 
projection approach which reduces the dimensionality of biological data by identifying 
directions called principal component along which the variance of the data is maximum. So 
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PCA ignores those dimensions in which the data can be much variabe. Given a high 
dimensional data, PCA calculates a new system of coordinates. The directions of this new 
coordinate system calculated by PCA are the eigenvectors of the covariance matrix. In 
mathematical terms, the Eigen vector with the highest Eigen value computed from the 
covariance matrix is the first principal component. So intuitively covariance matrix reflects 
the shape of data points. With the help of Eigen vectors PCA captures the main axes of the 
shape formed by the data in n-dimensional space. Given a large dataset like microarray with 
multiple variables, by applying PCA we can identify variables with the highest correlation 
with the dependent variable (Ringnér 2008).  
Singular Value decomposition: SVD is a dimensionality reduction algorithm. 
Mathematically SVD is matrix decomposition technique which is also the mathematical 
framework of PCA. Microarray data can be represented as real valued m-by-n matrix (say X). 
The same matrix can also be represented as the product of three matrices (Liu & Zhao 2006).  
A = QDR
T  
Q: Eigenvectors of AA
T 
which will
 
be m-by-m matrix 
D: Eigenvectors of A
T
A which will be n-by-n matrix 
R: Diagonal matrix with square root of the Eigen values of AA
T 
and
 
A
T
A (Korol, A.B., 2003) 
 
Unsupervised Clustering: Clustering without prior knowledge about the data is termed as 
unsupervised clustering. Algorithms in this category treat all inputs of a set of n numbers or 
an n-dimensional vector. Unsupervised clustering can be done on genes, samples, time points 
in a time series experiment. Unsupervised clustering is based on the measure of similarity. 
The similarity measure between objects is also referred as a distance matrix. There are 
several mathematical algorithms to calculate similarities which are described below (Korol, 
A.B., 2003).   
Suppose we are having two n-dimensional vectors X = (x1, x2, …., xn) and Y = (y1, y2, …, yn)  
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a. Euclidean distance 
dE = √(𝑥1 − 𝑦1)2 + (𝑥2 − 𝑦2)2 + ⋯ + (𝑥𝑛  − 𝑥𝑛+1) 
The Euclidean distance counts both direction and magnitude of the vector (Korol, A.B., 2003).  
b. Manhattan distance is calculated as follows: 
dm(x, y) = |x1-y1| + |x2-y2| + …. + |xn-xn+1| 
Manhattan distance represents the absolute value of the difference between xi and yi. 
However, cluster using distance calculated by applying Euclidean matrix is much more 
compact than applying Manhattan distance (Korol, A.B., 2003).   
c. Chebychev distance is calculated as follows:  
dmax (x, y) = max |xi - yi| 
As the formula indicates the Chebychev distance will simply pick the largest distance 
between two corresponding entities. The distance matrix is very robust in avoiding the noises 
as long as the values do not exceed the maximum distance (Korol, A.B., 2003).   
d. Correlation distance is calculated as follows:  
dr(x, y) = 1- rxy 
rxy is the Pearson correlation coefficient calculated as rxy =  
∑ (𝑥𝑖−𝑥𝑚)(𝑦𝑖 −𝑦𝑚)
𝑛
𝑖=1
√∑ (𝑥𝑖−𝑥𝑚)
2𝑛
𝑖=1  √∑ (𝑦1−𝑦𝑚)
2𝑛
𝑖=1
 
xm and ym are the mean values of x and y variable. The correlation distance can vary between 
0 and 2 as the correlation coefficient rxy takes values between -1 and 1. This distance matrix 
does not incorporate the magnitude of the coordinates (Korol, A.B., 2003).  
e. Mahalanobis distance is calculated as follows: dml (x, y) = √(𝑥 − 𝑦)𝑇𝑆−1(𝑥 − 𝑦)  
S is any n*n positive definite matrix and (x-y)
T 
is the transposition of (x-y). The role of the 
matrix S is to distort the space as desired. If S is an identity matrix then Mahalanobis distance 
reduces to the classical Euclidean distance (Korol, A.B., 2003).   
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Clustering algorithms have been extensively used in phylogenetic analysis. The algorithm has 
also been adopted by the gene expression community for its accuracy and usefulness. Some 
of the extensively used clustering algorithms are discussed in detail in the next section.  
Non-hierarchical clustering 
K-Means: At first the algorithm estimates a number of clusters then calculates the centroid of 
each cluster and finally find out the closest cluster for each data point by minimizing the 
objective function (J).  
J = ∑ ∑ |𝑥𝑖
𝑗 − 𝑐𝑗|
2
𝑛
𝑖=1
𝑘
𝑗=1  
Where |xi
J
 - cj|
2
 is the calculated distance between a data point xi 
j
 and cluster centre cj. The 
distance is calculated for n data point over k cluster.  After all the objects have been assigned 
into cluster the k centroids are recalculated followed by calculating the objective function. 
This process continues until the centroid no longer moves. K means clustering is one of the 
fastest and simplest clustering algorithms (Ma et al. 2005).  
SOM: Self-organizing maps or SOM is an application of self-organizing neural network to 
cluster multi-dimensional data to recognise and classify features. The algorithm has a set of 
nodes with simple topology (two dimensional grid) and a distance function d(N1, N2) on the 
nodes. Nodes are iteratively mapped into k-dimensional “gene expression” space. The 
position of node N at iteration i is denoted fi(N). The initial mapping f0 is random. After 
subsequent iterations, a data point P is selected and the node NP that maps nearest to P is 
identified. The mapping of node then adjusted by moving points toward P by the following 
formula:  
fi+1 (N) = fi (N) + γ(d(N, NP), i) (P – fi(N)) 
The learning rate γ decreases with distance of N from NP with iteration number i. The point P 
used at each iteration is determined by random ordering of the n data points generated once 
and recycled as needed.  The function γ is defined by γ(x, i) = 0.02T/(T + 100 i) for x = α(i) 
and γ(x, i) = 0. Otherwise where the radius α(i) decreases linearly i(γ(0) = 3) and eventually 
become zero and T is the maximum number of iterations (Korol, A.B., 2003, Tamayo et al. 
1999).  
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Figure 8: Principle of SOMs (Tamayo et al. 1999). 
 Initial geometry of nodes in 3*2 rectangular grids is indicated by solid lines connecting the nodes. Hypothetical trajectories 
of nodes as they migrate to fit data during successive iterations of SOM algorithm are shown. Data points are represented by 
black dots, six nodes of SOM by large circles, and trajectories by arrows. 
Hierarchical clustering: As the name indicates hierarchical clustering uses a progressive 
combination of elements that are most similar and clustered them into higher order as 
dendrograms. Different experimental conditions can be clustered based on genes expression 
and different genes also can be clustered based on their expression values in different 
experimental conditions. Then different cluster can also be clustered by an inter-cluster 
distance to make a higher level cluster. So unlike k-means clustering, one can deduce the 
relationship between different clusters based on their distance from the root, i.e. closer the 
clusters are from the roots more similar they are. The hierarchical clustering are built based 
on two approaches top-down and bottom-up. In bottom-up method first the distance between 
all data points are calculated based on the different distance calculation algorithms described 
before to cluster the data points into the initial cluster. Next the distances between different 
clusters are calculated and the processes continue to group most similar clusters into higher 
level clusters. The formalism of top-down algorithm is quite reverse that bottom-up method. 
First all the data points are considered to be a part of a super cluster in the top-down 
approach. Next cluster is divided into two clusters by applying k-means clustering (k=2). 
This process is repeated until reaching cluster contains only one data point (Obulkasim & van 
de Wiel 2015) 
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Figure 9: Hierarchical clustering based on gene expression of microarray data 
(Ducray et al. 2008). 
Figure 9 demonstrates A typical example of application of hierarchical clustering using microarray data in cancer research. 
The analysis was completed on 4 oligodendrogliomas with 1p19q codeletion and 9 gliomas with EGFR amplification. 
Unsupervised hierarchical clustering was performed using the 1366 probe sets whose expression varied the most across the 
13 samples (probe sets with a robust coefficient of variation superior to the 97.5th percentile). 1p19q = 1p19q 
codeletion, EGFR = EGFRamplification. The gliomas were classified into 2 groups according to their genomic profile. 
Gliomas with EGFR amplification were classified into one cluster irrespective of their histology (red = glioblastoma, green = 
grade III oligodendroglioma, blue = grade III oligoastrocytoma). Gene cluster A was enriched in genes involved in 
proliferation, extracellular matrix, immune response, embryonic development and angiogenesis. Gene cluster B was enriched 
in genes involved in synaptic transmission. Gene cluster C was enriched in genes involved in neurogenesis and synaptic 
transmission. 
 
2.1.3.3. Classification algorithms 
The supervised clustering or classification algorithms are developed to assign objects to 
predetermined classes. Supervised methods generally involve the use of a training data set 
and an independent validation data set. The aim is to obtain a function or rule that uses 
expression data to predict its class. In cases where the dataset is too small to be effectively 
split, a cross-validation method such as leave-one-out or class permutation procedure is often 
used. Classification algorithms are also widely applied to analyse gene expression data with 
the aim either to discover new categories within the dataset or to assign classes to a given 
category. Genes or samples are classified into specific groups based on the values of a set of 
computed variables by unsupervised clustering. Typically genes are grouped into classes 
based on the expression profiles in different biological conditions. In the next section state of 
art classification algorithms which are predominantly used for the analysis of microarray 
experiment are described in detail.  
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Linear discriminant analysis (LDA): Classical LDA projects the data onto a lower-
dimensional vector space such that the ratio between classes distances is maximized, thus 
achieving maximum discrimination between classes. The objective is to classify unknown 
samples into one of the k classes nk training samples per class, k = 1, 2, 3, …, K with m genes 
in each microarray. For each training sample, we observe class membership Y. and 
expression profile X. For simplicity, the classes has been represented by the numbers 1, 2,..., 
K. Note that each expression profile is a vector of length m. We assume that expression 
profiles from class k are distributed as N (µk, ∑), the multivariate normal distribution with 
mean vector µk and covariance matrix ∑. Call L(µk, ∑) the corresponding probability density 
function. Finally, we agree upon prior probabilities πk that an unknown sample comes from 
class k, k = 1, 2,..., K (Dabney 2005).  
Bayes’ theorem states that the probability of a sample comes from class k, given that 
sample’s expression profile, is proportional to the product of the class density and prior 
probability (Dabney 2005):  
Pr (Y = k|X=x) ∞ L (x; µk, ∑) * πk 
We call Equation (n) the posterior probability that array x comes from sample k. LDA assigns 
the sample to the class with the largest posterior probability (Dabney 2005):   
Ŷ = arg maxk {L(x; µk, ∑)* πk}  
 
Prediction analysis of Microarray (PAM): PAM is an application of LDA based classifier for 
microarray analysis. PAM applies nearest shrunken centroids for class prediction. Let aij be 
the expression of genes i = 1, 2,…, K and let Ck be indices of the nk samples in class k. The i
th
 
component of the centroid for class K is āik = ∑ 𝑎𝑖𝑗/𝑛𝑘𝑗∈𝐶𝑘 . Then the i
th
 component of the 
overall centroid is āi = ∑ 𝑎𝑖𝑗/𝑛
𝑛 
𝑗=1    Hence the class centroids shrink towards the overall 
centroids after standardizing by the within-class standard deviation for each gene. This 
standardization has the effect of giving higher weight to genes whose expression is stable 
within samples of the same class (Tibshirani et al. 2002) .  
dik = 
āik−𝑎𝑖
𝑚𝑘(𝑠𝑖+𝑠0)
 
Where si is the pooled within-class standard deviation for gene i: 
48 
 
si
2
 = 
1
𝑛−𝐾
∑ ∑ (𝑎𝑖𝑗 − āik)
2
𝑗∈𝐶𝑘𝑘  
and mk = √
1
𝑛𝑘
+
1
𝑛
 makes the mk.si equal to the estimated standard error of the numerator in 
dik. In the denominator, the value s0 is a positive constant (with the same value for all genes), 
included to guard against the possibility of large dik values arising by chance from genes with 
low expression levels. s0 is set to equal the median value of the si over the set of genes. Thus 
dik is a t statistic for gene i, comparing class k to the overall centroid.  
āik =  ā + mk(𝑠𝑖 + 𝑠0)𝑑𝑖𝑘 
The PAM method shrinks each dik toward zero, giving d
'
ik and yielding shrunken centroids or 
prototypes.  
āik′
 = āi + 𝑚𝑘(si + s0) 𝑑𝑖𝑘′
 
 
 Support vector machine (SVM): SVM is supervised machine learning analysis as the 
method uses prior knowledge to assign the class of a test set. The key idea behind the SVM is 
the concept of decision plane which defines decision boundaries to separate a set of objects 
into a different class. In doing that the algorithm often constructs hyperplanes in multi-
dimensional space in separating multiple classes. Often mathematical functions or kernels are 
applied to transform a non-linear decision tree into a linear one. The mathematical features of 
SVM i.e. flexibility in choosing a similarity function, sparseness of solution when dealing 
with large data sets, the ability to handle large feature space have made extremely popular 
method for analysing microarray data (Rojas et al. 2009). 
  
Decision Tree: Decision tree is essentially a classifier that classifies the data by posing a 
series of question about the features associated with the data. Each question is designated to a 
node and every internal node points to a child node for each possible answer to its question. 
The questions represented as hierarchy and encoded as a tree and that is why the classifier is 
called “decision tree”. An item is sorted into a class by following the path from the topmost 
node i.e. the root to a node without children called a leaf. The item is assigned the class of the 
leaf it reaches. In certain variations, each leaf contains a probability distribution over the 
classes that estimate the conditional probability that an item reaching the leaf belongs to a 
given class. Decision trees are grown by adding question nodes incrementally by using 
labelled training examples to guide the choice of questions. A good question will split a 
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collection of items with heterogeneous labels, stratifying the data in a way that there is little 
variance in each stratum. The most common measures to evaluate the impurity within a 
decision tree are entropy and Gini index. Let assume that we are building a classifier based 
on the decision tree using a set of E training items into m classes. Suppose pi (i=1, …., m) be 
the fraction of items of E that belong to class i. The entropy of the probability distribution 
(pi)
m
i=m gives a reasonable measure of the impurity of set E. The entropy, -∑ pi
𝑚
𝑖=1 𝑙𝑜𝑔𝑝𝑖 is 
the lowest when a single pi equals 1 and all others are 0. But it is maximized when all pi are 
equal. The Gini index is computed as 1- ∑ 𝑝𝑖2
𝑚
𝑖=1
. The Gini index will be 0 when the set E 
contains items from only one class. Given a measure of impurity I, we choose a question that 
minimizes the weighted average of the impurity of the resulting children nodes. That is, if a 
question with k possible answers divides E into subsets E1, …, Ek; we choose a question to 
minimize ∑ (|𝐸𝑗|/|𝐸|)𝐼(𝐸𝑗)
𝑘
𝑗=1  (Kingsford & Salzberg 2008).  
Random Forest: Random forest method is an application of the Decision Tree model based 
on the generation and comparison of an ensemble of trees. RF works as a large collection of 
uncorrelated decision trees. It applies bagging to construct a collection of decision trees 
aiming at identifying a complete set of significant features. After many decision trees are 
generated the class assignment goes with the most predominant assigned class by those trees.  
Given an ensemble of classifiers h1(x), h2(x), . . . , hK(x), and with the training set drawn at 
random from the distribution of the random vector Y, X, define the margin function as: 
mg(X,Y) = ask I(hk(X) = Y) - max avk I(hk(X) = j) 
Where I(·) is the indicator function. The margin measures the extent to which the average 
number of votes at X, Y for the right class exceeds the average vote for any other class. The 
larger the margin, the greater is the confidence in the classification. The generalization error 
is given by: PE∗ = P X,Y (mg(X,Y) < 0)  
Where the subscripts X, Y indicates that the probability is over the X, Y space. (Breiman 
2001, Enot et al. 2006)  
2.1.4. Challenges of biomarker discovery 
The described data mining algorithms have been instrumental in identifying biomarkers in 
different forms of cancer. However, comparing the number of approved biomarkers to those 
mentioned in the public domain reveals that majority of candidate biomarkers either failed or 
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did not reach the clinic yet. Even in the case of strong signal derived from analysis of high 
throughput data by data mining algorithms, its conversion to clinical practice meets with 
challenges of accurate functional interpretation. The interpretation of the high throughput 
data in the context of molecular pathophysiology of an underlying disease and specific 
treatment is the current rate-limiting step in the biomarker identification and validation. If 
properly identified, extracted and interpreted; OMICS datasets can provide valuable 
biological insights. Functional analysis of OMICS data requires knowledge of the molecular 
interactions and pathways underlying pathophysiology of diseases as well as the treatment’s 
mode of action. Accumulated biological knowledge across different system’s levels therefore 
needs to be collected, annotated, transformed into computer-readable form and stored in a 
semantically enhanced knowledge base. Such knowledge bases can then be used for 
knowledge-based analysis of OMICS datasets through integrative approaches that aim at 
finding key biological processes, pathways, interaction modules or causative network 
signatures that could be used as candidate biomarkers (Deyati et al. 2013). In the next section, 
the development and analytic view of existing knowledge bases have been presented. The 
focus will be on the interpretation of functional role of promising candidate biomarkers after 
statistical analysis of gene expression data. The emphasis will also be on biomarker 
identification in the scientific literature and the state-of-art knowledge representation 
techniques for modelling and mining approaches.     
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3. Knowledge Management for 
Biomarker Discovery 
The mission of knowledge bases is to collect and systematize biomedical information through 
manual information extraction from primary publications in so-called curation process. The 
curation process organises knowledge via mapping of extracted information to an underlying 
ontology. Such knowledge bases provide a number of features for analysis of expression data 
by overlying the data onto the known pathways. Identification of the key affected pathways 
within the expression data followed by network analysis can potentially identify key 
regulatory molecules behind the respective gene signatures. The functional interpretation of 
microarray starts with the identification of genes with characteristic biological function. 
National Centre for Biotechnology Information (NCBI) developed and maintained Entrez 
Gene database which provides unique identifiers for gene and associated biological function. 
The database also provides links to external databases dedicated for the biological function 
and pathway association of the gene i.e. Gene Ontology (GO), KEGG, Reactome.  
3.1. Gene ontology  
In 2000, The Gene Ontology Consortium (http://geneontology.org/) was established with the 
mission to provide a controlled vocabulary for annotating homologous genes and proteins 
across organisms. Genes and its products are classified into three hierarchical structures to 
describe associated biological processes, cellular components and molecular functions 
(Ashburner et al. 2000)]. Quite a few bioinformatics analytical tools i.e. MAPPFinder 
(Doniger et al. 2003), GoMiner (Zeeberg et al. 2003)], Onto-Express (Draghici et al. 2003)] 
have been developed to functionally interpret high throughput data with the knowledge from 
Gene Ontology (GO).  
However the complex biological relationship of genes, proteins and their interactions can be 
oversimplified by annotating them into categories of GO. Protein-protein interaction 
databases and Pathway databases are more potent representation of the biological systems in 
its entirety. So interpreting microarray data in terms of over or under expressed biological 
pathways leading to certain phenotypes, can better reflect systems behaviour in different 
experimental conditions. Nevertheless, GO contains a systematic hierarchical nomenclature 
of genes and proteins which has played a vital role for batch processing and future design of 
pathway databases (Tsui et al. 2007).    
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3.2. Proteins-protein interaction (PPI) 
databases 
Ever increasing number of publications in biology provides a great source to screen 
molecular interactions in human and in other model organisms. However, the actual 
challenge lies in retrieving those interactions from the literature and deciphering the 
dynamics of the interaction network. In recent years, great amount of effort has been 
undertaken to construct the several proteins-protein interaction (PPI) database described in 
Table 3.  
Database Properties 
Intact 
(Orchard et 
al. 2014) 
 Manually curated or user submitted PPIs. 
 Knowledge of experimental details, such as the 
experimental technology used, cellular context, protein 
modifications, expression systems, and a confidence value 
is added to each interaction.  
 Interactions can be downloaded in MI-Tab, MI-XML, 
BioPAX, XGMML, RDF format for visualization in 
different software.  
 MINT database has been merged with Intact.  
 Currently contains 87,006 interactors having 529,495 
interactions.  
HPRD 
(Keshava 
Prasad et al. 
2009) 
 Manually curated PPI database based on experimental 
evidence.  
 Knowledge on post translational modification, tissue 
expression, subcellular location, domain architecture, 
disease association is added to each interaction.  
 Interactions can be downloaded as XML or tab delimited 
format.  
 Currently contains 30, 047 proteins having 41,327 
interactions. 
DIP 
(Xenarios et 
al. 2000) 
 Manually curated as well as automatically extracted 
experimentally validated PPIs.  
 Knowledge on protein-protein relationship, properties of 
interacting networks, evaluation of PPIs have been added.  
 The interactions can be downloaded as native XML based 
XIN format, tab delimited format and Molecular Interaction 
Format (MIF) 
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 Currently the database contains 27,701 proteins having 
79,339 interactions.  
BioGrid 
(Stark et al. 
2006) 
 A manually curated protein and genetic interaction 
database. 
 Knowledge on organism specificity, proteins function and 
interaction detection technology has been added.  
 Data can be downloaded in tab delimited and PSI-MI XML 
format.  
 Currently the database holds 557,106 unique interactions 
from 56,907 proteins.    
MINT  
(Licata et al. 
2012) 
 A manually curated and experimentally validated molecular 
interaction database.  
 MINT was one of the first interaction databases to score 
each interaction reflecting its reliability.  
 Interaction data can be downloaded as PSI-MI XML format.  
 As of 2011, 235,000 binary interactions were stored in the 
database.      
STRING  
(Szklarczyk 
et al. 2014) 
 Curated as wells as predicted PPI database.  
 The database contains both physical and functional 
interactions from four sources i.e. genomic context, high-
throughput experiments, co-expression and manual curation 
of published articles.  
 Each interaction has been scored and organism specific 
interactions can be screened. The proteins have been 
annotated with its structure and function.  
 Currently STRING database covers 9,643,763 proteins from 
2,031 organisms.  
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BIND  
(Bader et al. 
2003)  
 Biomolecular interaction database Network or BIND 
archives PPIs screened through yeast two hybrid, mass 
spectrometry, genetic interactions and phage display.  
 The BIND data now has been incorporated within 
Biomolecular Object Network Databank (BOND).  
 The PPIs and interaction network with BOND can be 
visualized within Cytoscape.  
Table 3: Protein-Protein interaction data bases 
3.3. Pathway databases  
In the past decades of research has led to the understanding of the protein-protein interactions 
(PPIs) within cells in different physiological conditions. But individual PPI cannot elucidate 
how cell collectively responds to cues in their internal or external environment. In addition, 
the discovery of the connections between each of these components promoted the 
reconstruction of the chain of reactions, which subsequently give rise to a signaling pathway. 
Ultimately, our ability to interpret the function and regulation of cell signaling pathways is 
crucial for understanding the ways in which cells respond to external cues and how they 
communicate with each other (Bauer-Mehren et al. 2009)]. So building pathways and its 
databases is an important milestone in the quest of functional interpretation of expression 
data. In the next section (Table 4) the most crucial open source pathway databases are 
discussed.   
Pathway 
Databases 
Description 
KEGG  Established in 1995 Kyoto Encyclopedia of Genes and Genomes 
(KEGG) contains manually assembled pathway maps based on the 
duration of published literature.  
 KEGG pathways can be grouped together into five categories 
namely metabolic pathways, Cellular processes, Genetic 
information processing pathways, Environmental processing 
pathways and pathway for human diseases.  
 Most of the cancer associated pathways fall into the category of 
environmental information processing group. This section is 
further grouped together into membrane transport, signal 
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transduction and signaling pathways.  
 Other than human pathways, KEGG also contain pathways for 
other model organisms like rat, mouse, chimpanzee, cow and pig.  
 The granularity, hierarchy and graphical representation as well as 
annotation of the nodes of all the KEGG pathways are stored in 
KEGGML (KEGG Markup Language) format.   
(Kanehisa & Goto 2000)  
Reactome   Reactome is a manually curated peer reviewed pathway database 
based on published literature. It was established in 2003 in 
collaboration with European bioinformatics institute, Ontario 
Institute of Cancer Research and New York University of Medical 
Center. 
 Human pathways are hierarchically structured into following 
categories: cell cycle, cell-cell communication, cellular responses 
to stress, chromatin organization, circadian clock, developmental 
biology, disease, DNA repair, DNA replication, extracellular 
matrix organization, Hemostasis, Immune System, metabolism, 
metabolism of proteins, muscle contraction, expression, neuronal 
system, organelle biogenesis and maintenance, programmed cell 
death, reproduction, signal transduction, trans membrane transport 
of small molecules, vesicle-mediated transport.   
 Other than human pathways, Reactome contain pathways from 18 
different organisms.  
 Reactome is open-source, open-data and have continuously 
supported the major open-data standards in the domain; including 
BioPAX levels 2 and 3, PSI MITAB, SBML-ML (25) and SBGN 
export format (Croft et al. 2014). 
BIOCARTA 
Pathways 
 Biocarta pathway is an open source, community fed pathway 
database maintained within Biocarta. Human and mouse Pathways 
are manually curated from the scientific literature.  
 Pathways are clustered into developmental biology, expression, 
hematopoiesis, immunology, metabolism and neuroscience.  
(Diez et al. 2010) 
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Pathway 
Interaction 
Database 
 Pathway interaction database is a collection of human signaling 
and regulatory pathways curated from peer-reviewed literature 
with a focus on cancer pathways. Since its inception in 2006, the 
database has been created in collaboration between US national 
cancer institute and Nature Publishing group.  
 The database was designed to deal with two issues affecting the 
pathway representation i.e. the arbitrariness of pathway boundaries 
and the need to capture knowledge at different levels of details.   
 The database is open-source, open-data and has continuously 
supported BioPAX levels 2 and XML format (Schaefer et al. 
2009).  
Table 4: Open source pathway data bases 
As the protein-protein interaction and pathway databases started to grow, a surge for software 
systems providing statistical analysis of the gene expression data followed by functional 
interpretation was imminent. Capturing the trend several public and commercial knowledge 
bases have been introduced that offer an integrated environment consisting of an annotated 
knowledge base and analytical tools to analyse gene expression data. The aim is to perform a 
full-fledged statistical analysis with GUI following functional interpretation. Overviews of 
knowledge bases summarizing their main features as well as published examples of their 
application in biomarker discovery are discussed in next section. 
 
3.4. Integrated software systems for analysis 
and interpretation of expression data  
3.4.1. Metacore 
Metacore is an integrated commercial knowledge base from Thomson Reuters (previously 
GeneGo) which can support functional analysis (pathways, networks and maps) of OMICS 
data including microarray, sequence based gene expression, SNPs and CGH arrays, 
proteomics and metabolomics. It can rank the affected pathways and networks from the 
experimental date based on proprietary algorithms. The tool has also got filters based on 
disease, tissue, sub cellular localization and functional processes to capture specific network. 
The toxicology application of Metacore is specifically designed to discover safety, efficacy 
and toxicity biomarker to a chemical compound. (see: 
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http://www.genego.com/metacore.php). Brentnall et al. in collaboration with Institute of 
Systems Biology completed a quantitative proteomic analysis to investigate differentially 
expressed proteins associated with ulcerative colitis (UC) neoplastic progression. Functional 
analyses of differentially expressed proteins with Metacore software identified Sp1 and c-
MYC as biomarkers of early and late stage of UC tumorigenesis.  The same collaborative 
group made an ICAT-based quantitative proteomics research to analyze protein expression in 
chronic pancreatitis in comparison with a normal pancreas. Metacore assisted pathway 
analysis revealed that c-MYC as a prominent regulator in the networks of differentially 
expressed proteins common in pancreatic cancer and chronic pancreatitis. Another 
collaborative group with Bayer Schering Pharma discovered the functional link between the 
KRAS mutation and Erlotinib resistance in non-small cell lung carcinoma (NSCLC). The 
functional analysis of RNA expression data with Metacore indicated a possible correlation 
between differential expressions of cell adhesion proteins to NSCLC (Brentnall et al. 2009, 
Chen et al. 2007, Fichtner et al. 2008). 
3.4.2. IPA 
IPA is a manually curated commercial knowledge base from Ingenuity systems (now a part of 
Qiagen).  Its biomarker filter is specialized to prioritize the molecular biomarker based on 
species specific connection to diseases, detection in body fluid, expression in specific cell 
type, cell line, clinical samples and also in stratification biomarker discovery based on 
disease state or drug response. The tool also can produce functional annotation of the 
biomarker including pathway association (see: 
http://www.ingenuity.com/science/knowledge_base.html). Using Ingenuity pathway analysis 
Merck & Co predicted and then experimentally validated that phospho-PRAS40 (Thr246) 
positively correlates with PI3K pathway activation and AKT inhibitor sensitivity in PTEN 
deficient mouse prostate tumor model and triple-negative breast tumor tissues. Bristol-Myers 
Squibb has analyzed gene expression signature of responders and non-responders to 
neoadjuvant ixabepilone therapy in breast cancer. Functional analysis of the data with IPA 
has indicated that significant deregulation of certain proliferation and cell cycle control genes 
can potentially predict treatment sensitivity. Cleveland clinic reported a functional analysis 
with IPA of the genes carrying non synonymous SNPs that may be associated with the 
severity of sunitinib-induced toxicity in metastatic clear cell renal cell carcinoma. As per the 
functional analysis those genes clustered around biological processes like interferon gamma, 
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TNF alpha, TGF beta 1 and amino acid metabolism molecular pathways (Andersen et al., 
2010; H. Chang, C. E. Horak, P. Mukhopadhyay, C. Lowery, 2011; P. W. Faber et al 2008).   
 
3.4.3. Pathway Studio 
Pathway Studio is commercial software from Ariadne Genomics (now Elsevier) for pathway 
analysis as well as analysis of high throughput OMICS data. It is based on proprietary 
databases from Ariadne like ResNet, DiseaseFx, ChemEffect, Mamalian and Plant database 
to build relationships between biomolecules and design pathways. The databases are built 
based on proprietary NLP based relationship extraction from scientific literature. The 
software suite also provide state of the art network algorithm to indicate important nodes 
from the network perspective.  The researcher can also put weightage on each relationship in 
the pathways based on the number of literature evidence (see: 
http://www.pathwaystudio.com/). A group from Harvard Medical School published 
functional connection of 117 highly differentially expressed genes to endometrial cancer. 
Pathway Studio assisted analysis of the data predicted that many of these genes are correlated 
to angiogenesis, cell proliferation and chromosomal instability. Furthermore, they also 
reported 10 key differentially regulated genes to be associated with tumor progression. Xiao 
et al. published functional analysis of EGFR regulated phosphorproteome in nasopharyngeal 
carcinoma (NPC) to shed light on EGFR downstream signaling. They first identified 33 
unique phospho proteins by 2D-DIGE and mass spectrometry. Based on the proteomic data 
the group built EGFR signaling in NPC by using Pathway Studio and also validated GSTP1 
as one of the key EGFR-regulated proteins which is involved in chemo-resistance in NPC 
cells (Wong et al. 2007; Ruan et al. 2011). 
3.4.4. Oncomine 
Oncomine was originally developed under Compendia bioscience (now a part of Thermo 
Fisher Scientific). At the moment, the service is limited to breast and colon cancer (see: 
http://www.compendiabio.com/). Using Oncomine a group from the University of Michigan 
predicted that decreased protein expression of Raf kinase inhibitor protein (RKIP) is a 
prognostic biomarker in prostate cancer. Another group from the same University predicted 
that high expression of EZH2 and ECAD was statistically significantly associated with 
prostate cancer recurrence after radical prostatectomy (Fu et al. 2006; Rhodes et al. 2003).  
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3.4.5. NextBio 
NextBio (now a part of Illumina) has got two major components namely NextBio clinical and 
NextBio research described as follows. NextBio Clinical involves semantic based integration 
of the proprietary OMICS data with public knowledge to get better insight further leading to 
discovery of drug targets and biomarkers. NextBio Research can specially identify crucial 
pathways leading to a disease phenotype supported by cross studies and multiple data points.  
The tool also elucidates the identification of disease biomarker and analysis of 
pharmacokinetic profiles or toxicity indications. NextBio uses proprietary algorithms to rank 
the search outcomes based on the statistical significance of the correlation supported by 
biological data points (see: http://www.nextbio.com/b/nextbioCorp.nb).  Using the NextBio 
platform Walia et al. reported that loss of breast epithelial marker hCLCA2 (chloride channel 
accessory protein) promotes higher risk of metastasis (Walia et al. 2012).     
3.4.6. BEL and Reverse Causal Reasoning  
Selventa introduced a proprietary technology called Reverse Causal Reasoning (RCR), a 
proprietary technology introduced by Selventa. It is a computational methodology for the 
interpretation of large-scale biological datasets (microarray, RNA-Seq, 
proteomic/phosphoproteomic and metabolomic) designed to compare different biological 
states (e.g., treated versus control, diseased versus normal or time course and dose analyses). 
RCR is an automated reasoning technique to generate novel hypothesis by processing 
networks of causal relationships. The generated hypotheses are also evaluated by the tool 
against the available data sets of differential measurements. Next, each hypothesis links a 
biological entity to measurable quantities that it can influence. RCR analysis attempts to 
answer the question “What signaling differences could lead to the observed differences in 
measured quantities?” As a reference for reasoning, RCR uses a network data structure called 
a Knowledge Assembly Model (KAM). KAM is a directed network of experimentally 
validated causal interactions between biological entities (e.g., mRNAs, protein activities, 
chemicals, processes). The causal relationships within a KAM are encoded as BEL 
(Biological Expression Language) statements. BEL was developed with the aim to support 
biological knowledge curation by providing qualitative causal inference using large data sets. 
Within a KAM causal edge from A to B represents prior scientific knowledge, asserting that a 
change in A was demonstrated to cause a change in B in one or more controlled experiments 
supported by a specific citation (Selventa 2011). The platform has enabled the discovery of 
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predictive response biomarkers by reverse engineering disease mechanisms a priori from 
molecular patient data (OMICS data). It identifies disease- and tissue-specific biomarker 
content that can match targeted therapies to sub-population of patients. Reverse Causal 
Reasoning (RCR) algorithm is used for identification of master regulators. Very recently, 
Selventa has introduced its open BEL framework for biomarker discovery based on 
mechanistic causal reasoning and demonstrated its application in stratifying responders to 
ulcerative colitis drug, infliximab, from non-responders based on identification of IL6 as the 
biomarker for alternative disease mechanisms in non-responders (Mal et al. 2012).    
3.4.7. transMART 
A knowledge management platform enabling integration of the OMICS data with published 
literature, clinical trial outcome and established knowledge from Metacore, Ingenuity IPA 
and NLM resources. The applications of this platform include making novel hypothesis, 
validating them, disease association of certain pathways, genes, SNPs and biomarker 
discovery. Analysis of transcriptomic data from melanoma patients using k-means clustering 
facility in tranSMART showed that the expression levels of cyclin D1 increase from benign 
to malignant whereas in metastatic melanomas the expression level decreases, clearly 
delineating multiple subgroups of samples in the presumably homogenous metastatic 
melanoma cohort (Szalma et al. 2010). 
3.4.8. KeggArray 
A microarray gene expression and metabolomics data analysis tool from KEGG. It is able to 
map OMICS data to KEGG Pathways, Brite and genome maps (see: 
http://www.kegg.jp/kegg/download/kegtools.html). KeggArray was used to investigate 
metabolic pathways associated with the marker metabolites that were detected by two-
dimensional gas chromatography mass spectrometry in tissues from 31 patients with 
colorectal cancer. The results led to the identification of chemically diverse marker 
metabolites and metabolic pathway mapping suggested deregulation of various biochemical 
processes (Mal et al. 2012). 
 
Although all these databases contain manually curated knowledge, their differences in the 
coverage and granularity of the information reflects underlying differences in methodology of 
information retrieval, variability of the resources used for knowledge extraction as well as the 
difference in interpretation of the experimental results by the annotators. Shmelkov et al. 
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have recently carried out a comparative analysis on quality and completeness of human 
regulatory pathways among ten public and commercial pathway knowledge bases and found 
that surprisingly there is little overlap in the knowledge content of these databases (Shmelkov 
et al. 2011a). The authors reported that the only exception was the MetaCore pathway 
database whose content was validated in 84% of the cases with experimental results, 
compared to the low overlap of 24% obtained from KEGG database.  
Beside the issue of coverage and quality, the lack of consistent standard scheme for 
biomarker classification and biomarker knowledge representation hampered literature 
searches about biomarkers. The fact that qualification of translational biomarkers requires a 
wide range of information on the level of sensitivity, specificity, the mechanisms of action, 
toxicity, and clinical performance, emphasizes the need for standardization of biomarker 
vocabularies and classification. Recently, a prototypical process has been suggested to ensure 
qualification of biomarkers based on seven types of scientific evidence (Altar et al. 2008). 
Similarly, the Pistoia Alliance, established by information experts from several 
pharmaceutical companies, has launched a project focused  on developing ontological and 
data standards for integrating biomarker assay data and handling different endpoints [see: 
http://www.pistoiaalliance.org/]. Although in their nascent stages, such developments can 
form the basis for future biomarker standardization efforts. Therefore, next-generation 
knowledge bases should address above challenges by introducing efficient information 
retrieval/extraction tools as well as biomarker data standards (Deyati et al. 2013). Taken all 
together, there are both advantages and disadvantages associated with existing knowledge 
bases, which are summarized as in Table 5. 
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Advantages Disadvantages 
Evidence-supported data content Poor annotation of metadata  
Structured data representation Lack of standard representation model  
Enhanced retrieval and retention of 
information 
Lack of flexible filtering criteria 
Focused semantic context  Divergent in content and subject focus 
Table 5: Summary of cons and pros of biomarker-related knowledge bases (Deyati 
et al. 2013). 
 The resolution and quality of knowledge bases are largely dependent on the granularity of 
the underlying ontology, quality of data retrieval and experience of annotators. Creation and 
maintenance of manually curated knowledge bases is becoming a tremendous task in times of 
ever accelerating speed of publication growth different from the slow steady process of 
manual curation. For example, a recent report shows that assembling a compendium of 
potential biomarkers for pancreatic cancer, which was carried out by systematic manual 
curation of the literature, took over 7,000 person hours (Harsha et al. 2009). In the absence of 
automated methods for retrieval of biomarker information, the slow pace of manual curation 
cannot guarantee that the current content of knowledge bases is comprehensive and sufficient 
for functional interpretation of OMICS data. Novel high throughput text-mining approaches 
are essential for automated biomarker knowledge processing. In the next section we describe 
automated biomarker information retrieval methods that can be used in support of systematic 
update of knowledge bases and acceleration of the biomarker-related information extraction 
from the unstructured text (Deyati et al. 2013). 
3.5. Text-mining for identifying biomarker 
related information 
To accelerate the speed of curation process, emerging state-of-the-art information retrieval 
and extraction technologies are under active development. Such tools are being powered by 
text-mining algorithms that automatically recognize potential biomarkers such as genes and 
proteins in text by a process called ‘named entity recognition’ or NER (Pennings et al. 2009). 
However, existing NER approaches are not sufficiently selective for the retrieval of 
biomarker-related content information (such as its association with drug or disease) from the 
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literature. Consequently, studies on biomarker relation extraction from text are considered on 
the basis of semantic relations between named entities such as the relation between diseases 
and genes or proteins (Bundschus et al. 2008). Some efforts have been recently dedicated to 
mining and extraction of such relationships using semantically enhanced methods (Jessen et 
al. 2012). One limitation of these approaches is that they do not consider additional properties 
of candiadate biomarker, such as measurement evidence and technique besides disease and 
gene names. In an attempt to overcome this limitation, Ongenaert and Dehaspe (2010) have 
employed different keyword lists containing terms that specify methylation biomarkers in 
cancer and used them in conjunction with gene names from GeneCards to generate the 
methylation database in cancer, PubMeth (Ongenaert et al. 2008; Deyati et al. 2013).  
As a step in this direction, we have recently developed a dedicated biomarker terminology 
organized in six proposed classes and used it for information retrieval and extraction of 
biomarker knowledge embedded in the literature (Younesi et al. 2012). It was demonstrated 
that the application of this dedicated biomarker terminology could enhance the retrieval 
performance significantly through combined search for cancer-related genes and selected 
classes of the biomarker retrieval terminology. Further evaluation of this terminology in an 
independent disease area, namely Alzheimer’s disease, showed that not only well-known 
biomarkers were retrieved successfully but also new biomarker candidates could be 
identified. Integration of such terminologies into search tools supporting semantic and 
ontological search can reduce the high number of unspecific search results and improve the 
retrieval rate of informative documents (Deyati et al. 2013). 
Ultimately, context-sensitive biomarker information extracted from literature can be used for 
automated enrichment of knowledge bases and/or combined with OMICS data may generate 
a basis for integrated models of disease or and drugs mode of action with the aim of 
prospective prediction of candidate biomarkers (Butcher et al., 2004). 
3.6. Knowledge representation 
Currently, research within biology rapidly generates new knowledge on how genes, proteins 
and other substances interact. A complete description of the protein interaction network 
underlying cell physiology is seen as one of the major goals for proteomics by the Human 
Proteome Organization. The US National Human Genome Research Institute recognizes the 
understanding of genetic networks and protein pathways as crucial parts for two out of three 
important areas outlined for future genomics research. In particular, the understanding of how 
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pathways contribute to the function of the cells and organisms, and the development of 
therapeutic approaches to diseases based on this knowledge are stated as two of the grand 
challenges for future research. They also recognize the development for reusable software 
modules, new ontologies and improved technologies for database and knowledge 
management as means for finding solutions to these challenges in the future. To fulfill this 
vision a format for representation of molecular pathways that allow for exchange, integration 
and easy creation of software tools are needed. Evaluations have shown that XML is an 
interesting and easy-to-use format for information representation and recent XML-based 
exchange formats for pathway information, e.g. SBML, PSI MI and BioPAX (BioPAX 
working group, 2004, http://www.biopax.org), have been proposed (Strömbäck & Lambrix 
2005). 
3.6.1. BioPAX 
Biopax or Biological Pathways Exchange is a standard language with the aim to integrate, 
exchange, visualize and analyze biological pathway data at the cellular or molecular level. 
BioPAX is an open collaborative effort that supports data exchange between pathway data 
groups and thus reduces the complexity of interchange of pathways by standardizing pathway 
data format. BioPAX is defined in OWL DL and represented in RDF/XML format. The 
progress of BioPAX is defined as levels and currently three levels are available. Level 1 
focus on standardizing the metabolic network, level 2 adds molecular interaction network and 
the most recent level 3 deals with genetic interaction and signal transduction. Prote'ge' is 
widely used for viewing and editing of BioPAX ontology. In BioPAX all objects are 
described in a class hierarchy with Entity as the most general class. Figure 10 shows the 
BioPAX hierarchy when loaded in Prote'ge'. Entity has three subclasses PhysEntity, 
representing the interacting objects; Interaction, representing the interactions and Pathway, 
representing a set of interactions that together form a pathway model. PhysEntity has five 
subclasses, complex, protein, DNA, RNA and small molecule, describing different kinds of 
objects that may interact. There is a large number of subclass for interaction. To unify 
concepts and entities between data sources containing the same or similar information about a 
biological phenomenon, it is possible to provide cross reference in BioPAX format (Demir et 
al. 2010). 
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Figure 10: The hierarchical structure of BioPAX data format (Strömbäck & Lambrix 
2005). 
Demonstrating the , BioPAX hierarchy of “physical entities”, their “interaction” within a living biological systems.  
3.6.2. PSI MI 
Proteomic Standard Initiative (PSI) was developed in 2002 at the HUPO meeting aiming two 
key areas of proteomics field i.e. mass spectrometry and protein-protein interaction data. The 
scope of PSI MI (Proteomic Standard Initiative for Molecular Interactions) is to exchange 
protein-protein interaction data. The root element of any PSI MI XML is an entry set. One or 
more protein-protein interactions are grouped together as an entry set based on a common 
reason. Each entry is a self-contained unit with six descriptions namely source, availability 
list, experiment list, interactor list, interaction list and attribute list.  There are two forms for a 
PSI MI format i.e. a compact and expanded form. In the compact form, all interactors 
(proteins), experiments and availability statements are described once in the respective list 
elements, and then only referred to by references from the individual interactions in the 
interaction list. The expanded form contains all proteins, experiments and availability 
statements which are described directly in the interaction elements. In PSI MI the source of 
the data can be either a database or a publication. Each interaction can be specified with a 
type of interaction i.e. aggregation, binding, phosphorylation etc. It is also possible to set a 
confidence level for detecting this protein in the experiment, the role of the protein and 
whether the protein was tagged or over-expressed in the experiment (Strömbäck & Lambrix 
2005). An example of PSI MI format is provided in Figure 11. 
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Figure 11: Example of PSI MI data format (Strömbäck & Lambrix 2005). 
 
The BioPAX and PSI MI are designed for data exchange to and from databases, pathways 
and network data integration. Dynamic and quantitative aspects of biological processes, 
including temporal aspects of the feedback loops are not supported with those two data 
formats. Data format like SBML, CellML are created to support kinetic behaviour of 
biological systems and SBGN represents pathway diagrams.   
3.6.3. SBML 
Systems Biology Markup Language or SBML is an open interchange format for computer 
models of biological processes such as metabolism, cell signalling, gene regulatory network 
and infectious diseases. Currently there are three levels of SBML; level 1 was dedicated to 
model the metabolic network, level 2 was developed to model/simulate biomolecular 
network. Level 3 added a number of features like model composition, description of molecule 
complexes, display and layout information and spatial characteristics of models. Every 
SBML model contains a number of compartments where the reaction occurs. The entities 
involved in the reaction are called species. A range of biological objects ranges from proton, 
atom, complex molecule like glucose, RNA or proteins can be defined as species within a 
SBML model. Species can also be defined with its spatial size and charge. The interactions 
between molecules are represented as reactions and there can be several types of reactions i.e. 
transformation, transport, binding etc. Reactants, products and modifiers for reactions are 
specified by giving references to the relevant species. The initial concentration or change in 
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concentration of any reactant over time can be saved inside SBML format. The reaction 
kinetics, mathematical and kinetic laws of the reaction can be encoded with SBML format. In 
addition to reactions, SBML also contains events, defined as discrete changes in the model. It 
is also possible to specify what triggers the event, its time constraints and the result of the 
event (Strömbäck & Lambrix 2005). In systems biology community SBML largely serve the 
purpose to encode the semantic. As a result, it is particularly well suited to encoding models 
of processes such as biological reactions. The mathematics may then be derived from these 
process descriptions as a series of ordinary differential equations (ODEs) by simulation 
software when desired (Smith et al. 2014). An example of an SBML representation is 
provided in Figure 12. 
 
Figure 12: Example of SBML data format (Strömbäck & Lambrix 2005). 
 
3.6.4. CellML  
CellML is an extensible markup language by the international Union of Physiological 
Sciences, Physiome and European Virtual Physiological Human (VPH) projects. It aims to 
encode mathematical models of biological processes based on systems of ordinary 
differential equations (ODEs) and differential algebraic equations (DAEs). The scope of 
CellML is to support sharing of biological models by having a unified model structure (the 
inter-relatedness of each part of the model); mathematical equations describing biological 
processes; other important metadata of the model.  CellML is built on Mathematical Markup 
Language (MathML) for encoding the mathematical part of the model and Dublin Core for 
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bibliographic information. A format of CellML is presented in Figure 13. Current version of 
CellML is complementary to SBML (Beard et al. 2009).  
 
Figure 13: Entities in a CellML model (Beard et al. 2009).  
The CellML model file on the left part depicting the base model with its imports, units, components, connections and groups 
described in XML format. The corresponding metadata is shown in RDF format. The annotation of CellML variables with 
biological and biophysical meaning is handled via cmeta:id links to terms stored in RDF format in a separate OWL file.  
Traditionally, biochemical and cellular pathways have been graphically represented in the 
text books. The trend also followed in the first databases for pathways and metabolic 
reactions i.e. within EMP, EcoCyc and KEGG. More notations have been defined by virtue of 
their implementation in specialized pathway visualization software tools such as NetBuilder, 
Patika, JDesigner, CellDesigner. But the graphical notations used by these software tools 
were not standardized and their understanding relied mainly upon relating examples with 
one’s pre-existing knowledge of biochemical processes. This ambiguity in presenting a graph 
was first addressed by Kurt Kohn in his Molecular Interaction Map (MIM). Nevertheless, 
none of these notations could become the community standard. The SBML group tried to 
bridge the gap with the development of SBGN (Systems Biology Graphical Notation).  
3.6.5. SBGN 
SBGN was formulated with the aim to specify the connectivity of the graphs and the types of 
the nodes and edges, but not the precise layout of the graphs. Semantics of the SBGN 
diagrams do not depend on the relative position of the symbols, colours, patterns, shades, 
shapes and thickness of the edges. There are three types of languages within SBGN.  
a. SBGN process diagram: It represents biochemical reactions that change location and 
state of physical entities. To enable such representations different states of the 
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physical entities are represented separately. Process diagram cannot properly 
represent reaction with combinatorial explosions of states and processes. The process 
diagram is particularly useful to represent metabolic pathways with unambiguous 
transcription into biochemical events and mechanistic description of the processes.  
b. SBGN entity relationship diagram: It represents the interaction between entities and 
rules all the controlling factors of the interaction. Unlike process diagram, physical 
entities are represented only once. Mechanistically it describes the relationships of the 
entities. The reactions with creation, destruction and translocations are not easily 
represented by an entity relationship diagram. Entity relationship diagram is most 
suitable to represent signaling pathways involving multi-state entities.  
c. SBGN active flow diagram: Active flow diagram is uniquely suited to represent the 
influence of biological activities on each other. As it represents different activities of 
physical entities differently. Active flow diagram is not suitable to represent reactions 
with association, dissociation and multi state entities. SBGN active flow diagram is 
most suitable to represent functional genomics reactions and signaling pathways with 
simple activities (Le Novère et al. 2009). The components of SBGN diagram are 
represented in Figure 14.  
 
 
Figure 14: A SBGN representation of protein phosphorylation reaction catalyzed 
by an enzyme and modulated by an inhibitor (Le Novère et al. 2009).  
(a) SBGN Process Diagram: Four states of ERK i.e. phosphorylated and non-phosphorylated on the tyrosine and threonine 
residues as well as the processes of phosphorylation by MEK and the inhibition of MEK by complexation with u0126. Note 
that the relationship between MEK and u0126 is not represented here. (b) Entity relationship diagram: It also shows ERK 
phosphorylation. At the same time relationship between MEK and u0126 is also clear. The phosphorylation sites are 
represented by variables, which in this example are labeled simply as ‘Y’ and ‘T’. Unlike process diagram ERK is 
represented only once without the description of its different states, in entity relationship diagram. (c) Activity flow diagram: 
representing the activation of ERK by MEK and the inhibition of MEK by u0126. This is a simplistic representation of the 
activities of u0126, MEK and ERK with the abstract representations of the influences of activities on each other. But the 
biochemical details are missing (Le Novère et al. 2009).    
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BioPAX and SBGN communities have collaborated to ensure that SBGN can be used to 
visualize pathways in BioPAX format. The relationship among popular standard format for 
pathway related data is provided in Figure 15. The purpose of BioPAX and PSI-MI is to 
exchange the data to and from databases, pathways and biomolecular networks. SBML and 
CellML are designed to support mathematical simulations of biological systems. The SBGN 
represents a uniform notation for pathway diagrams. For example controlled vocabularies 
developed by PSI-MI and BioPAX can be used to annotate SBML and CellML models.    
 
Figure 15: Inter-relationship of popular pathway data format and standard 
Knowledge Management Tools to represent/analyse pathway data and its 
downstream phenotype (Demir et al. 2010). 
MIASE: Minimum Information About a Simulation Experiment (MIASE) describes the minimum set of information that 
must be provided to make the description of a simulation experiment available for others to use. It includes the list of models 
to use with their modifications, all the simulation procedures to apply according to order, the processing of the raw 
numerical results, and finally the description of the final output to ensure the reproducibility of simulation experiment 
[(Waltemath et al. 2011)].   
MIMIx: Minimum Information required for reporting a Molecular Interaction Experiment (MIMIx) represents the depth of 
information required to describe all relevant aspects of an interaction experiment. The purpose is to ensure that the bench 
scientist has a checklist of the information to be supplied when describing experimental molecular interaction data in a 
journal article (Orchard et al. 2007). 
MI: Molecular Interaction (MI) is an outcome of HUPO ProteOMICS Standards Initiative. The aim is to improve the 
annotation and representation of published molecular interaction data (Deutsch et al. 2015).   
SO: Sequence Ontology (SO) is an ontology project for the definition of sequence features used in biological sequence 
annotation. SO was initially developed by the Gene Ontology Consortium (Ashburner et al. 2000).   
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GO: In 2000, The Gene Ontology Consortium (GO) was established with the mission to provide a controlled vocabulary for 
annotating homologous genes and proteins across organisms. Genes and its products are classified into three hierarchical 
structures to describe associated biological processes, cellular components and molecular functions (Ashburner et al. 2000). 
PATO: Phenotypic Attribute Trait Ontology (PATO) designated for defining composite phenotypes and phenotype 
annotation (Knowlton et al. 2008). 
 
3.7. Knowledge Visualization 
Computational models of biological networks are a cornerstone of systems biology research. 
Over the years, quite a few modelling software tools have been developed to simulate 
biochemical reactions, gene transcription kinetics, cellular physiology and metabolic 
network. Such models promise to transform biological research by providing a podium for 
the following research objectives:  
1. To systematically interrogate and experimentally verify knowledge of a pathway, 
2. Efficiently manage the immense complexity of hundreds or potentially thousands of 
cellular components and interactions.  
3. Reveal emergent properties and unanticipated consequences of different pathway 
configuration.  
 The major objectives of building systems biology models are to understand cellular 
processes, disease mechanism or drug mode of action. The snap shot of these models are built 
based on literature knowledge. But the dynamic properties or emergent behavior of these 
models are achieved with differential and/or stochastic equations based on the available 
contextual OMICS data.  The scientific communities are looking for software tools to 
process, analyse and visualize these OMICS data. Several tools i.e. Pajek, Graphlet, daVinci 
has been published to view molecular interaction network in two dimensional space.   
Software like Osprey and PIMrider has got the added feature to import PPI from BIND and 
DIP databases.  In the same way several software platforms i.e. GeneCluster, TreeView and 
GeneSpring have been developed for gene expression profiles.  There was a need to merge 
molecular interaction and pathways with OMICS data in a common framework and bridging 
them with several other model building parameters.  This need has been addressed with the 
development of popular platforms like Cytoscape, Celldesigner (Shannon, Markiel, Ozier, 
Nitin S. Baliga, et al. 2003).  
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3.7.1. Cytoscape 
Cytoscape is a general purpose modelling environment for integrating bimolecular interaction 
network and states. The bimolecular interactions are represented as a network graph with 
nodes representing the biomolecules and edges representing the relationships between two 
biomolecules. Its core software component provides basic functionality for integrating 
arbitrary data on the graph, a visual representation of the graph, selection/filtering tools and 
an interface to external analytics implemented by plug-ins. The main feature of Cytoscape is 
described below.   
Data Integration: Each data point is integrated within the network graph using Attributes. 
Attributes are the (name, value) pairs that map node or edge to a specific data value.  The 
name of the node can be gene id, gene symbol, Uniprot accession no or any other ids/names. 
The attribute values may assume any type (e.g. text string, discrete or continuous numbers, 
URLs, lists).  
Transfer of Annotations: The annotation feature within Cytoscape enable assigning 
hierarchical classification i.e. ontology of progressively more specific description of groups 
of nodes or edges. Annotation typically corresponds to an existing repository of knowledge 
that is large, complex and relatively statics such as gene ontology.   
Graph Layout: This feature enable Cytoscape to visualize complex network of nodes and 
edges into two dimensional space. A variety of automated network layouts algorithms i.e. 
spring-embedded layout, hierarchical layout and circular layout are supported within 
Cytoscape. The spring embedded is the most widely used method for arranging general two-
dimensional graphs.  
Attribute-to-Visual Mapping: Attribute-to-Visual mapping is one of the most powerful 
visualization capabilities of Cytoscape. It controls the appearance of their associated nodes 
and edges based on the data attribute. Cytoscape supports a wide variety of visual properties, 
such as node color, shape, size, thickness as well as edge colour, thickness, shape. The data 
attributes are mapped to a visual property using either a lookup table or interpolation, 
depending on the continuous or discrete nature of the attribute.  
Graph Selection and Filtering: This feature allows Cytoscape to selectively display subsets 
of nodes and edges according to a wide variety of criteria including by name, list of names or 
on the basis of attributes. More complex network selection queries are supported by a 
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filtering toolbox that includes a Minimum Neighbours filter, which selects nodes having a 
minimum number of neighbours within a specified distance in the network; a Local Distance 
filter, which selects nodes within a specified distance of a group of preselected nodes; a 
Differential Expression filter, which selects nodes according to their associated expression 
data; and a Combination filter, which selects nodes by arbitrary and/or combinations of other 
filters. The typical components of Cytoscape are represented in Figure 16.   
 
Figure 16: The components of Cytoscape (Shannon et al. 2003). 
The figure shows the schematic overview of the Cytoscape core architecture. The Cytoscape window is the primary visual 
and programmatic interface to the software which contains the network graph and attributes data structures. Core methods 
that operate on these structures are graph editing, graph layout, attribute-to-visual mapping, and graph filtering. Annotations 
are available through a separate server. 
  
3.7.2. CellDesigner  
CellDesigner is another very popular stand-alone application for modelling and simulating 
biochemical networks. CellDesigner is unique software which supports the following:  
a. Diverse biological objects and interactions are well defined and can be uniquely 
represented.  
b. It is semantically and visually unambiguous. 
c. It able to incorporate varied notation.  
d. It can convert a graphically represented model into mathematical formulas for 
analysis and simulation.  
e. It ensures community can freely use a notation schema.  
CellDesigner supports two classes of vertexes and edges.  One class of vertex, called ‘state 
node’ (SN), represents biomolecules within a biological process such as proteins, small 
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molecules, ions, genes and RNA. The other class is ‘transition node’ (TN), represents 
modulations imposed on the reaction, such as catalysis, inhibition, association and 
dissociation. In a process diagram, different states of one molecular species are represented 
by different SNs. SNs that represent complexes are called complex SNs (CSNs), and there are 
two or more SNs as components of the node. There are two types of edges: edges from a state 
node to a transition node (ST-Edge) and edges from a transition node to a state node (TS-
Edge). There are two types of TS-edges; one that represents state changes in the molecular 
species (represented by a closed arrow), and one that represents translocation of the molecule 
(represented by an open arrow). A reaction is represented as two or more state nodes 
connected by edges that are connected through a transition node. Each SN may have a 
hierarchical internal structure defined as N-tree to represent members of a complex that are 
also SNs. Connectivity of internal nodes is defined by the connectivity matrix, which defines 
bindings among proteins that constitute a complex, as well as domains that constitute a 
protein. Each SN may have features that represent the modification state of residues as well 
as allosteric configurations (Kitano et al. 2005). Graphical notation of process diagrams are 
represented in Figure 17.  
 
Figure 17: CellDesigner process diagrams (Kitano et al. 2005). 
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The figure demonstrates a set of symbols for representing biological networks with process diagrams within CellDesigner. 
Symbols in the process diagrams consist of visual icons for state nodes and arcs. Each arc consists of a transit node and 
edges. Currently, there are four reduced notations that display simplified diagrammatic symbols. The category-I reduced 
notation can be used during editing of the network. The category-II reduced notation is limited to viewer software, and is not 
permitted during the editing process because of potential confusion that could arise from the implicit nature of state 
transition description. 
  
Currently pathway analytics and knowledge bases represent a useful tool for the 
interpretation of OMICS data, identification of upstream mechanistic drivers as well as 
visualisation of OMICS data assisting scientific understanding of the underlying biological 
processes. Though certain limitations of conventional pathway analytics hinder the use of 
knowledge bases as predictive tools for biomarker discovery and were recently reviewed by 
A. Butte (Khatri et al. 2012).  Most pathways accumulated in the knowledge bases represent a 
mixture of findings described in different healthy and pathological conditions in various 
biological systems and tissues. Creation of the tissue, treatment or condition specific 
pathways is a challenge and is currently in focus of many commercial knowledge bases 
providers. Since today’s knowledge bases transform multiple transcripts and SNPs to Entrez 
Gene id in pathway representation, granularity of the pathways should be further improved 
for the analysis of RNA and DNA-sequencing-derived OMICS data. Finally, existing 
knowledge bases contain only static information that represents “snapshots” of the system 
behaviour for particular condition under which the data has been obtained. Pathway 
interdependencies reflecting the sequence of events in pathological processes is not captured 
thereby limiting their use for modelling and prediction (Deyati et al. 2013).  
Despite these success stories of companion diagnostics, a significant gap exists between the 
R&D expenditure, number of biomarker related research grants and available clinically 
validated biomarkers (Ptolemy & Rifai 2010). The technological advancements in the fields 
of genomics, transcriptomics, proteomics, metabolomics lead to a deluge of publicly 
available biomedical data. On the other hand, there is a vast amount of biomedical knowledge 
accumulated in the textual body of scientific literature and patents that could be of 
tremendous value for translational efforts. The lack of standardized translational algorithms 
allowing the use of OMICS data along with knowledge derived from scientific literature, is 
one major reason behind the scarcity of biomarkers currently used in the clinic. To fill the 
gap of OMICS data interpretation, a number of system biology approaches are suggested by 
the scientific community, however there is no proof of concept methodology, which can lead 
to the successful biomarker prediction, and it is not clear how the success of OMICS 
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technologies can be translated from research discovery to clinical biomarker (Deyati et al. 
2013). 
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4. Summary of the thesis 
 
Currently major effort in drug discovery is focused on heterogeneous disorders like cancer. 
The success of targeted drug development in cancer depends on how efficiently the patient 
will be stratified before treatment. The first scope of this thesis is to understand which 
OMICS technologies are currently being used for the identification of oncology biomarkers 
in the clinical trials and the existing methodologies for recovering biomarker-related 
information from the text. It also aims to draw a perspective in the integration of data and 
knowledge for the identification of biomarker in oncology.  
Secondly the thesis strives to decipher the impact of stratified biomarker on clinical 
development, a retrospective analysis of clinical trials with stratified biomarker registered in 
ClinicalTrials.gov was achieved. The following questions were analysed: 
a. What is the current frequency of stratified molecular biomarkers in clinical development? 
b. What are the key technologies for biomarker identification in clinical trials? 
c. What are the major funding organizations in the clinical biomarker field? 
d. Which are the major disease indications targeted by stratified biomarker program? 
e. At which phase stratified molecular biomarkers are mainly explored in clinical 
development?  
f. What is the impact of biomarker program on clinical trial duration and chance of 
completion? 
Next aim was to research the need and prospect of a novel class of biomarker i.e. miRNA to 
stratify the cancer patients to benefit from targeted therapy. But lack of translational 
algorithm which can integrate OMICS data and knowledge to predict the causal relationship 
between candidate miRNA and clinical outcome of a treatment in a disease condition 
potentially hamper the discovery of miRNA as stratified biomarker. In this direction a novel 
integrative algorithm i.e. SMARTmiR has been developed by combining literature 
knowledge and available OMICS data to identify specific miRNA as therapeutic biomarker. 
Finally the thesis aims to design a prospective plan on future scenario of biomarker research 
during cancer drug development to reduce the risk of most expensive phase III drug failures.  
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5. Clinical Trials and Previous Text 
Mining Efforts on Trials Data 
Clinical trials are studies performed on number of volunteers with the aim to evaluate safety 
and efficacy profile of a new treatment. The concept of randomized clinical trials was first 
implemented in 1931 by Amberson et al. to study a pulmonary tuberculosis therapy. The 
randomizations implemented the concept of distributing patients randomly in the case control 
groups with sole purpose of avoiding the bias. The concept of blinded trial was also first 
implemented in this trial. So the patients in this trial were not aware whether they took the 
treatment or placebo. The volunteers need to also go through a set of stringent selection 
criteria termed as “Eligibility Criteria”. A clinical trial is conducted through three to four 
phases measuring dosage, safety, and efficacy profile of the treatment (Friedman, Lawrence 
M., Furberg, Curt D., DeMets 2010).  
5.2. ClinicalTrials.gov database   
As of 1
st
 August, 2015; ClinicalTrials.gov lists 195,624 trials covering 190 countries 
worldwide. All the trials are downloadable from the database as XML files. The clinical 
information like <<drugs>>, <<diseases>> are structured MeSH (Medical Subject Headings) 
terms. But the XML entries have got unstructured data as well, like trial description, 
eligibility criteria and other descriptions. Over the years there has been extensive focus on 
text mining of MEDLINE articles and abstracts but lesser text mining has been achieved has 
been done on clinical trials entries of ClinicalTrials.gov database. So resources of 
ClinicalTrials.gov can be used for potential new discoveries by text mining. Additionally trial 
results are often accessible much before the trials are officially completed and published 
making them an attractive biomedical resource to decipher trends in clinical trial domain 
[see: Clinicaltrials.gov].  
There has been previous text mining efforts on ClinicalTrials.gov entries by using Part of 
Speech tagging and dictionary based approaches to simply tag an entry of interest in the trial 
description. The focus of this initiatives ranges from identification of gene-drug-disease 
relationships or development of tools for better management of clinical trials. In the next 
section these initiatives are reviewed in details. 
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5.3. Previous text mining on ClinicalTrials.gov 
In 2008, Cao et al. completed a text mining analysis of 645 clinical trials from 
ClinicalTrials.gov on cancer vaccine and presented number of clinical vaccine trials per 
cancer type, over time, by phase, by lead sponsors, as well as trial activity relative to cancer 
type and survival data. The group also found out the neglected cancer areas such as bladder, 
liver, pancreatic, stomach, esophageal cancer in those trials. The text mining system consists 
of a back-end XML database, a front-end visualization interface, and the analysis component 
(Cao et al. 2008) 
  
In October, 2011 Korkontzelos et al. presented ASCOT (Assisting Search and Creation Of 
Clinical Trials), an efficient search application customized for clinical trials. ASCOT uses 
text mining and data mining methods to enrich clinical trials with metadata to narrow down 
search. In addition, ASCOT integrates a feature for clinical trial practitioners in 
recommending eligibility criteria to volunteers based on a set of selected protocols. ASCOT 
employs state-of-the-art text mining technologies, clustering and term extraction algorithms 
applied on large clinical trial collections (Korkontzelos et al. 2012). 
 
In 2012, Tasneem et al. developed a database called AACT (Aggregate Analysis of 
ClinicalTrials.gov) that contains data from 96,346 trials as of 27
th
 September, 2010. The 
group has formulated the project with two major purposes: A) to extend the usability of 
ClinicalTrials.gov for research purposes. B) to develop and validate a methodology for 
annotating studies by clinical specialty with the help of a custom taxonomy by applying an 
NLM algorithm which uses Medical Subject Heading (MeSH) terms. Key design features of 
AACT include 1) the capacity to extend the dataset by parsing existing data; 2) linking to 
additional data resources, such as the Medical Subject Headings (MeSH) thesaurus; and 3) 
integrated metadata (Tasneem et al. 2012) . 
  
In 2012, Li et al. developed a systematic approach to automatically identify 
pharmacogenomics (PGx) relationships between genes, drugs and diseases from trial records 
in ClinicalTrials.gov database.  The group found out that the extracted relationships overlap 
significantly with the curated factual knowledge through the literature in a PGx database i.e. 
PharmGKB. The most relationships also appear on average 5 years earlier in clinical trials 
than in their corresponding publications. This suggest that clinical trials may be valuable for 
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both validating known and capturing new PGx related information in a more timely manner. 
The group collected 93,661 clinical trials as of August 2010. The group first processed these 
records and identified sections of interest. Second, a dictionary-based method was applied to 
identify PGx concepts (i.e., diseases, drugs and genes) from the pre-processed trial records. 
The reported gene–drug–disease relationship extraction is based on their co-occurrence in 
one trial record (Li & Lu 2012).  
 
In November 2014, He et al. designed and built COMPACT (Commonalities in Target 
Populations of Clinical Trials) database to store structured eligibility criteria and trial 
metadata in a computable format indexed by disease topics. The COMPACT database is 
highly useful for clinical trial practitioner to identify common eligibility features for clinical 
research participant selection for a given disease indication. The group has collected 159,891 
trials from ClinicalTrials.gov as of 27
th
 January 2014 and parsed, indexed eligibility criteria 
text, extracted common eligibility features and developed an example analytic module called 
CONECT, which enables a user to mine contextual common eligibility features for trials on a 
certain disease from COMPACT (He et al. 2014).  
 
In 2014, Bell et al. published a comprehensive characterization of clinical trials on rare 
diseases compared to trials on non-rare diseases registered in ClinicalTrials.gov. The group 
downloaded 133,128 trials as of 27
th
 September, 2012 and by annotating medical subject 
heading (MeSH) descriptors to condition terms they could identify rare and non-rare disease 
trials. A total of 24,088 Interventional trials registered after January 1, 2006, conducted in the 
United States, Canada and/or the European Union were categorized as rare or non-rare.  Then 
the group made a comparison of trials on rare and non-rare disease indication based on 
number of participants, number of single arm trials, number of non-randomized trials, open 
label, number of terminated trials, actively pursuing or waiting to commence or enrolling 
trials (Bell & Tudur Smith 2014)].  
 
But none of these analyses of ClinicalTrials.gov focuses on trials with biomarker across 
different disease indication areas and to figure out the impact on biomarker program on 
clinical trials. The increasing literature evidence shows the future treatment on heterogeneous 
disease indication will be based on biomarker. So an analysis of trials with biomarker will 
provide us future landscape of stratified medicine as trials appear on an average 5 years 
earlier in ClinicalTrials.gov than in their corresponding publications (Friedman, Lawrence 
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M., Furberg, Curt D., DeMets 2010). This really motivates us to analyze Clinicaltrials.gov 
focusing on trials with biomarker. In the next section the analysis is described in details. 
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6. Impact of biomarker on drug 
discovery and development (Deyati, 
A; 2014) 
 
Despite the advantages of the stratified medicine approach for patients and payers, such as 
prevention of overtreatment and an early decision for an alternative therapy (Frank & 
Hargreaves 2003b), the business incentive for pharmaceutical companies to invest into the 
co-development of the stratified molecular biomarker early on is less clear (Davis et al. 
2009). Also financially it can be seen as a burden for the pharmaceutical companies as they 
have to bear the added cost of companion diagnostic development and yet have to cope with 
the reduced market size due to patient stratification (Davis et al. 2009). However, recent 
observations show that stratified biomarker-aided drug discovery is commercially more 
viable for pharmaceutical companies than post-approval research for diagnostic testing. For 
example clinical development of trastuzumab and imatinib with stratified biomarker have 
enhanced clinical, commercial success but post approval application of KRAS mutation test 
for cetuximab and panitumumab might not be commercially very rewarding (Loupakis et al. 
2008). In order to understand the degree to which biomarker programs are implemented as 
well as the current trends and risks of inclusion of stratified biomarkers in clinical trials, we 
decided to analyse more than 150,000 clinical trials entries accumulated in ClinicalTrials.gov 
database.   
Since the inception of ClinicalTrials.gov database in 2000 (in response to US congress law 
obliging NIH to publish private and federally-sponsored trials) it has rapidly become the most 
favoured publicly available search engine in clinical trials registry covering trials from all the 
geographical locations in the world. Although the database was launched in the year 2000, 
clinical trials with start date as early as 1970 (NCT00005125) has been incorporated in it, 
thus representing 43 years of clinical research. Despite the known issues with the updates, 
consistency and completeness of the data (Wadman 2006; Innocenzi et al. 1984), it is the 
oldest and largest clinical trial registry containing the information on more than 150,000 trials 
(August, 2013). Choosing between the clinical trials registries, we reckoned that the analysis 
of the largest database will give us a representative picture of the historic and current trends 
on the use of stratified molecular biomarkers in clinical trials.  
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The major question we have investigated here are as follows: 
Q1. Frequency of stratified molecular biomarkers in clinical development 
Q2. Key technologies for biomarker identification in clinical trials  
      Q3. Major funding organizations in the clinical biomarker field 
      Q4. Major disease indications targeted by stratified biomarker program 
      Q5. Phase wise distribution of stratified molecular biomarker trials 
Q6. Impact of biomarker program on clinical trial duration and chance of completion 
Semi-automated curation of ClinicalTrials.gov 
We downloaded the entire database as XML files on 02 August, 2013 for the analysis. On 
that date the total number of clinical trials registered in the database was 150,504. The bigger 
half of the studies (121,922) was interventional i.e. analysing clinical outcome after 
intervention. The remaining 27,886 studies were observational. The analysis started by 
selecting three groups. 
Interventional trials (Group 1): Focusing on 121,922 interventional trials we further filtered 
trials by excluding those with unknown “Overall status” to remove uncertainty regarding 
updates of the database. To avoid time confounders, interventional trials with “start date” 
between 1991 to 2013 were programmatically filtered as first trial with stratified biomarker 
was registered in 1991 (NCT00001271). In many trials “intervention name” and targeted 
disease (“condition”) field can be empty, so we programmatically checked “intervention 
name” and “condition” field of each trial to select only those 60,629 interventional trials with 
a drug/biologics term as “intervention name” and a disease term as “condition”.  
Interventional trials with Biomarker as outcome measure (Group 2): In selecting Group 2 
the “outcome measures” field of interventional trials was checked and only those with 
“biomarker” in it, were selected. Next, similar to Group 1 “start date”, “intervention name” 
and “condition” fields were programmatically checked. Finally we filtered 4745 trials with 
biomarker as outcome measure.  To check the quality of the screening method for the 
selection of Group 2 trials, we randomly checked 10% of it and could not find out any false 
positive.  
Interventional trials with stratified molecular biomarker (Group 3): The prime focus of 
our analysis was trials with stratified molecular biomarker hence we developed a set of 
keywords derived from the manual annotation of 80 studies (when searched 
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ClinicalTrials.gov with “Cetuximab AND KRAS”). The aim of this manual annotation was to 
look for intuitive words which can filter a trial with stratified biomarker and a search 
keyword was developed (please look at Figure 18).  22,273 trials were filtered by searching 
the ClinicalTrials.gov with the developed keyword. Focusing on the trials that are using 
molecular biomarkers, we further filtered the resulting list by excluding trials without any 
gene or protein names by automated tagging and attained the list of 5,420 interventional 
studies. All the 22,273 trials with outcome of the above mentioned tagging and presence of 
“intervention name” are presented in Supplementary Table 1 (See: 
https://drive.google.com/file/d/0Bw_MQVhSKAMXSmR6TzhDcEE4eDQ/view). Automated 
tagging was done by running an internally developed script containing a list of all gene and 
its synonyms obtained from NCBI database (http://www.ncbi.nlm.nih.gov/gene/).  Using the 
script, we screened the important XML fields of each clinical trial i.e. “title”, “purpose”, 
“official title”, “primary outcome measures”, “secondary outcome measures”, “detailed 
description” and “keywords” to filter out the trials with gene names.  Further focusing on the 
trials that use molecular biomarkers for patient stratification prior to treatment; we manually 
curated those 5,420 trials. Finally 1,701 trials with stratified molecular biomarkers were 
filtered, and these trials were further analysed and became the basis of this paper. In ensuring 
the authenticity of this screening, we randomly checked 10% of the trials which did not 
appear in the result set (i.e. 5420-1701) for the presence of any gene names. We found out 
that none of the trials were false positive either.  The examples of the trials filtered out by 
manual curation as trials with stratified molecular biomarker, please refer to Supplementary 
Table 2 (See: https://drive.google.com/file/d/0Bw_MQVhSKAMXZ24yLWxiak5qcjQ/view). 
Trials in Group 1, Group 2 and Group 3 are not overlapping.  
Identification of disease terms and segmentation into therapeutic categories: One of the major 
aims of this analysis was to elucidate therapeutic focus of Group 3 trials. To achieve it, at 
first “condition” i.e. targeted disease of 1701 trials belonging to Group 3 was collected. Next, 
all those targeted diseases were manually curated and segmented into 15 major therapeutic 
areas based on MeSH disease tree. Next important focus of the analysis was to investigate the 
impact of stratified biomarker on trial duration of “completed” trials and trial’s status across 
different therapeutic categories curated in the earlier step. In order to have a balanced 
comparison of trial duration between target group (Group 3) and control group (Group 2), the 
duration period were calculated in months. The assessment of trials status was determined as 
follows: a trial was considered successful when “Overall status” was “completed” whereas, a 
trial was considered unsuccessful if “Overall status” was “terminated” (definition of 
85 
 
terminology: http://clinicaltrials.gov/ct2/about-studies/glossary). The comparison has been 
done between Group 3 and Group 1 i.e. all other interventional trials excluding Group 3 
(Figure 18). For the quantitative analysis, formatting has been completed with Perl 
programming language based on the Document Type Definition (DTD) 
(http://clinicaltrials.gov/ct2/html/images/info/public.dtd) of ClinicalTrials.gov. To map 
diseases related synonyms to a unique identifier, MeSH disease dictionary was applied. 
Figure 18 shows a flow chart describing the logic and steps of our meta-analysis. All the 
manually curated individual disease indications belonging into 15 major therapeutic 
categories are listed in Supplementary Table 3 (See: 
https://drive.google.com/file/d/0Bw_MQVhSKAMXWHAwaFJ0b2hrUWM/view).  
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Figure 18: Workflow for the selection of trials with, without stratified molecular 
biomarker and meta-analysis of the ClinicalTrials.gov  
Q1, Q2, Q3, Q4, Q5, Q6, Q7: major investigated questions as mentioned in page 73. The detailed description of the meta 
analysis consists of three steps described below.  
 
Step1: The step1 can be separated in selection of two groups: 
Group1 (Interventional trials): We used “Advanced Search” option of ClinicalTrials.gov 
database with two following criteria.  
Criteria1: In the “Study Type” field selected “interventional studies”.  
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Criteria2: In order to remove uncertainty regarding updates of the database, so to remove all 
interventional trials with unknown “overall status” from our analysis by marking “Exclude 
Unknown Status” in “Advanced Search”.  
Then we downloaded all the trials as XML file. 
In avoiding time confounders interventional trials with “start date” between 1991 to 2013 
were programmatically (PERL) filtered as first trial with stratified biomarker was registered 
in 1991 (NCT00001271). We also checked “intervention name” and “condition” field of each 
trial with PERL program to select only those interventional trials with a drug/biologics term 
as “intervention” and a disease term as “condition”. As in many trials those fields can be 
empty. This filtering resulted in 60,629 intervention trials (Group 1).  
Group2 (Interventional trials with Biomarker as outcome measure): We used “Advanced 
Search” option of ClinicalTrials.gov database and applied Criteria1 and Criteria2 (see step1). 
Further as third criteria in the “Outcome Measures” field typed “biomarker”. Next, similar to 
Group1 programmatically checked “start date”, “intervention name” and “condition” fields. 
Finally we filtered 4745 trials with biomarker as outcome measure.   
Step2: The prime focus of our analysis was to find trials with stratified biomarker. In 
achieving this we first downloaded a set of 80 trials by searching ClinicalTrials.gov with 
keyword “Cetuximab AND KRAS”. Then manually curated those 80 trials for intuitive 
words which can possibly filter a trial with stratified biomarker and came up with following 
search  
Keyword: “(biomarker OR resistance OR marker OR positive OR mutation OR miRNA OR 
sensitivity OR Sensitive OR genomic OR microarray OR proteomic OR metabolomic OR 
polymorphism OR SNP OR Negative) NOT (respirat OR airway)”  
Finally applied the above search keyword in “Advanced Search” option of ClinicalTrials.gov 
database followed by applied Criteria1 and Criteria2 (see step1). The above criteria could 
filter 22,273 trials. Next to find out genes and proteins, automatic tagging has been applied on 
22,273 trials as we wanted to screen trials with stratified molecular biomarker 
(genes/proteins). We filtered out 5420 trials with tagging criteria. Finally to confirm the 
molecular stratification program of each of those 5420 trials, we manually curated all of them 
and it turn out 1701 (Group3) trials having molecular stratified biomarker program before the 
treatment.   These 1,701 trials were further analysed and became a basis of this paper.  
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Step3: There are seven major questions we are investigating in this paper. In answering those 
questions we collected certain fields of each xml files of each clinical trial downloaded from 
ClinicalTrials.gov database. Below in Table 6 we listed the XML fields which were 
programmatically extracted for further analysis. 
 
Question 
no. in 
Introduction 
XML field 
Q1 “start_date” 
Q2 “intervention_name” when “intervention_type” is “Genetic” 
Q3 “lead_sponsor” 
Q4 “condition” 
Q5 “clinical_phase” 
Q6  “overall_status”, filtered when value is “Completed”. Duration 
of trials filtered through first criteria was calculated based on 
(“trial_start _date” – “trial_completion_date”) 
Q7 “overall_status” 
Table 6: The analysed XML fields to answer questions rose in the introduction 
Any overlap between Group 1 and Group 2 has been removed from Group 1. Similarly any 
overlap between Group 1 and Group 3 has been removed from Group 1. Overlap between 
Group 2 and Group 3 has been removed from Group 2. 
6.2. Frequency of stratified molecular 
biomarkers in clinical development  
Our primary goal was to understand whether the stratified medicine trend as a consequence of 
the genetic revolution, widely discussed in biomedical scientific forums; is actually 
translating in the use of molecular biomarkers in clinical trials. At very first step, we 
collected “start date” of each trial and calculated the percentage of clinical trials that are 
using molecular biomarkers for patients’ stratification. Comparing them to the total number 
of clinical trials registered in the database we found 1.39% of all interventional clinical trials 
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(i.e. 1,701 trials out of total 121,922 interventional trials) belong to this category. In order to 
figure out what is the trend in implementation of biomarkers in clinical research, we analyzed 
the historical record of trials with stratified molecular biomarker (TSMB). The first trial using 
stratified molecular biomarker was registered in 1991 when CD22(+) B cell lymphoma 
patients were selected for treatment with IgG-RFB4-SMPT-dgA antibodies (NCT00001271). 
Since then, the number of such clinical trials is steadily growing and attending the peak in 
2011 with 214 trials registered that year (Figure 19 a). We further calculated year wise 
proportion of trials with stratified molecular biomarker compare to total number of 
interventional trials with 95% confidence interval (CI) starting from 2000 to August, 2013. In 
Figure 19b, we have plotted year wise lower and upper limits of the proportion with 95% CI. 
Based on Figure 19b with 95% CI we can see that less than 5% of all interventional trials are 
using molecular biomarker for patient stratification. All the trials with stratified molecular 
biomarker and its start year can be found in Supplementary Table 4 (See: 
https://drive.google.com/open?id=0Bw_MQVhSKAMXWE1mNmFSUDRQX0U).    
 
 
Figure 19 A: Growth of trials with stratified biomarker from 1991 to 2013. B: Year 
wise proportion of trials with stratified molecular biomarker compared to trials 
from 2000 to 2013  
In figure 19 A, the steady growth rate of trials with stratified biomarker is evident. Year wise proportion of trials from 2000 
to August, 2013 with stratified molecular biomarker compare to total number of interventional trials with 95% confidence 
interval (CI) was calculated. In Figure 19b, we have plotted year wise lower and upper limits of the proportion with 95% CI.     
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6.3. Key technologies for biomarker 
identification in clinical trials 
In order to understand the technologies being applied in clinic for the detection of stratified 
biomarkers and their frequency of application, the “intervention name” from each TSMB was 
selected when “intervention type” is “Genetic”. Unfortunately less than 10% of trials specify 
this information in the registry. TSMB trials with specified technologies are listed in 
Supplementary Table 5 (See: 
https://drive.google.com/open?id=0Bw_MQVhSKAMXeHlYN3NoVjVrQVE). After 
programmatically retrieving the technologies, they were manually curated and then 
segmented into three different OMICS technologies i.e. genomics, transcriptomics and 
proteomics. Genomic technologies including detection of mutations and polymorphisms by 
PCR, gene sequencing and cytogenetic analyses were used in 50% of trials. Supplementary 
Figure1 (See: 
https://drive.google.com/file/d/0Bw_MQVhSKAMXaHJIeUZ2bnhaNUU/view). Genomic 
technologies were followed by transcriptomics analysis combining various gene expression 
arrays and used in about 40% of trials reporting biomarker detection techniques. Different to 
the traditional single biochemical and histopathological measurements, expression profiles 
represent a fingerprint containing multiple biomarkers, which collectively indicate a 
particular pathophysiology (Bhattacharya & Mariani 2009). The rest 10% of the trials were 
using proteomics technologies for detection of stratified biomarker, starting from Western 
Blotting in early studies and ending with mass spectrometry based proteomic profiling (e.g. 
NCT01658566, NCT00601913).  The leading role of genomic technologies in biomarker 
detection clearly represents the current trend in clinical biomarker discovery reflecting both 
stability of the genomic signal and commoditization of the genomic technologies. 
6.4. Major funding organizations in the clinical 
biomarker field 
Focusing on the 1,701 trials, we extracted the “lead sponsor” of the trials; to investigate the 
major players in the field investing heavily into the stratified biomarker programs. Three 
pharmaceutical companies such GSK, Roche and Novartis appear to be the main industrial 
sponsors with 3.7%, 3.1% and 2.7% (Figure 20) of all trials with stratified molecular 
biomarker. Therefore it is not surprising that those companies are behind most recent 
breakthroughs in the field of stratified medicine. GSK compound Dabrafenib with the 
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companion diagnostics for detection of BRAF mutation has received FDA approval for the 
treatment of melanoma (Ouellet D, Grossmann KF, Limentani G, Nebot N, Lan K, Knowles 
L, Gordon MS, Sharma S, Infante JR, Lorusso PM, Pande G, Krachey EC, Blackman SC 
2013). Another GSK’s MEK inhibitor trametinib has been approved with BRAF mutation as 
stratified biomarker (Gilmartin et al. 2011). Roche antibody-drug conjugate trastuzumab 
emtansine has been approved for the treatment of Her2-positive advanced breast cancer 
patient (Verma et al. 2012). Another Roche compound vemurafenib has been approved for 
the treatment of BRAF-mutated metastatic melanoma (Bollag et al. 2012). Imatinib of 
Novartis has got the approval for the treatment of leukemia patients with specific PDGFR and 
C-Kit mutations (Dupart et al. 2011). Pfizer compounds Crizotinib with the companion 
diagnostic (ALK5 mutation) (Sahu et al. 2013) and Maraviroc with the companion diagnostic 
TM test for the viral tropism have also been approved (Obermeier et al. 2012). Vast 
experience of these companies in conducting trials with stratified biomarker allowed for these 
targeted approaches and in case of Crizotinib unprecedentedly shortened the development of 
the drug leading to millions of savings for the company (S.-H. I. Ou et al. 2012). National 
Cancer Institute (12.35%) and NIAID (4.41%) seem to have the major academic drivers of 
trials with stratified molecular biomarker. As European agencies are not obliged to fill into 
the database, there was no mention of European academic player in the top 15 clinical 
research organizations. Other proprietary databases such TrialTrove or PharmaProjects would 
be better for the analysis of the European situation in the field of clinical biomarker research. 
Trials with stratified molecular biomarker and its lead sponsor can be found in 
Supplementary Table 6 (See: 
https://drive.google.com/open?id=0Bw_MQVhSKAMXRk1kTUxSSUVvU2M).  
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Figure 20: Major funding organizations sponsoring trials with stratified 
molecular biomarker. 
The figure demonstrates what percentage of trials with stratified biomarker is funded by top 15 organisations driving such 
trials.  
6.5. Major disease indications targeted by 
stratified biomarker program  
According to our analysis (Figure 21), oncology represents more than 75% of all the trials 
with stratified biomarker program. Infectious disorders are next major focus of trials with 
stratified biomarker representing about 10% of all the analysed studies (Figure 21a). Other 
therapeutic areas combined, represent the rest 15% of the trials with molecular stratified 
biomarker and metabolic diseases leading this group (Figure 21b).  Closer look at the 
individual indications of oncology therapeutic area reveals that most of the registered 
stratified molecular biomarker studies are in the field of breast cancer comprising 478 studies 
and constituting 28% of all trials (Figure 21c). This extensive clinical effort is translated into 
the marketed companion diagnostics and breast cancer patients are benefiting from it.  In this 
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indication hormone-dependency tests, genetic susceptibility tests (such as BRCA1/2 
mutations) and gene expressions analysis (such as Mammaprint and OncotypeDX) became a 
part of a standard clinical care (Tessari et al. 2013; Deyati et al. 2013). Lung cancer is the 
second most frequently targeted (20.8%) by trials with stratified molecular biomarker with 
353 studies registered in ClinicalTrials.gov. Years of clinical research are translated in a 
number of approved biomarkers in this therapeutic area, such as Crizotinib approved in 
combination with the companion genetic test for the ALK5 gene for late stage lung cancer 
(S.-H. I. Ou et al. 2012). Leukemia and Lymphoma are the next largest oncological 
indications benefiting from the early discovery of stratified molecular biomarkers such as 
Philadelphia chromosome or other genetic translocations such as RAR-PML fusions that 
brought to the early discovery of the target-specific treatments, celebrating the first wins of 
molecular biology in clinics. Trials with stratified molecular biomarker and its targeted 
disease indications can be found in Supplementary Table 7 (See: 
https://drive.google.com/file/d/0Bw_MQVhSKAMXbHFRQTNPQ0NrZTg/view).  
 
Figure 21: Major targeted therapeutic areas by trials with stratified molecular 
biomarker. 
(A) Major indication areas targeted by trials with stratified biomarker; (B) Other targeted indication areas; (C) Major types 
of targeted cancer. 
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6.6. Phase wise distribution of stratified 
molecular biomarker trials  
Further analysing at which stage of the clinical development the stratification biomarkers are 
explored, we extracted the information on the “phase” from all 1,701 TSMB (Figure 22). 
Around 93% of trials with stratified molecular biomarker contain the information on clinical 
phase. According to our analysis most of the trials, around 60%, are in phase II. This category 
includes the trials indicated to be in the phase I-II as well. Fifteen percent trials with stratified 
molecular biomarker are in phase I and III.  It was interesting to see that almost 6% of all 
stratified molecular biomarker-associated trials are conducted at phase IV. It clearly reflects 
that search for stratified biomarkers are continued in the post-marketing phase as well. Trials 
with stratified molecular biomarker and its clinical phase can be found in Supplementary 
Table 8 (See: https://drive.google.com/open?id=0Bw_MQVhSKAMXQkptRTluNnRFY2s).      
 
Figure 22: Phase wise distribution of trials with molecular stratified biomarker. 
The figure demonstrates what percentage of trials with stratified biomarker lies in what phase.  
6.7. Impact of biomarker program on clinical 
trial duration and chance of completion  
Our next question was to analyze whether the inclusion of stratified molecular biomarker has 
any impact on trial duration. To answer that clinical trial duration was calculated in months as 
(“start date” - “completion date”). Statistical distribution of clinical trials duration, targeting 
disease indications of Group 2 (interventional trials with biomarker as outcome measure) and 
Group 3 (interventional trials with stratified biomarker) and falling into six therapeutic areas 
were compared in Figure 23a. The three letter abbreviations used along the x axis of Figure 
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23a, represents each category. The first letter of the abbreviation represents targeted therapy 
(e.g. O: oncology, I: infectious diseases, M: metabolic disorders, R: respiratory disorders, C: 
cardiovascular diseases and N: neurologic disorders) followed by two other letters 
representing groups (WB: Group 2, SB: Group 3). As can be seen in Figure 23a,  addition of 
molecular stratified biomarker into clinical trials targeted to oncology, infectious diseases and 
neurologic disorders extend the trial duration, evident from the difference in the central 
tendency of data (i.e. median). We also calculated therapeutic area specific mean trial 
duration and difference of means with 95% confidence interval (CI) between Group2 and 
Group 3 trials by Welch two sample t-test and represented in Table 7. With 95% confidence 
interval stratification step increases trial duration by 13.3 to 2.7 months in oncology, by 27 to 
7.5 months in infectious diseases and by 32.4 to 8 months in neurologic disorders. In 
metabolic and cardiovascular diseases the application of stratified biomarker seems to be less 
significant in affecting clinical trial duration. On the other hand in respiratory disorders 
stratified biomarkers on mean scale shorten the trial duration by 19.7 to 8 months. All the 
completed trials belonging to Group 2 (WB) and Group 3 (SB) and falling into above 
mentioned six therapeutic categories are presented in Supplementary Table 9 (See: 
https://drive.google.com/file/d/0Bw_MQVhSKAMXb3NocGFXRXE1TlU/view) along with 
its “start date”, “completion date”, trial duration in months.  
Therapeutic area Group 2 
abbreviation, Mean 
trial duration in 
months 
Group 3 
abbreviation, 
Mean trial 
duration in months 
Difference of means 
between Group 2 to 
Group 3 with 95% 
CI 
Oncology  OWB, 42.2 OSB, 50.2 -13.3  to -2.7 
Infectious diseases  IWB, 32 ISB, 49.3 -27 to -7.5 
Metabolic disorders  MWB, 26.6 MSB, 27.5 -8 to 6.2 
Respiratory 
disorders 
RWB, 25 RSB, 11.2 8 to 19.7 
Cardiovascular 
disorders 
CWB, 27.8 CSB, 30.2 -18 to  13.3 
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Neurologic 
disorders 
NWB, 21 NCB, 41.2 -32.4  to -8  
Table 7: Therapeutic area specific mean trial duration and difference of means 
with 95% CI between Group2 and Group 3 trials 
 
 
 
Figure 23: Impact of stratified biomarker program on trial duration and 
completion  
(A) Comparative statistical distribution of clinical trials duration between Group 2 and Group 3. (B) Comparative 
proportion of completed trials between Group 1 and Group 3. (C) Comparative proportion of terminated trials 
between Group 1 and Group 3. Impact of stratified biomarker program on trial duration and completion.  
The three-letter abbreviations used along the x axis in (A) represents each category. The first letter of the abbreviation 
represents targeted therapy (O: Oncology; I: Infectious diseases; M: Metabolic disorders; R: Respiratory disorders; C: 
Cardiovascular diseases; N: Neurologic disorders) followed by two other letters representing groups (WB: Group 2; SB: 
Group 3) 
As we see, the duration of trials could be affected by the inclusion of stratified molecular 
biomarker; however question arises if completion itself is affected by inclusion of stratified 
molecular biomarkers? In addressing this question we compared the proportion of 
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“Completed” trials across six most targeted therapeutic areas between Group 1 (all 
interventional trials) and Group 3 (interventional trials with stratified biomarker) as a 
measure of success. To measure the rate unsuccessful trials proportion, “Terminated” trials 
across same six targeted therapeutic areas between Group 1 and Group 3 was compared. 
Proportion of “Completed” trials across six therapeutic categories of each group was 
calculated based on number of “Completed” trials in given therapeutic category of a group 
divided by total number of trials targeting the same therapeutic category of the same group. 
The proportion of “Terminated” trials was calculated using the same formula. Patient 
stratification by molecular biomarkers significantly affect the fate of the trial whether it will 
be successful or unsuccessful (Figure 23b, 23c). In metabolic, cardiovascular and neurologic 
disorder, trial termination rate is significantly higher in Group 1 (trials without a biomarker). 
However, fewer trials targeting respiratory and cancer disorders, are completed in Group 3 
compared to the Group1 trials. If in other therapeutic areas the average percentage of 
terminated studies is about 8%, addition of stratified biomarkers to trials targeting respiratory 
disorders, doubles the chance of the trials to be terminated prematurely. In the case of 
oncology every third molecular biomarker trial is completed compared to every second in the 
non-biomarker group. According to our analysis, more than one third of Group 3 trials started 
after 2009 and cancer being most frequently targeted (Figure 19; 21a). Knowing that the 
median trial duration is ~45 months (Figure 23a), most of them were still ongoing and ~31% 
(411 out of 1317) of oncology trials with stratified biomarker are still in the recruiting phase. 
At the same time slightly higher termination of stratified biomarker trials targeting cancer, 
reflects the hard road of clinical development (well standardized tests, trained personnel and 
dedicated resources) targeting highly heterogeneous diseases like cancer (Ludwig 2012). 
Among all studied therapeutic areas, respiratory disorders are more challenging for 
stratification due to heterogeneity of the population and the fact that biomarker studies in 
respiratory disorders are still in their infancy (Taylor 2011; Penaloza et al. 2012; Lee et al. 
2012). The result is evident in our study, which shows that more clinical trials are terminated 
and less completed when stratified compared to the non-stratified group. Group 3 and Group 
1 trials with its “overall status” can be found in Supplementary Table 10 (See: 
https://drive.google.com/file/d/0Bw_MQVhSKAMXWmpid3QzUmUxT0E/view) and 
Supplementary Table 11 (See: 
https://drive.google.com/file/d/0Bw_MQVhSKAMXYjFaTWZUSG9lX0E/view).  
 
98 
 
It is evident from this analysis that percentage of the trials including patients’ stratification 
based on molecular differentiation is still very low (less than 5%) reflecting all the challenges 
of biomarker development. All though a variety of OMICS technologies have been developed 
in recent years with the aim to identify biomarker in oncology by detailed understanding of 
disease pathophysiology and drug mode of action. But the search for potent biomarker is far 
from being over. A new class of stratified biomarker i.e. miRNA is rapidly emerging in 
cancer treatment with the promise of stratifying the patient population with greater 
confidence. But lack of translational algorithm which can integrate data and knowledge to 
predict the causal relationship between candidate miRNA biomarker and clinical outcome of 
a treatment in a disease indication potentially hamper the endeavor. In this direction a novel 
translational algorithm i.e. SMARTmiR, has been developed to predict the pharmacogenomic 
role of miRNA when treating the colorectal cancer patients with cetuximab therapy.  
 
Next three chapters (i.e. 7, 8, 9) have been dedicated to describe each of those three concepts 
i.e. miRNA, colorectal cancer and cetuximab. Finally in chapter 10
th
 the published 
methodology of SMARTmiR has been discussed in detail.  
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7. microRNA 
7.1. History of miRNA discovery:  
The team of Victor Ambros, Rosalind Lee and Rhonda Feinbaum discovered the existence of 
microRNA and its regulation.  They reported lin-4 gene controls the timing of C.elegans 
larval development stages. But to their surprise this gene did not code any protein instead 
only translated into two small RNAs 22 and 61 nucleotide long. The Ambros and Ruvkun 
labs also discovered that lin-4 miRNA has several anti-sense complementarities to the 
3΄untranslated region (UTR) region of lin14 gene. Ruvkun lab further demonstrated that after 
complementary binding of lin-4 RNA to lin-14, the concentration of lin-14 protein was 
substantially reduced without negligible changes in lin-14 mRNA. These discoveries initiated 
a series of other discoveries producing ample evidences of the existence and post 
transcriptional regulation of small RNAs, known as microRNA or miRNA (Bartel 2004). 
miRNA are the main regulators at post-transcriptional level. However let-7 is the first 
identified miRNA in human (Bartel 2004).               
7.2. miRNA gene  
In 2001 Lau et al reported that most miRNA genes transcribed from a distant part of the 
genome from previously annotated protein coding genomic region. This fact implies that 
there is independent transcriptional machinery for miRNA (Lau et al. 2001). In 2003, a group 
of scientists published that a minor proportion of miRNA was located in the introns of pre-
miRNA. These miRNA are not transcribed from their own promoter but instead processed 
from the introns (Aravin et al. 2001; Aravin et al. 2003). However, in late 2004 Rodriguez et 
al proved 117 miRNAs out of 232 mammalian miRNA (~51%) are in the intronic region 
(Rodriguez et al. 2004). Many miRNA genes are also clustered in a certain portion of the 
genome. The expression of these types of miRNA falls into the category of multi-cistronic 
transcription (Lagos-Quintana et al. 2001).  Although based on the scientific discoveries until 
now, majority of human miRNA genes are not clustered but isolated (Lim et al. 2003). 
However, these perceptions are subject to change as miRNA is comparatively new research 
area and new miRNA genes are constantly being reported. In 2010, a group at the Whitehead 
Institute sequenced 60 million small RNAs in mouse and identified 108 novel miRNA loci. 
The discovery opened the question how many more miRNA remain to be discovered (Chiang 
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et al. 2010). There are several mechanisms through which a novel miRNA can be formed 
which are discussed in the next section. 
7.2.1. Formation of novel miRNA gene  
a. As described in Figure 24 novel miRNA gene can be formed by the duplication of 
local or non-local miRNA gene. In case of local duplication the newly formed 
miRNA gene is located in the close proximity of the original and both the gene share 
the same transcription mechanism. miRNA gene evolved from non-local duplication 
are located in far apart from its original partner and has got independent transcription 
mechanisms (Berezikov 2011).  
b. Unstructured transcripts from intron often rearrange itself into hair pin like structure 
which successively evolved into novel intronic miRNA (Berezikov 2011) .  
c. De-novo emergences of miRNA often evolved into a transcriptional unit and produce 
unstructured transcripts. Later the unstructured transcripts go through the process of 
forming a hair-pin like structure which successively evolved into a novel miRNA 
(Berezikov 2011). 
d. Often transposable elements can lead to the formation of novel miRNA by the 
formation novel miRNA like hair pin stage (Berezikov 2011).  
e. tRNA, small nucleolar RNA (snoRNA) often forms miRNA through hair-pin stage.  
f. Existing miRNA loci sometime undergoes antisense transcription leading to the 
formation of miRNA hairpins with novel mature miRNA and mRNA* (Berezikov 
2011).  
g. Theoretically after two rounds of genome duplication, a locus can retain a gene and 
miRNA in its intron or either one is lost or the entire locus can be lost (Berezikov 
2011).                 
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Figure 24: Genomic Sources of novel miRNA genes (Berezikov 2011).  
Each biological processes (a to g) is described in detail in previous page.   
7.3. miRNA biogenesis 
The formation of mature miRNA is a series of processes which start with the transcription of 
miRNA gene followed by the nuclear and cytoplasmic processing by two RNases. The 
process is described in the following section.   
7.3.1. Transcription of miRNA 
In eukaryotes, miRNAs are transcribed by RNA polymerase II and activity of the enzyme is 
controlled by RNA polymerase II-associated transcription factor and epigenetic regulators. 
Transcription factors like p53, MYC, ZEB1, ZEB2 and MYOD1 can be positively or 
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negatively regulate miRNA expression. Different epigenetic events such as DNA methylation 
and histone modifications can also regulate the miRNA gene expression (Ha & Kim 2014). A 
schematic presentation of miRNA biogenesis and its control is presented in Figure 25 a and 
25 b.   
 
Figure 25: Nuclear event in miRNA biogenesis pathway (Ha & Kim 2014).  
Schematic model of microRNA (miRNA) transcription by RNA polymerase II (Pol II), nuclear processing by the 
Microprocessor complex (comprising Drosha and DGCR8) and export by exportin 5 (EXP5) in complex with RAN GTP.  
7.3.2. miRNA processing 
After transcription miRNA goes through a series of processes to form mature miRNA. Pri-
miRNA is 1 kilobases long with local stem loop structure. A typical pri-miRNA consists of 
33-35 base pairs long stem, a terminal loop and single stranded RNA segments at both 3' and 
5' ends. The maturation process initiates within the nucleus by Drosha, an RNase III enzyme. 
Drosha crop the stem loop to release small hairpin shaped RNA of ~65 nucleotide long. 
Unlike plants, Drosha forms a microprocessor complex with its cofactor DGCR8 for the 
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RNase activity in most of the animal. Before the processing of pri-miRNA, the precise 
recognition of pri-miRNA by the microprocessor complex is of paramount importance. The 
two double stranded RNA binding domain of DGCR8 precisely recognize a pri-miRNA. 
Drosha cleaves the hairpin structure at approximately 11 base pairs away from the basal 
junction between single stranded RNA and dsRNA and approximately 22 base pairs away 
from the apical junction linked to the terminal loop (see Figure 25). It is still quite unclear 
how Drosha and DGCR2 cumulatively interact with junction and the stem before cropping. 
The UG and CNNC motif at the basal junction and UGUG motif at the apical junction (see 
Figure 26) may also play a crucial role in binding other determinants for the processing of 
pri-miRNA. These three motifs are quite conserved and 79% of human miRNAs has got at 
least one of these three motifs.  
 
Figure 26: Recognition sites of Drosha and microprocessor complex (Ha & Kim 
2014). 
The Microprocessor complex (comprising Drosha and DGCR8) recognizes the single-stranded RNA tails, the stem of ~35 
bp in length and a terminal loop of the primary microRNA (pri-miRNA). Microprocessor measures ~11 bp from the basal 
junction. ~22bp from the apical junction, and Drosha cleaves the pri-miRNA at this position | Dicer recognizes pre-miRNA. 
The termini of pre-miRNA are recognized by the PAZ (PIWI –Argonaute (AGO)–ZWILLE) domain of human Dicer, which 
contains two basic pockets: one that interacts with the 5ʹ-phosphorylated end of the pre-miRNA and one that interacts with 
the 3ʹ end105,106. The stem of the pre-mRNA is aligned along the axis of the protein in a way that Dicer can measure a set 
distance from both termini (like a ‘molecular ruler’), because the catalytic domains of RNase III domain a (RIIIDa) and 
RIIIDb are placed ~22 nucleotides (nt) away from the termini. P, phosphate.  
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7.3.3. Nuclear export 
After the first processing of pri-miRNA by Drosha, resulting pre-miRNA is exported into the 
cytoplasm. In cytoplasm, the maturation process can be completed. The EXP5 protein forms 
a transport complex with GTP-binding nuclear protein RAN and pre-miRNA. This complex 
passes through the nuclear pore complex. Next GTP is hydrolysed, thus complex is 
disassembled and pre-miRNA is released into the cytosol.         
 
Figure 27: Cytoplasmic processing of miRNA processing (Ha & Kim 2014). 
Schematic model of Dicer-mediated processing and Argonaute (AGO) loading. Dicer interacts with a double-stranded RNA-
binding domain (dsRBD) protein (TAR RNA-binding protein (TRBP) in humans. 
7.3.4. Cytoplasmic processing pre-miRNA  
The released pre-miRNA in the cytoplasm is cleaved near its terminal loop by the Dicer 
complex.  The Dicer interacts with double stranded RNA–binding domain (dsRBD) protein 
i.e. TRBP in human. The cleaving of pre-miRNA by Dicer forms a RNA duplex (see Figure 
27). This RNA duplex is released and subsequently loaded onto human AGO1-4 to form 
RNA induced silencing complex (RISC). RISC further binds to a complex made of Heat 
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shock cognate 70 (HSC70) and heat shock protein 90 (HSP90). Successively the passenger 
strand (Blue region of the duplex in Figure 26) is discarded and remaining mature part (red 
part in Figure 27) remains attached to AGO1-4. Through consecutive steps mature miRNA 
formation and targeting of mRNA is achieved through RICS assembly. Dicer processing is 
also tightly regulated by post translational modification of TRBP and AGO proteins.        
7.4. miRNA nomenclature 
The nomenclature of miRNA is not completely consistent. The early discovered miRNA 
were named after their phenotypes i.e. lin-4, let-7 and lys-6. Recently discovered miRNAs 
are published with a sequential numbering after “mir”, such that mir-2 has been discovered 
after miR-1. The organism specificity of a miRNA is designated by a three letter code, for 
example miR-1 in human will be designated as has-miR-1. If a miRNA gene encodes two 
sisters miRNA then they are designated as miR-125-a and miR-125-b. If identical mature 
sequences are expressed by distinct precursor sequences, genomic loci then numeric suffix 
are added at the end of the name e.g. miR-125-b-1 and miR-125-b-2.  Each miRNA gene 
locus code two mature miRNA one from the 5' end the other from 3' end, the stand specificity 
is denoted as follows: miR-125-a-5p and miR-125-a-3p. However, only one of them is 
biologically more active and abundant called “guide” and the other “passenger” one often 
represented as miRNA* (Ambros et al. 2003).   
7.5. miRNA expression 
The miRNA has got very interesting yet very intriguing expression pattern. Several miRNA 
in C.elegans i.e. lin-4 and let-7 have developmental stage specific expression pattern. Many 
mammalian miRNAs express in specific tissue and organ, to name just a few; miR-1 
primarily found in mammalian heart, miR-122 in liver, miR-223 in macrophages. Even the 
degree of expression of a miRNA which is only expressed in specific organ may have 
differential expression correlated to different development stages (Minami et al. 2014; 
Vacchi-Suzzi et al. 2013).    
7.6. miRNA function 
Intensive research over the years has discovered the role of miRNA in key cellular processes, 
i.e. development, differentiation, proliferation, cell death and metabolism. Some examples 
showing the relation of miRNA to those cellular processes are summarised below. The first 
discovered miRNA lin-4 and let-7 known to regulate the developmental stages of C.elegans 
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and without the expression of lin-4, C.elegans is unable to make the transition from first to 
second larval phase. The coordination of miR-48 and miR-84 is essential to end the larval 
monitoring cycle (Abbott et al. 2005). The over expression of miR-181 is the prerequisite for 
the terminal differentiation of the myoblasts. Expression of miR-309 cluster is responsible for 
the zygotic onset of Drosophila (Bushati & Cohen 2007). The expression of miR-214 plays 
an important role throughout embryogenesis of Zebrafish (Flynt et al. 2007).  miR-15, miR-
16, miR-17 cluster and miR-21 regulate cell death or apoptosis (Jovanovic & Hengartner 
2006). miR-196, miR-302, miR-27a, miR-224, miR-16, miR-223 are well known regulators 
of cell proliferation and differentiation (Tsai et al. 2010; Popovic et al. 2009; Lin et al. 2008; 
Mertens-Talcott et al. 2007; Venugopal et al. 2010; Guo et al. 2009; Fazi et al. 2007; Felli et 
al. 2009). miR-122 is the first miRNA linked to metabolic control. Expressing primarily in 
liver miR-122, regulate hepatic cholesterol and lipid metabolism. miR-195 regulate glucose 
uptake by directly regulating GLUT3. miR-32 regulate a glucose transporter SLC45A3. 
Hexokinase catalyses the first step of glycolysis and miR-143, miR-138 regulate hexokinase. 
miR-375 known to regulate the lactate metabolism. miR-375, miR-124a and miR-9 known to 
regulate insulin metabolism (Hatziapostolou et al. 2013).  
Different miRNAs are also showing the promise to be a powerful cancer biomarker (Chen et 
al. 2008; Bushati & Cohen 2007). These miRNAs are often referred as OncomiRs. A detailed 
discussion of different types of OncomiRs, their mechanism of action and involvement in 
different types of cancer are presented later.    
7.7. Bioinformatics approaches to study miRNA 
regulation 
The discovery of abundant miRNAs in diverse multi cellular eukaryotes raised many 
intriguing questions including the function of the miRNA within the cell. The key to finding 
out the answer lies in the way miRNA recognise its target mRNA and their cellular function. 
In RISC, processed mature miRNA pair with mRNA and repress the expression of target 
mRNA post transcription. At the beginning of the last decade, it was proposed that miRNA 
will specifically target a mRNA if it has sufficient complementarity to the target mRNA. 
Otherwise the miRNA will repress productive translation if target mRNA does not have 
sufficient complementarity but does have suitable constellation of miRNA complementary 
sites (Bartel 2009). The complementarity is mainly achieved by recognizing and binding to 
the 3' untranslated region of the target mRNA (Yue et al. 2009). A number of other predictive 
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features for miRNA target predictions have been discovered in recent times, such as 
dinucleotide composition of flanking sequence, strong base pairing between 3' UTR of 
mRNAs and miRNA seed region, thermodynamic stability of the binding site, evolutionary 
conservation of binding sites (particularly the seed region), secondary structure accessibility 
and host gene expression profile (Zheng et al. 2013).   Over the years many miRNA target 
prediction algorithms have been proposed and in the next section an overview of the current 
algorithms and their features have been summarized.  
7.7.1. miRNA target prediction algorithms 
A list of the most popular target prediction algorithms is provided in Table 8. In the Table 8 
seed matching is defined as sequence alignment between 1
st
 to 8
th
 nucleotide of the miRNA 5' 
end and target mRNA sequence, Conservation is defined as seed matching which is 
conserved across different species, Free energy refers to the minimum free energy which 
shows how strong the binding of miRNA with its target is (Yue et al. 2009). 
Algorithm Approach Features Availability 
TargetScan 
(S) 
Rule 
Based 
1.  The algorithm uses seed 
matching, free energy and 
conservation.   
2. Supported Organisms: 
mammals, worms, files. 
http://www.targetscan.org/ 
miRanda Rule 
Based 
1. Optimizes sequence 
complementarity based on 
position-specific rules and 
interspecies conservation.  
2. The algorithm also uses free 
energy and conservation.  
3. Supported Organisms: 
human, mouse, rats.  
http://www.microrna.org/micr
orna/home.do 
Pita Rule 
Based 
1. Investigate the role of target 
site accessibility, as determined 
by base-pairing interactions 
within the miRNA.  
2. Also uses seed match and 
http://genie.weizmann.ac.il/pu
bs/mir07/mir07_data.html 
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free energy.  
3. Supported Organisms: 
Human, mice, flies and worms 
DIANA-
microT 
Rule 
Based 
1.  Combines conserved and 
non-conserved miRNA 
recognition elements into a 
final prediction score. 
2. It uses a dynamic 
programming algorithm to 
have the highest scoring 
alignment between nine 
nucleotide long windows of the 
3' UTR with the miRNA driver 
sequence. It also applies to 
energy.  
3. Supported Organisms: 
Human 
http://diana.cslab.ece.ntua.gr/
microT 
Pictar Data 
Driven: 
Hidden 
Markov 
Model 
1. It checks the seed matching, 
conservation of seed alignment 
across multiple species. It also 
considers the miRNA-target 
binding free energy.  
2. Supported Organisms: 
vertebrates, flies and 
nematodes.  
http://pictar.mdc-berlin.de/ 
RNA-hybrid Rule based 1. It determines the most 
favourable hybridization 
between two sequences.  
2. The algorithm uses seed 
match and free energy as a 
feature.  
3. Supported Organism: any. 
http://bibiserv2.cebitec.uni-
bielefeld.de/rnahybrid 
MicroInspect Rule based 1. The software scans and http://bioinfo.uni-
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or detects miRNA binding sites 
and sort the possible target 
sites based on free energy.  
2. The algorithm uses four 
features seed match, free 
energy, binding structure and 
self-complementarity,  
4. Supported Organism: any. 
plovdiv.bg/microinspector/ 
Table 8: miRNA prediction algorithms (Yue et al. 2009; Zheng et al. 2013). 
Current miRNA target prediction algorithm suffers from a high false positive rate (FPR). FPR 
is higher than 0.3 which reflect that specificity is often lower than 70%. Using conservation 
and functional similarities have reduced the number of false positives for miRNA target 
prediction but it still needs improvement. It is noteworthy that different algorithm’s target 
prediction can vary and researchers often crosscheck or intersect predictions from different 
algorithms to get additional confidence on true positive (Yue et al. 2009).  
7.7.2. Computational Methods to detect miRNA-mRNA 
regulatory relationship  
Gene expression technology has emerged as important and promising evidence based 
resource for exploring miRNA-mRNA regulatory relationships with biological relevance.  
Figure 28 shows a common framework used by the state of the art computational methods to 
detect the regulatory relationship between mRNA-miRNA. A set of features is first selected 
followed by building a statistical model to predict the regulatory relationship between 
miRNA and its target miRNA (Figure 28). Statistical methods such as correlation, regression 
and Bayesian parameter learning have achieved significant results in inferring miRNA-
mRNA regulatory relationships (Le et al. 2014).  
110 
 
 
Figure 28: General workflow of existing computational methods to investigate 
miRNA-mRNA regulatory relationship (Le et al. 2014).  
 
The principal hypothesis of this type of analysis assumes if a mRNA is regulated by miRNA, 
correlation profile at the expression level should reveal the relationship. Some of these 
methods also consider availability of miRNA-mRNA sequence based targeting to reduce the 
false discovery rate.   
In 2009, Li et al. integrated miRNA expression data and mRNA target information to predict 
miRNA-mRNA interactions. The team has detected miRNA-mRNA interactions for different 
physiological conditions using Bayesian network structure learning with splitting-averaging 
strategy. The method has applied to heterogeneous data including miRNA targeting 
information, expression profiles of miRNAs and mRNAs, and sample categories. Variational 
Bayesian-Gaussian Mixture Model has been applied to integrate the score for over expression 
data and from sequence based prediction methods (Liu et al. 2009).  
 
In 2011, Liang et al. launched mirAct web service to explore miRNA activities based on gene 
expression data. Given the user-uploaded gene expression data, mirAct first transforms values 
to ranks or Z-scores. Then, mirAct infers the regulatory effect of a miRNA via a two-step 
procedure. First, a sample score measuring the activity of a miRNA in a sample is obtained 
by comparing the expression levels of its non-targets with those of targets. In the case of rank 
transformation, the difference of the average ranks between a miRNA’s non-targets and 
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targets is used. In the case of Z-score representation, the two-sample t-statistic is applied. 
Then, miRNA activity change across different classes of samples are investigated by 
examining the sample scores via Kruskal–Wallis test, (null hypothesis is that all classes have 
identical miRNA activity and supports the analysis of multiple-class data). In addition, 
Jonckheere–Terpstra trend test is implemented to examine any trend present in the miRNA 
activity, which might be useful for analyzing data at multiple stages (e.g. disease 
progression). Multiple comparisons are corrected using the Benjamini and Hochberg FDR 
method. It is the integration of information within a single sample and across different classes 
of samples that makes mirAct distinct from other tools. Furthermore, based on 
computationally determined miRNA sample scores, mirAct enables clustering analysis for 
samples and miRNAs, which facilitates the visualization and identification of miRNAs of 
interest (Liang et al. 2011). 
 
In 2013, Chen et al. integrated different gene expression data sets from TCGA (The Cancer 
Genome Atlas) into a model to infer miRNA-mRNA interactions in different forms of cancer.  
The group developed a novel statistical method to jointly analyze expression profiles from 
multiple cancers to identify miRNA–gene interactions that are both common across cancers 
and specific to certain cancers. At first, probabilities of miRNA–mRNA interactions are 
calculated with the Pearson correlation and the statistical significance level is calculated by 
Fisher transformation. Next, an empirical Bayes method was jointly applied to infer the 
posterior probability of interactions across cancers. The method is suitable for analyzing 
multiple expression data sets (miRNA and target mRNA) of the same physiological condition 
i.e. cancer in this example (Chen et al. 2013).  
 
rdjk   =  
∑ (𝑌𝑑𝑖𝑗  −  𝑌𝑑𝑗
𝑚)(𝑋𝑑𝑖𝑘  −  𝑋𝑑𝑘
𝑚 )
𝑁𝑑
𝑖=1
√∑ (𝑌𝑑𝑖𝑗  −  𝑌𝑑𝑗
𝑚)
2𝑁𝑑
𝑖=1
 (√∑ (𝑋𝑑𝑖𝑘  −  𝑋𝑑𝑘
𝑚 )
2𝑁𝑑
𝑖=1
)
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1
2
 ln (
1+𝑟𝑑𝑗𝑘
1−𝑟𝑑𝑗𝑘
) ~ 𝑁𝑜𝑟𝑚𝑎𝑙 (0,
1
𝑁𝑑−3
) 
where rdjk is the Pearson correlation coefficient between mRNA j and miRNA k in disease d; Ydij is the expression of gene j 
in individual i of disease d; Xdik is the expression of miRNA k in individual i of disease d; Nd is the number of individuals in 
disease d; zdjk is the z-score of each pair gained from the Fisher transformation of the Pearson correlation coefficient.  
In the same year, Jacobsen et al. also applied regression analysis to understand the regulatory 
relationship of miRNA and its target mRNA across different cancer using TCGA data. The 
team developed a computational method and statistical score i.e. the association recurrence 
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(REC) score by using miRNA and mRNA expression profiles across many cancer types. In 
individual cancer types, pairwise miRNA-mRNA relationships are evaluated using a 
multivariate linear model (Figure 29), which also factors in variation (noise) in mRNA 
expression induced by changes in DNA copy number and promoter methylation at the mRNA 
gene locus. Associations are rank transformed in individual cancer types, and the method 
subsequently evaluates the null hypothesis that no association exists between the miRNA-
mRNA pair in all cancer types to determine specificity (Jacobsen et al. 2013).  
 
Figure 29: Overview of the statistical approach. Statistical method i.e. the linear 
model has been applied to evaluate recurrence of miRNA-mRNA expression 
association across cancer types (Jacobsen et al. 2013). 
GBM: Glioblastoma multi forme, OVA: Ovarian serous cystadenocarcinoma, CRC: Colon and rectum adenocarcinoma, 
KIRC: Kidney renal clear-cell carcinoma, LUSC: Lung squamous-cell carcinoma, BRCA: Breast invasive carcinoma, 
UCEC: Uterine corpus endometrioid carcinoma, BLCA: Bladder urothelial carcinoma, HNSC: Head and neck squamous-cell 
carcinoma, LUAD: Lung adenocarcinoma 
 
In 2014, Goldenberg et al. developed a probabilistic scoring method called TargetScore. 
TargetScore predicts miRNA targets as the transformed fold-change weighed by the Bayesian 
posteriors given target features. The team integrated 84 datasets from Gene Expression 
Omnibus corresponding to 77 human tissue or cells and 113 distinct transfected miRNAs. 
TargetScore is a novel probabilistic method for miRNA target prediction problem by 
integrating miRNA-overexpression data and sequence-based scores from other prediction 
methods. Briefly, each feature is considered an independent observed variable as input to a 
variable Bayesian–Gaussian mixture model (VB-GMM).   Bayesian method was applied over 
a maximum likelihood approach to avoid over fitting. Specifically, given expression fold-
change (due to miRNA transfection), a three-component VB-GMM was used to infer down 
regulated targets accounting for genes with little or positive fold-change (Liu et al. 2009).  
In 2013, Le et al. designed a causality discovery-based method to uncover the causal 
regulatory relationship between miRNAs and mRNAs, using expression profiles of miRNAs 
and mRNAs. The algorithm does not incorporate any prior target information. The algorithm 
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basically learns the regulatory network from the expression data. Finally it simulates the 
intervention procedure to estimate the causal effect of miRNA on its target mRNA (Le et al. 
2013).  
7.8. OncomiR 
In 2002 miRNA dysregulation in cancer was first discovered in chronic lymphocytic 
leukemia (CLL). 13q14.3 a frequently deleted region in CLL holds two miRNA cluster loci 
in it i.e. miR-15, miR-16 (Calin et al. 2002). Recent evidences indicated that miRNA post 
transcriptionally regulates many oncogenes and tumor suppressor genes. In this process, they 
can control all the hallmarks of cancers i.e. tumor growth, apoptosis, invasion, angiogenesis 
and immune evasion (Stahlhut & Slack 2013). Multiple scientific studies also suggest that 
miRNAs are generally down regulated in cancer and mature miRNA present at a reduced 
level in tumors. This phenomenon can be due to genetic loss (like in CLL), epigenetic 
silencing, defects in their biogenesis pathway or wide spread repression in transcription 
(Jansson & Lund 2012). Corroborating to this, numerous studies find out that normal miRNA 
biogenesis often disrupts in cancer as reduced DICER expression presenting human tumors 
(Karube et al. 2005; Melo et al. 2009; Pampalakis et al. 2010; Zhu et al. 2012). The 
oncogenic transcription factor Myc control the expression of multiple miRNA which are well 
known for their anti-proliferative, anti-apoptotic, anti-tumor suppressor effects e.g. let-7, 
miR-15a/16-1, miR-26a and miR-34a (Bui & Mendell 2010). An abridged presentation on 
miRNA action in cancer is provided in the next section.  
7.8.1. Mechanism of action of OncomiRs 
The action of OncomiRs is mostly controlled through the following mechanisms:  
A. One to One miRNA-mRNA interaction: Some of the most important miRNA in 
cancer fall into this category i.e. they repress expression of a single target and 
regulation manifest as certain phenotype (Hayes et al. 2014).  
B. One to many miRNA-mRNAs interactions: In some cases the expression of several 
miRNAs are controlled by a single miRNA resulting a sum effect determining a 
common phenotype (Hayes et al. 2014).  
C. The functional approach: This special type of regulation where miRNA not only 
regulate expression of transcripts and decide the cellular fate but the targets are 
functionally related in a way they control expression of each other (Hayes et al. 2014).  
114 
 
D. The pathway approach: In pathway approach one or multiple miRNAs from same 
cluster i.e. regulated by the same transcription factor target several proteins’ 
transcripts within a specific pathway.  In this scenario, the pathway has several 
regulations at several nodal points (Hayes et al. 2014).  
A schematic representation of all the four possible mechanisms is presented in Figure 30. 
 
Figure 30: Mechanisms of action of OncomiRs (Hayes et al. 2014). 
Approaches to studying microRNA networks. (A) The ‘basic’ approach: single microRNA–mRNA interaction. (B) The 
‘broad’ approach: one microRNA to many mRNAs. (C) The ‘functional’ approach. (D) The pathway-based approach.  
 
7.8.2. OncomiRs in Clinical Development 
Several ongoing clinical trials aim to decipher miRNA role where specific miRNAs are being 
monitored for safety, pharmacokinetics, pharmacodynamics profile and for patient 
stratification purpose.  Such clinical trials are presented in Table 9 (Hayes et al. 2014).  
MicroRNA Trial reference Disease 
miR-34a NCT01829971 Liver cancer and liver metastases 
Numerous NCT01964508 Thyroid cancer 
Circulating NCT01722851 Breast cancer 
Numerous NCT01220427 High-risk prostate cancer 
miR-10b NCT01849952 Glioma 
miR-29b NCT02009852 Oral squamous cell carcinoma 
Numerous NCT02127073 Breast cancer 
Circulating NCT01595139 Low-grade glioma 
Numerous NCT01828918 Colorectal carcinoma 
Numerous NCT01119573 Endometrial cancer 
Circulating NCT01595126 Central nervous system cancer 
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miR-29 family NCT01927354 Head and neck squamous cell 
carcinoma 
Numerous NCT01453465 Rhabdoid tumors 
Circulating NCT01391351 Ovarian cancer 
Circulating NCT01505699 B-cell acute lymphocytic leukemia 
Numerous NCT01957332 Breast cancer 
Circulating NCT01556178 Pediatric brain cancer 
Numerous NCT01050296 Pediatric solid tumors 
Numerous NCT00864266 Non-small-cell lung cancer 
Table 9: miRNA in Clinical Trials (Hayes et al. 2014). 
 
 
One of the major focuses of the thesis is to investigate the prospective role of miRNA for the 
stratification of colorectal cancer patient who can benefit from anti-EGFR therapy. To 
familiarize the reader to each of those concepts next chapter have been dedicated to describe 
colorectal cancer in detail.  
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8. Colorectal Cancer 
8.2. Colorectal cancer: Definition 
The colon and rectum together constitutes the terminal part of the human digesting tract, 
commencing at the ileocecal valve and ending at the anus. Colorectal cancer (CRC) arises in 
the epithelial cells lining the lumen of the colon; resulting from a multistep process. Initially 
neoplastic tubular adenomas originate as polypoid structures growing into the colon lumen 
which gradually acquire disordered villous histology (Markowitz et al. 2002). Cancerous 
growth is recognized when the invasive cells rupture the underlying epithelial basement 
membrane of the colon. 
8.3. Epidemiology 
Colorectal cancer is the third most common form of cancer accounting for 10% of all cancer 
incidence worldwide and the fourth most common cancer cause of death globally (Ferlay et 
al., 2012). Almost 55% of the cases occur in more developed regions of Europe, North 
America, Australia and New Zealand, whereas incidence is lowest in some countries of south 
and central Asia, parts of Africa and South America (Center et al. 2009). There is wide 
geographical variation in incidence across the world with incidence rates varying ten-fold in 
both sexes worldwide. In 2012, estimated age-standardised incidence by region for men and 
women ranged from 4.5 and 3.8 per 100,000 in Western Africa to 44.8 and 32.2 per 100,000 
in Australia/New Zealand respectively (Ferlay et al., 2012; Jemal et al., 2011). However, in 
the USA and several other high income countries, incidence has stabilised or started to 
decrease, probably because of increased use of sigmoidoscopy and colonoscopy with 
polypectomy (Stock et al. 2012). 
 
Mortality in CRC is lower (694,000 deaths, 8.5% of the total) with more deaths (52%) 
occurring in the less developed regions of the world. There is less variability in mortality 
rates worldwide (six-fold in men, four-fold in women), with the mortality rates for men and 
women ranging from 3.5 and 3.0 per 100,000 in Western Africa to 20.3 and 11.7 per 10,000 
in Central and Eastern Europe (Center et al., 2009; Ferlay et al., 2012). Mortality has been 
decreasing since the 1980s in several high-income countries and countries of east Asia and 
eastern Europe, most probably because of improved early detection and treatment. However, 
the rise in mortality rates have continued in countries with poor healthcare resources 
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including countries in Central and South America and rural areas in China (Guo et al. 2012; 
Bosetti et al. 2011) 
 
Figure 31: Colorectal cancer epidemiology 
The figure shows the estimated age-standardised incidence by region for men and women in the world.  
8.4. Risk factors 
Several risk factors are associated with the occurrence of CRC (Brenner et al. 2014; Haggar 
& Boushey 2009). The factors ranging from the demographic to lifestyle and dietary factors 
are briefly described as following; 
8.4.1. Age & Sex 
The overall risk of developing CRC is equal among both gender, however, women have a 
higher risk for colon cancer, while men are more likely to develop rectal cancer  (DeCosse et 
al. 1993). The chances of developing CRC increases after the age of 40, sharply inclining 
after the age of 50 and more than 50% CRC cases are diagnosed in individuals aged above 
50. The incidence rate is more than 50 times higher in persons aged 60 to 79 years than in 
those younger than 40 years (Ries et al., 2008; World Cancer Research Fund, 2007)  
8.4.2. Heredity 
The hereditary factors contribute to substantial number of CRC cases. Studies show that 20% 
patients have a family history of CRC while 5-10% of the cases are a consequence of 
recognized hereditary conditions (Jackson-Thompson et al., 2006; Skibber et al., 2001)]. The 
most common inherited conditions are familial adenomatous polyposis (FAP) and hereditary 
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nonpolyposis colorectal cancer (HNPCC), also called Lynch syndrome (discussed in section 
3.5.5.) 
8.4.3. Inflammatory Bowel Disease (IBD) 
Inflammatory bowel disease (IBD) is a term used to describe two diseases, ulcerative colitis 
and Crohn disease. The presence of IBD considerably increases the risk of CRC and the 
relative risk has been estimated to be between 4 - 20 fold (Janout, 2001). 
8.4.4. Dietary habits 
Dietary intake strongly influences the development of CRC with studies demonstrating that 
change in food habits might reduce the cancer burden up to 70% (Willett 2005). High red 
meat and processed meat consumption (Larsson & Wolk 2006; Santarelli et al. 2008) along 
with high fat intake (Janout, 2001) are implicated in the development of CRC, both 
characteristics of typical Western diet. In addition, it is considered that consuming diet low in 
fruits and vegetables may have a higher risk of CRC (National Institutes of Health 2006) 
8.4.5. Lifestyle factors 
Cigarette smoking has been found to be critical for CRC development with 12% deaths 
attributed to smoking (Zisman et al. 2006). The carcinogens found in tobacco expedites 
cancerous growth in colon and rectum with studies revealing that smoking habits could lead 
to an average earlier age of disease onset in men and women (Tsong et al. 2007). Alcohol 
consumptions is associated with early onset of CRC (Zisman et al. 2006; Tsong et al. 2007) 
as well as disproportionate increase in tumor in distal colon (Bazensky et al. 2007). 
8.5. Stages of colorectal cancer 
Staging in CRC defines the process of finding out how far the cancer has spread. The stage of 
a cancer is one of the most important factors in determining prognosis and treatment options. 
The common method for CRC classification is the TNM system adopted by American Joint 
Committee on Cancer (AJCC) (Edge, 2010; Greene et al., 2002). As described in Figure 32, 
the TNM system describes 3 key pieces of information local invasion depth (T stage), lymph 
node involvement (N stage) and presence of distant metastases (M stage). The stage is based 
on the results of the physical exam, biopsy, along with imaging tests and called clinical stage.  
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Figure 32: Stages of Colorectal Cancer 
The figure demonstrates the anatomy of stage 0 to stage IV colorectal cancer.  [see: 
https://www.bowelcanceraustralia.org/images/About_Bowel_Cancer-Bowel-Cancer-Staging_770.jpg] 
 
Another classification system is adopted from the Union Internationale Contre le Cancer 
(UICC) which determines the pathologic stage after surgical removal (Sobin LH, Wittekind C 
2002). The stages in combination with the clinical stages are described in Table 10. 
 
UICC 
Stages 
TNM Description 
Stage 0 Tis N0 M0 This stage is known as carcinoma in situ when the tumor is 
in the earliest stage has not grown beyond the inner layer of 
the colon or rectum 
Stage I T1-T2 N0 M0 Tumor grows through the submucosa (T1) or it may also 
have grown into the muscularis propria (T2). 
Stage IIA T3 N0 M0 Tumor invades the subserosa (the layer between the 
muscularis propria and the serosa) or the surrounding tissue 
of the colon or rectum. 
Stage IIB T4a N0 M0 Tumor perforates the wall of the colon or rectum through 
the visceral peritoneum. 
Stage IIC T4b N0 M0 The tumor invades into other nearby tissues or organs 
through the wall of the colon or rectum by way of the 
serosa. 
Stage IIIA T1-T2 N1 M0 Tumor grows through the mucosa into the submucosa (T1) 
and also into the muscularis propria (T2) It has spread to as 
many as 3 regional lymph nodes. 
T1, N2a, M0 The tumor has grown through the mucosa into the 
submucosa (T1). It has spread to 4 to 6 nearby lymph nodes 
(N2a). 
Stage IIIB T3-T4a N1 M0 Tumor has grown into the outermost layers of the colon or 
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rectum (T3) or through the visceral peritoneum (T4a) and 
has spread to as many as 3 regional lymph nodes. 
T2-T3, N2a, M0 The tumor has grown into the muscularis propria (T2) or 
into the outermost layers of the colon or rectum (T3). It has 
spread to 4 to 6 nearby lymph nodes (N2a). 
T1-T2, N2b, M0 The tumor remains within submucosa (T1) or it may also 
have grown into the muscularis propria (T2). It has spread 
to 7 or more nearby lymph nodes (N2b). 
Stage IIIC T4a, N2a, M0 The tumor breaches through the wall of the colon or rectum 
(including the visceral peritoneum) but has not reached 
nearby organs (T4a). It has spread to 4 to 6 nearby lymph 
nodes (N2a). 
T3-T4a, N2b, M0 The cancer has grown into the outermost layers of the colon 
or rectum (T3) or through the visceral peritoneum (T4a) but 
has not reached nearby organs. It has spread to 7 or more 
nearby lymph nodes (N2b). 
T4b, N1-N2, M0 The tumor directly invades other organs or structures, 
including invasion of other segments of the colon or rectum 
by way of the serosa (T4b). It has spread to at least one 
nearby lymph node (N1 or N2). 
Stage IVA Any T, Any N, 
M1a 
The tumor may or may not have grown through the wall of 
the colon or rectum, may or may not have spread to nearby 
lymph nodes. It has spread to 1 distant organ (such as the 
liver or lung) or set of lymph nodes (M1a). 
Stage IVB Any T, Any N, 
M1b 
Tumor may or may not have spread through the wall of the 
colon or rectum and may or may not have spread to nearby 
lymph nodes. Cancer has spread to more than 1 organ or to 
the peritoneum that lines the inner wall of the abdominal 
cavity. 
Table 10: Colorectal Cancer stages based on Union Internationale Contre le 
Cancer (UICC) 
8.6. Molecular genetics 
CRC development is a gradual process often requiring 10 or more years with the dysplastic 
adenomas forming the common precursor lesion (Jass 2004). Sporadic CRC has been 
described as a multistep model of carcinogenesis in which multiple mutations are 
accumulated which results in uninhibited cell proliferation and tumor development (Fearon & 
Vogelstein 1990; Kinzler & Vogelstein 1996).  
8.6.1. Adenoma carcinoma sequence 
The main conclusions drawn regarding sporadic CRC are as follows; 
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 CRC is a result of mutational activation of oncogenes and the inactivation of tumor 
suppressor genes 
 The accumulation of multiple genetic mutations, rather than the order in which they 
occur, determines the biologic behavior of  the tumor 
 Somatic mutations in at least 4-5 genes are required for malignant transformation. 
Recent genome-wide sequence studies have enumerated about 80 mutated genes per 
colorectal cancer, however less than 15 mutations were considered to drive the tumor 
development (Wood et al. 2007) 
The distinct pathways which have been associated with CRC are as follows (Bogaert & 
Prenen 2014b); 
8.6.2. Chromosomal instability (CIN):  
This is the most common pathway (70%), incorporating numerical (aneuploidy) or structural 
chromosomal abnormalities resulting cell-to cell variability (Lengauer et al. 1997), 
characterized by frequent loss-of-heterozygosity (LOH) at tumor suppressor gene loci and 
chromosomal gene arrangements. CIN is an efficient mechanism for causing the physical loss 
of wild-type copy in specific oncogenes and tumor suppressor genes. 
8.6.3. Mutational inactivation of tumor-suppressor 
genes 
APC: Mutations in adenomatous polyposis coli (APC) gene are important in early cell 
transformation, with approximately 70–80% of sporadic colorectal adenomas and carcinomas 
have somatic mutations that inactivate APC (Kinzler & Vogelstein 1998; Segditsas & 
Tomlinson 2006). In fact, APC mutations are suggested to be the rate-limiting event in most 
adenoma development. The reason can be found in presence of somatic APC mutations even 
in earliest lesions within microscopic adenomas (Kinzler & Vogelstein 1996) as well the 
APC mutation frequency being same for minute adenomas and advanced carcinomas (Aoki & 
Taketo 2007; Polakis 2007). APC gene function is to modulate the levels of β-catenin protein 
by proteolysis as a component of the β-catenin degradation complex. Mutations in APC gene 
product leads to loss of function of oncoprotein β-catenin, which binds to its nuclear partner 
activating transcription factor which regulates cellular activation (Segditsas & Tomlinson 
2006; Markowitz & Bertagnolli 2009). This entire cascade of events causes the constitutive 
activation of Wnt signalling, regarded as the initial event in CRC. Somatic mutations and 
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deletions that inactivate both copies of APC are present in most sporadic colorectal adenoma 
and cancers. In a small subgroup of tumors with wild-type APC, mutations of β-catenin that 
render the protein resistant to the β-catenin degradation complex activate Wnt signalling 
(Vogelstein B 2002; Korinek et al. 1997).  
p53: Mutation of TP53 leads to inactivation of the p53, a key genetic step in CRC. 
Inactivated p53 is exhibited in sporadic CRC patients, in up to 75% cases. In most tumors, 
the two TP53 alleles are inactivated by a missense mutation that inactivates the 
transcriptional activity of p53 and a 17p chromosomal deletion that eliminates the second 
TP53 allele (Baker et al., 1990; DeVita et al., 2008). Wild-type p53 mediates G1 cell cycle 
arrest to facilitate DNA repair during replication or to induce apoptosis (Vazquez et al. 2008). 
Studies show that the inactivation of TP53 often coincides with the transition of large 
adenomas into invasive carcinomas (Baker, Preisinger, et al. 1990). Identification of p53 
mutations in colorectal cancer has prognostic significance. Persons with tumor that have a 
p53 mutation have worse outcome and shorter survival than persons whose tumor do not have 
a p53 mutation (Kressner et al. 1999). 
 
TGF-β: The mutational inactivation of TGF-β signalling pathway is a critical step in CRC. 
The frameshift mutation within the TGFBR2 coding sequence leads to mismatch-repair 
defects within about one third of CRC cases (Grady et al. 1999; Derynck et al. 2001). TGF-β 
signalling is abrogated in about half of CRC cases with wild type mismatch repair by 
missense mutations in TGFBR2 kinase domain, or by somatic mutations in the downstream 
components SMAD4, SMAD2 or SMAD3  (Sjöblom et al. 2006; Wood et al. 2007). Somatic 
mutations inactivating TGF-β signalling pathway mostly occur with the transition from 
adenoma to high-grade dysplasia or carcinoma (Grady et al. 1998). 
8.6.4. Activation of oncogenic pathways 
RAS & BRAF: Somatic mutations of RAS and BRAF activates the mitogen-activated protein 
kinase (MAPK) signalling pathway which develops in 37% and 13% of CRC cases 
respectively (Nosho et al. 2008; Davies et al. 2002). Mutations in RAS is considered to 
activate the GTPase activity that signals directly to RAF while mutations in BRAF signal 
BRAF serine–threonine kinase activity which in turn augments the MAPK signalling cascade 
(Tannapfel et al. 2003). BRAF mutations are detected even in small polyps are more common 
in hyperplastic polyps, serrated adenomas, and proximal colon cancers (Nosho et al. 2008). 
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8.7. Microsatellite instability pathway 
The microsatellite instability (MSI) pathway causes the inactivation of the DNA mismatch 
repair (MMR) genes characterised by the accumulation of many insertion or deletion 
mutations at microsatellites spread along the genome (Boland & Goel 2010). Microsatellites 
are nucleotide repeat sequences of 1-6 base pairs in length and insertion/deletions within the 
microsatellites located in DNA coding region leads to frameshift mutations. The silencing of 
the MMR genes inactivates the DNA repair activity and leads to accumulation of mutations  
(Bogaert & Prenen 2014b). MSI accounts for 15% of the sporadic CRC caused by 
hypermethylation of the gene promotor for the MMR enzyme (usually MLH1) leading to 
gene silencing (Weisenberger et al. 2006). MSI is frequently reported in HNPCC patients, 
which is caused by a germline mutation of one of the MMR genes (Boland & Goel 2010). 
The heightened forms of MSI cancers are characterised by the localisation at proximal colon, 
mucinous cell type, presence of tumor infiltrating lymphocytes and synchronous occurrence 
with additional tumors (Bogaert & Prenen 2014b; Jung et al. 2012).  
 
8.7.1. Inherited forms  
Hereditary forms contribute to 3-10% of all colorectal cancer cases. Inherited colon cancer is 
consequence of a germline mutation with the phenotypic features depending on the specific 
gene that is mutated (Calvert & Frucht 2002). 
 
8.7.1.1. Familial Adenomatous Polyposis (FAP) 
FAP is an autosomal dominant syndrome inherited by a germline mutation in the APC gene. 
FAP affects approximately 1 in 12,000 individuals and accounts for ∼0.5% of all CRCs 
(Fearon 2011). More than 1000 different mutations of the APC gene are described as a cause 
of FAP, resulting in a truncated APC protein (Zeichner et al. 2012). FAP is characterized by 
hundreds to thousands of adenomatous colorectal polyps that are developed by the third or 
fourth decade of life (Lynch & de la Chapelle 2003; Rustgi 2007). If left untreated at an early 
stage, there is a 100% risk of developing CRC by the age of 40, mean age being 36. Most 
patients have a family history of the disease, however approximately 25% emerge as ‘de 
novo’ gene mutations in the APC gene (Galiatsatos & Foulkes 2006). 
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8.7.1.2. Hereditary non-polyposis colorectal cancer 
(HNPCC) 
HNPCC or Lynch syndrome is the most common inherited form of CRC, caused by an 
autosomal germline mutation in one of several mismatch repair (MMR) genes (Jasperson et 
al. 2010). About 2-5% of all CRC cases are attributed to HNPCC. Germ-line MSH2 and 
MLH1 mutations account for approximately 70% of known mutations in HNPCC patients 
along with PMS1, PMS2, MSH3, and MSH6 contributing to other reported cases  (Abdel-
Rahman & Peltomäki 2008). The combination of a germline mutation in an MMR gene with 
inactivation of the remaining normal allele, results in loss of MMR function and 
accumulation of mutations in microsatellites (Bogaert & Prenen 2014b). Individuals with 
HNPCC have fewer polyps than FAP, however the polyps are highly likely to progress to 
cancer. In fact, the rapid progression of the polyps in HNPCC is termed as accelerated 
tumorigenesis requiring only 3–5 years instead of the 20–40 years estimated for most 
sporadic CRCs (Dove-Edwin et al. 2006).  
 
Indeed, a rich history of investigation has discovered several genes and pathways crucial for 
colorectal cancer initiation and progression; these include WNT, RAS-MAPK, PI3K, TGF-β, 
P53 and DNA mismatch repair pathways. Despite the background, we still did not have a 
fully integrated view of the genetic changes and system level understanding on CRC and their 
significance for colorectal tumorigenesis. A more integrated and comprehensive 
understanding of colorectal cancer achieved with worldwide collaborations on cancer 
research i.e. The Cancer Genome Atlas Network (TCGA).  As any other form of cancer CRC 
is a genetic disorder and manifest itself through a system of interlinked pathways. The 
knowledge on mutation rate and altered pathways conceded from TCGA research on CRC 
has been presented in the next section.  
 
8.8. Colorectal cancer through integrated 
OMICS data and computational models 
High throughput technological advancement has enabled scientists to comprehensively 
characterize colorectal cancer tumor in genomic, epigenomic, transcriptomic, proteomic and 
metabolOMICS level. In 2012, TCGA published multi-dimensional analysis of human 
colorectal cancer. A genome scale analysis of 276 samples analysing exome sequence, DNA 
125 
 
copy number, promoter methylation, mRNA and miRNA expression was conducted within 
TCGA consortium. The consortium has published that 16% of colorectal carcinomas were 
found to be hypermutated: three-quarters of these had the expected high microsatellite 
instability, usually with hypermethylation and MLH1 silencing and one-quarter had somatic 
mismatch-repair gene and polymerase ε (POLE) mutations. Significant mutations were 
observed in 24 genes i.e. ARID1A, SOX9 and FAM123B in addition to the expected APC, 
TP53, SMAD4, PIK3CA and KRAS mutations. Recurrent copy number alterations have been 
found in ERBB2, IGF2. Frequent chromosomal translocation includes fusion of NAV2 and 
TCF7L1 has been reported.   
8.8.1. Mutations 
TCGA consortium published 32 genes with recurrent somatic mutations in hypermutated and 
non-hypermutated colorectal cancers. Among non-hypermutated tumors eight most 
frequently mutated genes were APC, TP53, KRAS, PIK3CA, FBXW7, SMAD4, TCF7L2 
and NRAS as indicated in Figure 33. The mutations in KRAS and NRAS were mainly 
located in codon 12/13 and codon 61. Other frequently mutated genes are CTNNB1, 
SMAD2, FAM123B and SOX9. Disproportionate mutations also have been found out in 
tumor suppressor genes i.e. in ATM and ARID1A. Mutations in ACVR2A, APC, TGFBR2, 
MSH3, MSH6, SLC9A9 and TCF7L2 have been observed in hyper mutated tumors along 
with BRAF (V600E). However, two genes that were frequently mutated in the non-
hypermutated cancers were significantly less frequently mutated in hypermutated tumors: 
TP53 (60 versus 20%, P < 0.0001) and APC (81% versus 51%, P = 0.0023; both Fisher’s 
exact test) (Muzny et al. 2012). 
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Figure 33: Mutation Frequencies in Human Colorectal cancer (Muzny et al. 2012). 
a. Frequency of mutations in 224 studied colon and rectum cancer samples. Notably there is a clear separation 
between hypermutated and non-hypermutated samples. Red: MSI (Microsatelite Instability) high, CIMP (CpG 
island methylator phenotype) high. Light Blue: MSI low, CIMP low. Black: rectum, White: Colon. Grey: no data. 
b. Significantly mutated genes in hypermutated and non-hypermutated tumors. Blue bars represent genes identified 
by the MutSig algorithm and black bars represent genes identified by manual examination of sequence data.  
8.8.2. Altered Pathways in CRC  
Recurrent alteration in WNT, MAPK, PI3K, TGF-β and p53 pathways has been reported 
based on mutation, copy number and mRNA expression changes in 195 analysed tumors 
(Figure 34). WNT signaling pathways were altered in 93% of all tumors. Biallelic 
inactivations of APC or activating mutations of CTNNB1 were detected in 80% of cases. 
There were also mutations in SOX9 and mutations and deletions in TCF7L2 as well as the 
DKK family members and AXIN2, FBXW7, ARID1Aand FAM123B. A few mutations in 
FAM123B have previously been described in CRC and were also detected (Muzny et al. 
2012).  Genetic alterations in the PI3K and RAS–MAPK pathways are common in CRC. In 
addition to IGF2 and IRS2 overexpression, it was found that mutually exclusive mutations in 
PIK3R1 and PIK3CA as well as deletions in PTEN in 2%, 15% and 4% of non-hypermutated 
tumors, respectively. We found that 55% of non-hypermutated tumors have alterations in 
KRAS, NRAS or BRAF, with a significant pattern of mutual exclusivity. It has been 
observed co-occurrence of alterations involving the RAS and PI3K pathways in one-third of 
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tumors (P=0.039, Fisher’s exact test). The TGF-β signalling pathway is known to be 
deregulated in CRC. It has been reported that genomic alterations in TGFBR1, TGFBR2, 
ACVR2A, ACVR1B, SMAD2, SMAD3 and SMAD4 in 27% of the non-hypermutated and 
87% of the hypermutated tumors. It was also evaluated the alterations in TP53 in 59% of 
non-hypermutated cases and alterations in ATM, a kinase that phosphorylates and activates 
P53 after DNA damage, in 7% cases. Alterations in these two genes showed a trend towards 
mutual exclusivity (P = 0.016) (Muzny et al. 2012).  
 
Figure 34: Diversity and frequency of genetic changes leading to dysregulation of 
signalling pathways in colorectal cancer (Muzny et al. 2012).  
Non-hypermutated (nHM; n=165) and hypermutated (HM; n=30) samples with complete data were analysed separately. 
Alterations are defined by somatic mutations, homozygous deletions, high-level focal amplifications, and, in some cases, by 
significant up- or downregulation of gene expression (IGF2, FZD10, SMAD4). Alteration frequencies are expressed as a 
percentage of all cases. Red denotes activated genes and blue denotes inactivated genes. Bottom panel shows for each 
sample if at least one gene in each of the five pathways described in this figure is altered. 
 
8.8.3. Computational model in colorectal cancer 
research:  
Spurred by rapid advances in computational technology, modelling techniques, ever 
increasing collection of OMICS data and availability of well-defined pathways in CRC; 
mathematical modelling began to play a role in colorectal cancer research. In 2006, the 
dynamics of normal intestinal crypts has been already described with mathematical modelling 
by Van Leeuwen et al (Van Leeuwen et al. 2006)]. In 2011, Community Research and 
Development Information Service (CORDIS) under European commission has launched 
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SYSCOL (Systems biology of colorectal cancer) project. SYSCOL aims to systematically 
map out the changes and variations in the genetic code that increase individuals' risks of 
developing colorectal cancer, using the tools of systems biology. The knowledge on the 
variants will be used to identify the mechanisms of colorectal cancer growth and 
subsequently to develop a colorectal cancer model. The model will describe cellular 
pathways that contribute to tumor formation and explain in detail how the genetic disposition 
of an individual can activate the expression of genes that cause uncontrolled cell growth and 
lead to colorectal cancer. The dynamics of colorectal cancer is expected to be clear as the 
SYCOL project will conclude [See: http://cordis.europa.eu/result/rcn/53128_en.html].  In 2013 
Nyga et al. reported a novel three-dimensional in-vitro biomimetic colorectal cancer model 
using HT29 cells and connective tissues around the cells (Nyga et al. 2013)]. In the same 
year, Roznovăţ et al. built a network based model for genetic and epigenetic events observed 
at different stages of colon cancer with a focus on the gene relationships and tumor pathways 
(Roznovǎţ & Ruskin 2013)]. In March 2015, Sottoriva et al. reported a validated ‘Big Bang’ 
model to provide a quantitative framework to interpret tumor growth dynamics and the 
origins of intratumoral heterogeneity with important clinical implications (Sottoriva et al. 
2015).    
 
One of the major focuses of the thesis is to investigate the prospective role of miRNA for the 
stratification of colorectal cancer patient who can benefit from anti-EGFR therapy. In the 
previous two chapters the miRNA and colorectal cancer have been described in detail. The 
next chapter dedicated to describe the different treatments in colorectal cancer with major 
focus on cetuximab treatment thus explaining one of the key concepts of the thesis.  
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9. Treatment of Colorectal Cancer 
The choice of treatment in colorectal cancer depends on the stage of the cancer. The 
treatment options are as follows: surgery, radiation therapy, chemotherapy or targeted 
therapy.  
9.2. Stage specific treatment of colorectal 
cancer 
9.2.1. Stage 0 
In stage 0 the cancers have developed beyond the inner lining of the colon, the removal of the 
tumor by surgery is the most practiced treatment. The surgery can be done either by removal 
of the polyps also called polypectomy. In some cases colectocomy i.e. colon resection may 
also be required in case of bigger tumor (Society n.d.; NIH n.d.; ASCO n.d.).    
9.2.2. Stage 1 
In case of cancers that are a part of the polyp formation, the complete removal of the polyp 
without any cancer cells at the margin is the first line of treatment.  If there are cancer cells at 
the edges of the polyps additional surgery is often recommended. Additional surgery may be 
needed in case the polyps cannot be removed completely or has been removed in many 
differential pieces. If the cancer is not in polyps then colectomy i.e. removal of the colon that 
carry the cancer and nearby lymph node, are generally performed (Society n.d.; NIH n.d.; 
ASCO n.d.).  
9.2.3. Stage II  
In stage II cancers may have spread into nearby tissue but not spread to the lymph nodes, the 
first line of treatment is the removal of the part of the colon carrying the tumor along with 
nearby lymph nodes. But additional chemotherapy with 5-FU and leucovorin or capecitabine 
are often recommended for the following condition of the tumor (Society n.d.; NIH n.d.): 
i. Microscopy reveals that cancer is at high grade. 
ii. Cancer has been grown into nearby organs.  
iii. Less than 12 lymph nodes has been operated and removed.  
iv. Cancer cells have been found at the edge of removed specimen hence 
some cancer cells may have been left out.  
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v. The colon has been obstructed by the growth of cancer.  
vi. Cancer perforated the colon.  
 
9.2.4. Stage III 
In this stage cancer has been spread to the nearby lymph nodes but yet to spread other parts of 
the body. Partial colectomy (removal of the part of colon having the cancer along with nearby 
lymph nodes) along with adjuvant chemo i.e. either FOLFOX (5-FU, leucovorin and 
oxaliplatin) or CapeOx (Capecitabine and Oxaliplatin) are the most preferred treatment. If 
some cancer cells might have been left out additionally radiotherapy is performed (Society 
n.d.; NIH n.d.).  
9.2.5. Stage IV 
 The choice of surgery in Stage IV CRC depends on extent of metastasis. If there are small 
areas of lung or liver metastasis which can be completely removed along with cancerous part 
of the colon then surgical removal of those parts along with nearby lymph nodes is 
performed. In some cases hepatic artery infusion may be used if the cancer has spread to the 
liver. On the contrary if metastases in liver/lung are too larger to be removed then 
chemotherapy is applied before and after the surgery. In some cases cancer can be too 
widespread then chemotherapy is the main treatment option. But in most cases patient with 
stage IV CRC receives chemo along with targeted therapies to control the growth of cancer 
tumor. The most commonly used medicines are as follows (Society n.d.; NIH n.d.): 
i. Folfox: leucovorin, 5-FU, oxaliplatin 
ii. Folfiri: leucovorin, 5-FU, irinotecan 
iii. CapeOX: capecitabine and oxaliplatin 
iv. Any other combination from the above including bevacizumab or 
cetuximab 
v. 5-FU and leucovorin with or without bevacizumab 
vi. Capecitabine with or without bevacizumab 
vii. FOLFOXIRI: leucovorin, 5-FU, oxaliplatin, and irinotecan 
viii. Irinotecan, with or without cetuximab 
ix. Cetuximab alone   
x. Panitumumab alone 
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xi. Regorafenib alone  
 Based on the focus of this thesis cetuximab treatment has been discussed in next section.   
9.3. Cetuximab 
9.3.1. Background of inventing cetuximab 
In 1975 the team of Graham Carpenter identified a 170 KDa trans-membrane receptor which 
upon its ligand (EGF) binding increases 
32
p incorporation in A431 epidermoid carcinoma 
cells. To describe the receptor they coined the term EGFR i.e. epidermal growth factor 
receptor. During 1984 Eckhart et al demonstrated that the phosphorylation of the tyrosine 
residue of EGFR might be a crucial step for tumorigenesis. Two decade long researches  has 
identified EGFR as a receptor tyrosine kinase and further elucidate the process for EGFR 
activation, regulation of downstream pathways by activated EGFR as critical component for 
cell proliferation and survival (Toni M. Brand et al. 2011). In the year 1983 Sato et al 
identified four immunoglobulin G (IgG) and demonstrated that three of those antibodies 
namely M225 IgG, M528 IgG and M579 IgG blocked 95% of the EGF binding to EGFR in 
human A431 cells. The same group also shown that each antibody effectively blocked EGF 
induced phosphorylation of EGFR resulting reduced proliferative potential in the cell line 
model. M225 reported to have more affective anti-EFGR property (Toni M. Brand et al. 
2011; Gill et al. 1984; Kawamoto et al. 1983; Sato et al. 1983; Masui et al. 1984). These 
series of discoveries draws the attention of pharmaceutical industry sensing a potential 
targeted therapy in cancer.  
The phase trial of M225 was successful but all the patients produced human-anti-mouse 
antibodies. To nullify this immunologic reaction M225 was converted into human-murine 
chimera. The part of the variable region of mouse M225 which bind to EGFR was integrated 
IgG1 Fc isotype from human for its potential to enhance the immune contribution of C225. 
The structure of C225 is provided in detail in Figure 35 (Toni M. Brand et al. 2011).     
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Figure 35: The Structure of C225 (Toni M. Brand et al. 2011). 
 The design of cetuximab. Three murine antibodies designated M225 igG, M528 igG and M579 igG with activity against the 
eGFR were developed. Further testing identified M225 as being the most efficacious for anti-eGFR activity and was moved 
into Phase i clinical trials. Although successful, patients developed human-anti-mouse antibodies (HAMA) and therefore 
M225 was converted to a human:murine chimera, C225, with an igG1 FC isotype. 
Subsequently, the anti-EGFR antibody C225 IgG1 entered the clinical trial. The mode of 
action of this biologics is controlled by binding to the extracellular domain III of EGFR i.e. 
by blocking EGF binding to EGFR. Later this chimeric antibody was marketed as Cetuximab 
(ICM-225, Erbitux
TM
). To present a detail idea of the consequence of blocking EGF from 
binding on EGFR hence blocking all the downstream pathways are presented in the next 
section.   
9.3.2. EGFR biology and downstream pathway 
EGFR is a member of EGF receptor tyrosine kinase family with four other members 
ErbB1/HER1, Her2/neu (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). Structurally these 
receptors are similar, each having an extracellular ligand binding domain, single membrane 
spanning region, a juxtamembrane nuclear localization signal (NLS), a cytoplasmic tyrosine 
kinase domain and C-terminal tail housing several tyrosine residues for propagating 
downstream signalling.  Upon binding the extracellular ligand the receptor dimerizes, 
allowing cytoplasmic EGFR-TK to activate in a tail to head fashion as indicated in Figure 36.  
 
Figure 36: Modelling the effect of ligand binding to the EGFR receptors (Kumar et 
al. 2008). 
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A schematic diagram of EGFR family activation based on crystal structures. On extracellular ligand binding the receptor 
dimerizes allowing the cytoplasmic EGFR-TK to activate in a tail-to-head fashion. 
Upon ligand binding EGFR activate three downstream pathways RAS/RAF/MEK/ERK, 
PI3K/AKT/mTOR and PLCγ/PKC. Other two important downstream pathways are SRC 
tyrosine kinases and STAT activation.  
9.3.2.1. RAS/RAF/MEK/ERK pathway:  
This pathway leads to cell proliferation and play a central role in many human cancers. 
Ligand binding to EGFR triggers its activation and subsequent phosphorylation. Activated 
phospho-tyrosine residues in its C-terminal, act as a binding site for Grb2, a SH2-containing 
protein. In the next stage Grb2 recruits the guanine nucleotide exchange factor SOS through 
its SH3 domain. This promotes binding of GTP to RAS and subsequently activated RAS 
triggers the Map kinase (MAPK) cascade. Next Ras-GTP complex binds and activates RAF 
kinase (MAPKKK). Activated RAF binds to and phosphorylate MEK (MAPKK). Activated 
MAPKK then phosphorylate ERK1/2 (MAPK). Activated ERK kinases can activate several 
other kinases including MNK1, MNK2, MSK1, MSK2, RSK, MAPK. In turn these kinases 
phosphorylate several transcription factors including Elk-1, PPARγ, STAT1, STAT3, C-myc 
and AP-1. These activated transcription factors increased expression of several genes 
involved in cellular proliferation, most notably cyclin D1 (Sebolt-Leopold & Herrera 2004).  
9.3.2.2. PI3K/AKT/mTOR pathway 
Activated EGFR also recruit PI3K to the cell membrane. PI3K phosphorylation of 
phosphatidylinositol-4,5-biphosphate yields the second messenger phosphatidylinositol-3,4,5-
triphosphate (PIP3). PIP3 serves as a membrane bound docking site for AKT. Once PIP3 and 
AKT together stationed on the plasma membrane, AKT is phosphorylated by two kinases i.e. 
PDK1 and mTORC2. One of the crucial effector of AKT activation is mTORC1. AKT 
activate mTORC1 via TSC2. Phosphorylation of TSC2 by AKT cancels inhibition of the 
small G-protein RHEB. This initiates activation of mTOR. Activated mTOR phosphorylate 
p70-S6 kinase 1 initiate protein synthesis via S6 ribosomal subunit. Over all activation of 
protein synthesis is a crucial step in cancer cell growth and survival. Activated AKT also 
influence cell proliferation by activating ample cellular factors (Hanahan & Robert A. 
Weinberg 2011; Bogaert & Prenen 2014a).  
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9.3.2.3. PLCγ/PKC pathway:  
This pathway plays a crucial role in mediating the effects of activated EGFR. Phospholipase 
C (PLC) interacts with phosphor-tyrosine residues of EGFR via its SH2 domain. The 
interaction activates PLC mediated by PIP3. Activated PLC interacts with plasma membrane 
and it cleaves PIP2 to inositol triphosphate (IP3) and diacylglycerol (DAG). Subsequently 
IP3 bind its receptors at the endoplasmic reticulum to induce the calcium influx into the cell. 
DAG activates PKC at the plasma membrane. Activated PKC is a potent serine/threonine 
kinase second messenger capable of phosphorylating a plethora of substrates leading to cell 
proliferation, apoptosis, cell survival and cell migration (Hanahan & Robert A. Weinberg 
2011; Bogaert & Prenen 2014a).    
All these above mentioned pathways their downstream transcription factors and phenotypes 
i.e. cell survival, proliferation, invasion, metastasis and angiogenesis, are described in Figure 
37.       
 
Figure 37: Downstream signaling of activated EGFR (Li Gong n.d.) 
The figure shows the downstream signaling pathways which activate upon binding of EGF to EGFR leading to cell 
proliferation, invasion, metastasis and angiogenesis.   
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9.3.3. Mode of action and efficacy of cetuximab  
Cetuximab effectively blocks the binding of EGF to EGFR i.e. blocks EGFR 
phosphorylation. It also promotes EGFR internalization and reduces cell proliferation in 
metastasis colorectal cancer. Detailed mechanisms of actions of cetuximab treatment are 
summarized in Figure 38.    
a. Cetuximab has got more affinity for EGFR than two of its ligand namely TGFα, EGF 
i.e. cetuximab effectively block ligand induced EGFR phosphorylation. So all the 
three EGFR downstream pathways discussed in the previous section are blocked (Gill 
et al. 1984; Kawamoto et al. 1983; Sato et al. 1983; Masui et al. 1984).  
b. Other reports suggested that cetuximab sterically hinder the binding of EGFR to other 
HER family members (Li et al. 2005).  
c. Cetuximab also promotes the internalization or degradation of EGFR i.e. nullifying 
the chance of downstream signaling (Sunada et al. 1986).  
d. Cetuximab treatment in different cancer models or human tumor xenografts has 
shown an increased expression of cell cycle inhibitor p27
kip1
 which drives the 
formation of p27
kip1
-Cdk2 complexes. This complex arrests the cell cycle at G1 phase 
(Huang et al. 1999; Wu et al. 1996).  
e. Treatment with cetuximab dramatically decrease the pro-angiogenic factors i.e. inhibit 
angiogenesis. Cetuximab therapy may also lead to decreased invasion or metastasis 
spread of the tumor cells (Tortora et al. 1999; Liu et al. 2000).  
f. Cetuximab treatment increases expression of apoptosis promoting Bax and decreases 
cell survival promoting Bcl2. By modulating the expression of those two proteins the 
monoclonal antibody drives the shrinkage of tumor (Wu et al. 1995).  
g. Cetuximab also mediate antibody dependent cytotoxicity of the tumor cells (Kimura 
et al. 2007).   
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Figure 38: Mode of action of Cetuximab therapy (Toni M. Brand et al. 2011). 
The mechanism of action of cetuximab. All the biological processes (A to G) are described above.  
However, multiple lines of evidences suggest that only 10-20% patients with mCRC benefit 
from cetuximab treatment (Chung, Shia, Nancy E. Kemeny, et al. 2005; Cunningham et al. 
2004a). Over the years intense research has been undertaken to discover biomarker that can 
stratify metastasis colorectal cancer patients which are likely to respond prior to the 
treatment.  Some stratified biomarker has been identified and also approved by the regulatory 
bodies, described in the next section.  
9.3.4. Stratified biomarker of cetuximab therapy 
9.3.4.1. KRAS mutation 
KRAS mutation is one most important indicator whether a CRC patient will be sensitive or 
resistant to cetuximab therapy. KRAS is a GTPase which connect EGFR to RAF/MEK/ERK 
pathway. After binding to GTP, KRAS activate RAF i.e. triggers the pathway leading to 
cellular proliferation. Mutations in codon 12 or 13 impair the intrinsic GTPase activity and 
show resistance to GAPs. This causes the accumulation of active mutant RAS in the cancer 
cells. This accumulated active form of RAS still capable to trigger RAF/MEK/ERK pathway 
in EGFR independent manner (Trahey & McCormick 1987; Toni M. Brand et al. 2011). 
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Lièvre et al has shown that the KRAS mutation is significantly associated with the cetuximab 
resistance activity in CRC (Lièvre et al. 2006).     
9.3.4.2. BRAF mutation 
In 2008 Nicolantonio et al shown that efficacy of anti-EGFR monoclonal antibody in CRC 
hindered by BRAF V600E mutation (Di Nicolantonio et al. 2008). BRAF is kinase belong to 
RAF family. GTP bound KRAS activate BRAF which triggers RAS/RAF/MEK/ERK 
pathway (Niault & Baccarini 2010). But mutant BRAF can still activate 
RAS/RAF/MEK/ERK pathway in EGFR independent manner (Lito et al. 2013).  
9.3.4.3. EGFR gene copy number 
Increased gene copy number is associated with the response of cetuximab therapy in CRC 
(Mauro Moroni et al. 2005). Subsequent large clinical trials of CRC patients treated with 
cetuximab confirmed the relationship as well (Personeni et al. 2008). But the exact 
mechanism for this phenomena is unknown (Toni M. Brand et al. 2011). 
9.3.4.4. Over expression of EGFR ligand 
In 2007 Khambata-Ford et al has shown the correlation between expression of two EGFR 
ligands i.e. EREG and AREG to cetuximab treated CRC patients. CRC patients with high 
expression of Epiregulin (EREG) and Apiregulin (AREG) are more like to have disease 
control when treated with cetuximab treatment (Khambata-Ford, Christopher R. Garrett, et al. 
2007). 
 Discovery of these biomarkers has enabled clinicians to somewhat predict the response of 
cetuximab therapy in CRC patients prior to the therapy. However selection of right cohort of 
patients is still far from complete as cetuximab resistance mechanism remains poorly 
understood. To address the issue scientific community is looking for addition biomarkers 
predicting the efficacy of the treatment. In this regard miRNA has recently drawn the 
attention of scientific community for its capacity to regulate expression of multiple onco 
genes, tumor suppressor genes and pathways central to cancer formation.  Identifying the 
potential of miRNA as stratified biomarker, a novel SMARTmiR algorithm has been 
developed to predict the role of miRNA as therapeutic biomarker for cetuximab treatment in 
colorectal cancer. The SMARTmiR methodology is presented in the next chapter.  
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10. The Prospect of miRNA as 
Therapeutic Biomarker in Colorectal 
Cancer (Deyati et al., 2015) 
Colorectal cancer (CRC) is one of the most prevalent cancers, with 1.2 million new cases 
every year. It is the second most commonly diagnosed cancer in females and the third most 
common in males; the highest incidence occurs in developed countries. By the age of seventy 
years, one out of every two citizens in the Western world develop benign adenomas that 
evolve into malignant carcinomas at an estimated yearly rate of 0.1 to 0.25% (Jass 2004). In 
United States alone, the annual cost of CRC treatment is forecasted to reach $17.7 billion by 
2020. However, using simultaneous strategies that reduce risk factors, increasing screening 
and treatment could avoid 101,353 deaths resulting in $33.9 billion in savings in reduced 
productivity loss (Bradley et al. 2011). 
EGFR, a transmembrane receptor tyrosine kinase has been identified as one of the most 
promising targets for treating metastatic colorectal cancer (mCRC).  Among the 20 molecules 
listed by the National Cancer Institute for the treatment of mCRC (Anon n.d.), cetuximab is 
one of the most successful monoclonal antibodies  (Saltz et al. 2004; Chung, Shia, Nancy E 
Kemeny, et al. 2005).  However, multiple lines of evidence suggest that only 10-20% patients 
with mCRC benefit from cetuximab treatment (Chung, Shia, Nancy E Kemeny, et al. 2005; 
Cunningham et al. 2004b). The selective efficacy, side effects and high treatment costs of 
cetuximab result in the need for focused research to decipher the resistance mechanisms to 
cetuximab. The response of the scientific community to this need is evident through the 
increased number of publications suggesting that the mutational status of KRAS, BRAF and 
PIK3CA, differential expression of PTEN, EGFR ligand (AREG, EREG) and EGFR gene 
copy number variation could serve as therapeutic biomarkers for anti-EGFR monoclonal 
antibody treatment in CRC (Frattini et al. 2007; Sartore-Bianchi, Martini, et al. 2009; Perrone 
et al. 2009; Mauro Moroni et al. 2005; Prenen et al. 2009; Sartore-Bianchi, Di Nicolantonio, 
et al. 2009).  However, none of these singular molecular changes could accurately predict the 
response of CRC patients to cetuximab therapy. Because CRC is a system-level disorder that 
involves multiple molecular mechanisms to support proliferative signalling, resist cell death, 
induce angiogenesis and metastasis; molecules such as miRNAs that regulate signalling 
pathways by affecting the expression of multiple proteins might serve as more potent 
139 
 
therapeutic biomarkers (Hanahan & Robert A Weinberg 2011; Rukov et al. 2013). However, 
little is known regarding the role of miRNAs as a therapeutic biomarker for cetuximab 
treatment in CRC.  
miRNA expression is typically dysregulated in cancer cells and this dysregulation has a high 
degree of tissue specificity, miRNAs could be used as diagnostic and therapy-related 
biomarkers. Additionally, miRNAs have an unusually high stability in formalin-fixed tissues, 
from which they could be extracted with minimal degradation (Tang et al. 2006). Moreover, 
the techniques of miRNA analysis from a single cell are established, allowing for the analysis 
of small amounts of miRNAs with increasing sensitivity for potential biomarker assays (Lim 
et al. 2005). The roles of miRNAs in CRC, EGFR signalling regulation and cetuximab 
treatment outcome are also evident. Multiple reports regarding the miRNA dysregulation in 
metastatic colorectal cancer have been published. Some groups reported that major colorectal 
cancer biomarkers such as EGFR and RAS are regulated by mir-7 and let-7 respectively, thus 
profoundly affecting downstream signalling (Webster et al. 2009; Lee et al. 2011; Xu et al. 
2012; Liu et al. 2011; Li et al. 2012). Recently, Bissonnette et al. demonstrated the 
correlation between EGFR signalling and miR-143, mir-145 in murine colon cancer models 
(Zhu et al. 2011). Another group discovered that cetuximab-mediated EGFR inhibition 
abrogates the age-related increase of miR21, which is related to age-dependent colorectal 
cancer (Nautiyal et al. 2012).  
These findings cumulatively suggest a potentially significant role of miRNAs in EGFR 
signalling in CRC. Therefore, these evidences compelled us to create a workflow to identify 
the most critical miRNAs important for cetuximab resistance in CRC that could be further 
used for potential biomarker assay development. In this study, we propose ranked miRNA 
candidates that might contribute to cetuximab resistance in CRC patients. The inference is 
based on the integration of multiple published and predicted miRNA findings into cellular 
pathways that lead to oncogenesis and metastasis. We prioritised the biomarker candidates 
based on a novel algorithm, i.e., SMARTmiR (Scoring-based MARking of Therapeutic 
MIcroRna), that combines the network parameters and literature-derived evidence. Finally, 
the significance of our prediction was strongly supported by recently published experimental 
data that are derived from cetuximab resistant CRC patients. This study provides an 
actionable insight into the novel mechanism of cetuximab resistance mediated by miRNAs 
that might lead to identification of miRNAs as biomarkers, thereby predicting optimum 
responses to the drug.    
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10.2. SMARTmiR workflow 
Herein, we propose a predictive algorithm, i.e., SMARTmiR, that combines knowledge and 
data-driven approaches to identify miRNAs contributing to the therapeutic effects of 
cetuximab in CRC patients. The algorithm consists of the following four steps (Figure 39): 
Step 1: Construction of pathway maps leading to oncogenesis and metastasis in CRC. 
Step 2: Identification of miRNA candidate biomarkers via miRNAome screening. 
Step 3: Ranking of miRNAs based on accumulated evidence and the effects on the cellular 
process of CRC patients treated with cetuximab.  
Step 4: Validation of the prediction based on experimental data. 
 
 
Figure 39: SMARTmiR workflow for the selection of miRNAs as candidate 
biomarkers conferring cetuximab resistance in colorectal cancer  
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10.2.1. Construction of molecular pathway maps leading 
to CRC oncogenesis and metastasis 
Following the first step in the workflow as illustrated in Figure 39, we created a 
comprehensive bio molecular space for the mechanisms of action of cetuximab therapy in 
colorectal cancer. In doing so we assembled four pathway maps linked to four fundamental 
cellular processes in oncogenesis and metastasis; namely apoptosis, proliferation and 
differentiation, angiogenesis, and metastasis. These pathway maps integrate known pathways 
from Metacore (Thomson Reuters, New York, USA) that lead to the four cellular processes 
and protein-protein interactions from IntAct, BioGRID and HPRD (Human Protein Reference 
Database) Databases (Ekins et al. 2007, Shannon, Markiel, Ozier, Nitin S Baliga, et al. 2003). 
The pathways that were integrated to build the four pathway maps leading to the cellular 
processes are listed in Table 11. All of the molecules in the maps (nodes) are annotated with 
the Entrez gene ID, HGNC gene symbols and corresponding UniProt IDs. The distinct 
features of the pathways are as follows: (A) Node shapes and colours correspond to their 
functional category (e.g., receptor, ligand, transcription factor, kinase); (B) All of the edges 
have directionality; (C) The edges are differentiated by shapes and colour corresponding to 
the type of interaction (such as binding, catalysis, phosphorylation, transcription regulation, 
transformation etc.); (D) Reactions (edges) are tagged to PubMed IDs as evidence. Four 
pathway maps corresponding to proliferation and differentiation, apoptosis, angiogenesis, and 
metastasis are available in standardised SBML (Systems Biology Markup Language) (Hucka 
et al. 2003) for file exchange between different tools. The four pathways are provided as four 
Supplementary Pathway maps (i.e., Apoptosis.xml, Proliferation_Diffrentiation.xml, 
Angiogenesis.xml and Metastasis.xml) (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s16.zip). The Pubmed 
IDs supporting an edge can be found by selecting respective edge in the pathway map 
specific xml files after opening those in Cytoscape.  
TCGA RNA Seq data in colon and rectal adenocarcinoma (2012) has been analysed to 
demonstrate the CRC specificity of the constructed maps (Anon 2012). 
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Cellular 
processes 
Pathways assembled 
Proliferation 
and 
Differentiation 
EGFR signalling pathway, EGFR signalling via small GTPases, EGFR 
signalling via PIP3, EPO-induced MAPK pathway, ERK5 in cell 
proliferation, PDGF signalling via MAPK cascades, PDGF signalling via 
STATs and NF-kB 
Apoptosis Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway, 
Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/IAP pathway, 
Apoptosis and survival p53-dependent apoptosis, EPO-induced Jak-STAT 
pathway, EPO-induced PI3K, AKT pathway and Ca(2+) influx, Signal 
transduction of AKT signalling, Signal transduction of PTEN pathway 
Angiogenesis VEGF-family signalling and activation, Angiopoietin - Tie2 signalling, 
VEGF signalling via VEGFR2 - generic cascades, S1P1 signalling pathway 
Development Role of IL-8 in angiogenesis, Thrombospondin-1 signalling 
Metastasis TGF-beta receptor signalling, TGF-beta-dependent induction of EMT via 
MAPK, Regulation of epithelial-to-mesenchymal transition (EMT), Immune 
response of Oncostatin M signalling via JAK-Stat in human cells FGF2-
dependent induction of EMT, TGF-beta-induction of EMT via ROS, 
NOTCH-induced EMT, HGF-dependent inhibition of TGF-beta-induced 
EMT, TGF-beta-dependent induction of EMT via RhoA, PI3K and ILK, 
Immune response of Oncostatin M signalling via MAPK in human cells, 
HGF signalling pathway 
Table 11: Detailed listing of the pathways used for assembling the proliferation 
and differentiation, apoptosis, angiogenesis, and metastasis processes. 
 
10.2.2. Identification of miRNAs candidate biomarkers 
via miRNAome screening 
In the second step, we identified miRNA-target interactions (MTIs) for all of the nodes in the 
four constructed pathway maps. The exhaustive search for these miRNAs included both 
experimentally validated miRNAs and predicted miRNAs.  
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10.2.2.1. Experimentally validated and literature reported 
miRNAs 
Through screening public and commercial sources for experimentally validated MTIs, we 
identified two major resources that are widely used because of their extensive coverage and 
the quality of scientific evidence, i.e., TarBase and Pathway Studio (Elsevier, Amsterdam, 
Netherlands) (Nikitin et al. 2003). TarBase hosts manually curated MTIs that are 
experimentally validated (Vergoulis et al. 2012). It also incorporates entries from other well-
known databases, such as miRecords (Xiao et al. 2009), miRTarBase (Hsu et al. 2011) and 
miR2Disease (Jiang et al. 2009). All of the literature-derived MTIs that were extracted for 
our study from the two sources described above are included in Supplementary Table 12 
(See: http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s11.xls).  
10.2.2.2. Predicted miRNAs 
Several computer-aided algorithms are available for the identification of MTIs. We used 
Diana-Micro T 3.0, Pictar and TargetScanS to identify predicted MTIs for the four developed 
pathways, focusing in particular on their overlapping predictions. These identified miRNAs 
have not been encoded into the pathway maps and are used to further filter and rank potential 
candidate miRNAs (described below). 
10.2.2.3. Ranking of miRNAs based on accumulated 
evidence and their effect on the system 
A novel raking formula was developed to rank the miRNAs for their potential to serve as 
therapeutic biomarkers for cetuximab treatment in CRC patients (Equation 1). To enhance the 
accuracy of the ranking function, the four assembled processes were integrated in one 
Integrated map, representing a comprehensive knowledge space of functional molecular 
networks that lead to the cellular process those are mostly dysregulated in colorectal cancer. 
Each miRNA is ranked based on its topological properties, network properties of its targets 
and based on literature-derived evidence of miRNA regulating signalling pathways that are 
important for colorectal carcinogenesis, miRNA target’s (i.e., nodes in the Integrated map) 
relations to cetuximab. All of the literature-derived evidence for the candidate miRNA’s 
relationships to cellular processes, CRC and the target’s relations to cetuximab are provided 
in Supplementary Table 13 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s12.xls), 
Supplementary Table 14 (See: 
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http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s13.xls) and 
Supplementary Table 15 
(http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s14.xls); 
respectively. The network parameters (Betweenness centrality, Node degree) were calculated 
using the CentiScaPe plugin (Scardoni et al. 2009). 
𝑺𝒋
𝒎𝒊𝒓 = 𝐝𝐞𝐠(𝒎𝒊𝒓𝒋) +  
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Sj
mir
 is the score of j
th
 miRNA. Each feature is given equal weightage due its natural 
importance and is normalised between 0 and 1 such that the calculated score could have a 
maximum value of 5. The overall scoring function was implemented in the Perl programming 
language.  
The first feature of miRNA ranking is the node degree of the j
th 
miRNA, i.e., the no. of 
targets of the j
th 
miRNA in the Integrated map, as defined as the deg(mirj). The node degree 
corresponds to the no. of nodes adjacent to a given node v. The degree allows for an 
immediate evaluation of the regulatory relevance of the node. For example, in signalling 
networks, proteins with a very high degree are interacting with several other signalling 
proteins and are likely to be regulatory hubs.  The second parameter was calculated based on 
the weighted node degree of all of the targets of j
th
 miRNA, depicted as ∑ 𝑅𝑖 ∗
𝑛
𝑖=1 𝑇𝑖/ ∑ 𝑇𝑖
𝑛
𝑖=1 , 
where Ti is the node degree, and Ri is rank of i
th 
target based on node degree, targeted by j
th
 
miRNA.  Additionally, betweenness is calculated considering couples of nodes (v1, v2) and 
by counting the no. of shortest paths linking v1 and v2 and passing through a node n. The 
betweenness of a node in a biological network, such as a protein-signalling network, could 
indicate the relevance of a protein as functionally capable of holding together communicating 
proteins. Betweeness centrality was applied to identify the importance of a node in each of 
the four pathways (see the Results section). The additional features of SMARTmiR are 
literature-derived evidence reflecting the direct effect of each miRNA candidate in cancer 
aetiology, progression, spread and miRNA specific relationship to colorectal cancer. This 
third feature calculates the total amount of literature evidence (PubMed IDs) linking the jth 
miRNA to the four cellular processes relevant to tumor progression (proliferation and 
diffrentiation, apoptosis, metastasis, and angiogenesis), depicted as 𝐸𝑗
𝑃𝑎𝑡ℎ𝑤𝑎𝑦. Similarly, the 
fourth feature calculates the total amount of literature evidence (PubMed IDs) that reflects the 
association of the j
th
 miRNA to colorectal cancer, depicted as 𝐸𝑗
𝐶𝑅𝐶.  
145 
 
The ultimate goal of SMARTmiR is to prioritise the role of a candidate miRNA as a 
therapeutic biomarker for cetuximab treatment in CRC. Therefore, the last feature, 
∑ 𝐸𝑖
𝐶𝑒𝑡𝑢𝑥𝑖𝑚𝑎𝑏𝑛
𝑖=1 , calculates the total amount of literature evidence (PubMed IDs) of the j
th 
miRNA target’s (ith) related to cetuximab.  
Separately we have also calculated the miRNA scoring with betweeness centrality of the 
nodes as second feature; maintaining first, third, fourth and fifth features of SMARTmiR 
identical. The resulting scoring is provided in Supplementary Table 16 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s15.xls).  
10.2.3. Validation of predicted miRNA biomarkers 
We used a list of differentially expressed miRNAs in cetuximab sensitive and resistant CRC 
patients (KRAS and VRAF wild type) (Mosakhani et al. 2012) to validate the miRNAs 
predicted and ranked by our workflow as significant therapeutic biomarker candidates for 
cetuximab treatment. To further substantiate the expression of targeted mRNAs by the most 
significant miRNA biomarkers, we also analysed the mRNA expression data (Khambata-
Ford, Christopher R Garrett, et al. 2007). The mRNA expression data analysis was performed 
using the appropriate R software packages. In particular, we used the MAS5 normalisation 
method (Irizarry et al. 2003) and applied the SAM (Significance Analysis of Microarray) 
package to identify differentially expressed mRNAs (Tusher et al. 2001b).  All differentially 
expressed mRNA with its corresponding p-value can be observed in the fourth column of 
Table 13.  
10.3. Evalution of SMARTmiR workflow 
10.3.1. Construction of molecular pathway maps crucial 
for cetuximab mode of action in CRC 
The efficacy of cetuximab treatment in responsive colorectal cancer is mostly depend on the 
state of four cellular processes namely apoptosis, proliferation and differentiation, 
angiogenesis, epithelial-to-mesenchymal transition/metastasis (Toni M Brand et al. 2011a). 
First a comprehensive framework for the analysis and a structured overview of the bio 
molecular space for the mechanisms of action of cetuximab therapy in colorectal cancer was 
created by assembling four pathway maps which are representative of those cellular processes 
in CRC.  
146 
 
The landscapes of the calculated network parameters for each of the four constructed 
pathways are presented in Figure 40. The top three nodes of each pathway (Jak2, Akt, p53 in 
apoptosis; SMAD, TGF-β, Shc in metastasis; VEGFR, VEGF, Src in Angiogenesis; EGFR, 
c-Fos, c-Raf in proliferation and differentiation) are well-known players in the corresponding 
processes (Hanahan & Robert A Weinberg 2011; Toni M Brand et al. 2011a; Sakurai & Kudo 
2011; Wittekind & Neid 2005). The high no. of the nodes representing receptors and kinases 
in all four pathway maps emphasise the crucial role of these molecules in oncogenesis and 
metastasis. Our maps also demonstrate that the roles of some molecules, such as transcription 
factors, in metastasis are better understood and more well-known compared with the other 
three processes.   
To understand the degree of the cross-talk and the overlap between the four pathway maps, 
we integrated all four pathway maps into a resulting integrated map. Table 12 presents a 
statistical overview of the pathway maps and the percentage of literature validation of the 
nodes related to the corresponding cellular processes.  
 
Figure 40: Landscape of the four cellular processes in terms of the node degree, 
betweenness centrality, functional category of nodes and edges. 
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Node degree: no of edges connected a node; Betweenness centrality: the no. of shortest paths from all of the vertices to all of 
the others that pass through that node. 
A list of common nodes in all four pathways is provided in  
Supplementary Table 17 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s2.xls). 
Cellular Processes No. of 
Nodes 
No. of 
Edges 
Percentage of published 
relationships of nodes to the 
cellular processes 
Apoptosis 179 305 55.3% (99/179) 
Proliferation and 
Differentiation 
151 261 45% (68/151) 
Angiogenesis 201 289 36.8% (74/201) 
Metastasis 245 471 46% (113/245) 
Table 12: Statistical overview of the assembled pathway maps representing four 
cellular processes  
The high percentage of literature validations (4
th
 column of Table 12) confirms that the 
constructed pathways represent a good reflection of the current knowledge accumulated in 
the scientific literature. The metastasis pathway map is the largest in terms of the no. of nodes 
and edges, followed by angiogenesis, apoptosis, proliferation and differentiation. The 
integrated map consists of 465 nodes and 792 directed edges, demonstrating a large overlap 
among the molecules involved in the four processes. The literature validations of the node’s 
relationships to the cellular processes are provided in Supplementary Table 18 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s3.xls).  
To analyse the CRC specificity of the assembled pathway maps, we first explored the 
published TCGA (The Cancer Genome Atlas) data regarding the differential expression of 
the nodes’ mRNAs in colon and rectum adenocarcinoma (Anon 2012). This analysis 
demonstrated that 96% of the nodes’ mRNAs are differentially expressed (more than two 
standard deviations from the mean) in at least one of the 244 studied tumor samples. In 
addition, we examined the association of the pathway maps’ nodes to colorectal cancer in the 
published scientific domain and determined that 45.3% of them (211/465) have been reported 
in the literature to have a relationship with CRC. All of those relationships are included in 
Supplementary Table 19 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s4.xls). The 
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differential expression of each mRNA in the TCGA tumor samples is provided in 
Supplementary Table 20 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s5.xls). 
10.3.2. miRNAome screening for putative candidate 
biomarker  
Upon construction of comprehensive pathway maps and verification of their association with 
the four cellular processes and in CRC, we screened the published miRNAome for miRNAs 
targeting at least one node of the four pathway maps, which could serve as potential 
biomarkers for further analysis. In our screening, we considered experimentally validated 
miRNA target interactions (MTIs) and computationally predicted MTIs. To increase the 
chance of the predicted MTIs being biologically relevant, overlapping MTIs between three 
different miRNA-target prediction algorithms (Krutovskikh & Herceg 2010; Witkos et al. 
2011) were used. One method that can be used to compare the quality of MTI prediction is to 
calculate the percentage of the prediction that has already been experimentally validated. In 
that direction, the percentage of experimentally validated MTIs is calculated for predictions 
from three individual algorithms, i.e., Pictar, miRanda, DianaMicroT, and from the 
intersection of their predictions. Experimentally validated MTIs are obtained from TarBase 
and Pathway Studio. As demonstrated in Figure 41, the percentage obtained from intersection 
of the three prediction algorithms is higher than that obtained using any of the three 
prediction algorithms used individually (Figure 41). Using the intersection of three prediction 
algorithms, we are able to capture 17.5% of the experimentally validated MTIs (average for 
four processes). However, the results for each of the prediction algorithms are less 
impressive: Pictar (3.9%), miRanda (3.4%), DianaMicroT (1.7%). Therefore, the assumption 
of using the intersection of the three prediction algorithms proved to be a better approach and 
was used for further analysis. Total number of experimentally validated MTIs for all 
prediction software and their intersect for all four pathway maps are provided in 
Supplementary Table 21 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s6.xls). 
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Figure 41: Comparative performance of Pictar, miRanda, DianaMicroT and the 
intersection of the three algorithms in capturing validated miRNA-target 
interactions.  
 
The miRNAome screening revealed 335 miRNAs that target at least one node of the four 
assembled pathway maps. We further analysed the 335 miRNAs based on their ability to 
participate in all four processes, thus having a higher probability to be therapeutic biomarkers 
for cetuximab treatment in CRC patients. This analysis resulted in the selection of 188 
miRNAs that interact with targets in all four of the pathway maps, and these selected 
miRNAs were used for the ranking and validation (Figure 42). 
 
Figure 42: Quantities of miRNA species targeting each pathway and cross-
sections.  
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To evaluate the relationship of those 188 miRNAs to the four cellular processes and to the 
neoplasm, we performed a random sampling approach. We randomly selected 20 non-
overlapping sets containing 5 miRNAs each (S1, S2,.., S20 in Figure 43). Next the 
association between each miRNA (from each of those 20 samples) to four cellular processes 
(apoptosis, proliferation and differentiation, metastasis, angiogenesis) and to neoplasms were 
searched in the scientific literature. The number of miRNAs from each sample that are 
published to regulate at least one of those four cellular process and neoplasms are 
summarised in Figure 43. It is evident from Figure 43 that 74% of the miRNA candidates are 
known to regulate at least one of the four cellular processes and 51% of those miRNA are 
linked to different forms of neoplasms. 
 
Figure 43: The relationships of miRNAs from twenty randomly collected non-
overlapping samples (five miRNAs each) to cell processes (angiogenesis, 
apoptosis, proliferation and differentiation, metastasis) and neoplasms.  
The column S1, S2, S3, ……, S20; denote the 20 non overlapping samples having 5 miRNA in each of them. Each sample 
collected randomly from total 188 miRNA. The corresponding values in the shell for each sample with row starts with “Cell 
process” denote total no. of miRNA from that sample is linked to any of the four cellular processes and the relation is 
published. Similarly, the corresponding values in the shell for each sample with row starts with “Neoplasm” denote total no. 
of miRNA from that sample is linked to Neoplasms and the relation is published.        
 
All 20 of the samples and the relationship between the miRNAs from each sample to cellular 
process and the neoplasm are provided in Supplementary Table 22 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s7.xls), 
Supplementary Table 23 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s8.xls) and 
Supplementary Table 24 (See: 
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http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s9.xls).  Based on the 
node degree, the top 5 miRNAs from each of the four pathway maps are provided in 
Supplementary Figure 2 (See: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s1.pdf). 
10.3.3. Prioritization of the selected miRNAs  
Despite the potentially strong impact of the selected miRNAs on the fundamental molecular 
mechanisms underlying CRC, their relation to cetuximab treatment was not used in previous 
filtering of the 188 miRNAs, and the resulting candidate list remains too long for 
experimental validation. To further prioritise miRNA candidates that have the highest 
likelihood of acting as therapeutic biomarkers for cetuximab treatment, we ranked the 
miRNA candidates by applying a newly designed SMARTmiR algorithm, as described in the 
Materials and Methods section. The details of the 10 top-ranked miRNAs, including their 
scores and evidence of their interaction with cetuximab, and the role of the targets are 
summarised in Table 13. According to our predictions, those ten miRNAs might serve as the 
best candidates for therapeutic biomarkers for cetuximab treatment in CRC patients. All 188 
miRNA with its SMARTmiR score and Higo gene id of the targets are provided in 
Supplementary Figure 3 (See the second figure: 
http://www.nature.com/srep/2015/150126/srep08013/extref/srep08013-s1.pdf). 
miRNA Score No of 
Targets  
Hugo Gene Id of differentially 
expressed miRNA Targets in 
Cetuximab sensitive to resistant 
CRC patients 
No of 
TF, 
KNS 
miRNA 
Fold 
Change 
hsa-
miR-21 
3.57 33 NOTCH1 (0.004868), CD47 
(0.031247), BRCA1 (0.013018), 
APAF1 (0.012285) 
4, 3 8.1 
hsa-
miR-34a 
2.21 28 YY1 (0.029778), NOTCH1 
(0.004868), CD47 (0.031247), 
BRCA1 (0.013018), MYC 
(0.002497) 
4, 2 4.6 
hsa- 2.15 33 MKL2 (0.004586), CD47 7, 2 N/A 
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miR-145 (0.031247), MYC (0.002497)  
hsa-
miR-27a 
2.01 48 MAPK14 (0.009214), APAF1 
(0.012285) 
4, 9 5.8 
hsa-
miR-17 
1.85 35 MAPK14 (0.009214), BRCA1 
(0.013018), E2F1 (0.002186), 
EREG (3.41e-06) 
3, 8 9.7 
hsa-
miR-155 
1.73 29 CD47 (0.031247), FOXO3 
(0.012217) 
6, 4 N/A 
hsa-
miR-182 
1.65 39 MKL2 (0.004586), CD47 
(0.031247), FOXO3 (0.012217) 
5, 2 N/A 
hsa-
miR-15a 
1.59 25 BRCA1 (0.013018), PRKAR2A 
(0.021049) 
1, 4 6.2 
hsa-
miR-96 
1.53 38 PLCB4 (0.015726), FOXO3 
(0.012217) 
4, 5 N/A 
hsa-
miR-
106a 
1.48 26 NOTCH1 (0.004868), BRCA1 
(0.013018), E2F1 (0.002186) 
2, 6 N/A 
Table 13: Top 10 miRNAs along with their scores, expression values, MTI, 
expression of MTI and miRNA in cetuximab sensitive to resistant CRC patients  
1
st
 column: top 10 miRNA candidates; 2
nd
 column: calculated score based on developed 
scoring function; 3
rd
 column: total no of miRNA targets in the “Integrated map”; 4th column: 
Hugo gene ID of miRNA targets those  were differentially expressed in cetuximab sensitive 
compared with resistant CRC patients with significant p values; 5
th
 column: no of 
transcription factors (TFs) and kinases (KNSs) among the targets; 6
th
 column: expression 
value of the miRNA in cetuximab sensitive compared with resistant CRC patients (KRAS, 
BRAF wild type) published by Mosakhani et al (Mosakhani et al. 2012).  
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10.3.4. Validation of the prediction based on published 
experimental results 
The optimal method of validating any systems biology prediction is through experimental 
results. In our case, the analysis of differentially expressed miRNAs in cetuximab-resistant 
CRC tumor samples would provide such validation. Recently, a group at the University of 
Helsinki studied differential miRNA expression patterns of 33 cetuximab-treated patients 
with metastatic colorectal cancer (Mosakhani et al. 2012).  That group tested the association 
of each miRNA with the overall survival (OS) by applying a Cox proportional hazards 
regression model, and published a list of the 60 most differentially expressed miRNAs in 
patients with an extremely poor prognosis (resistant patients). According to our analysis, 85% 
(51 of 60 miRNAs) of the resistant patient-derived differentially expressed miRNAs are 
present in our list of the selected 188 miRNAs. Moreover, five of the ten top-ranked 
predicted miRNAs were found to be highly differentially expressed in resistant patients, 
exhibiting 4.6 to 9.7 fold changes (Table 13). More studies with greater no. of patients are 
needed to further validate our prediction; however, we consider this initial evidence to be 
very encouraging and to prove the applicability of our methodology. 
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11. Discussion 
FDA in its critical path initiative emphasized on applying biomarkers as an essential tool to 
combat current situation of late stage drug failures. Number of recent publications suggested 
that more efficient drug discovery model can be designed by applying biomarkers in all 
stages of drug discovery and development i.e. emphasizing biomarker usage from target 
identification to drug marketing (Colburn 2003; Bakhtiar n.d.).  However until now the usage 
of patient stratification biomarker in late stage clinical trials stands out among other 
biomarker applications to cope with the most alarming issue of expensive late stage failures. 
According to the simulation-based analysis performed by FDA and MIT consortium, early 
biomarker program is predicted to be an invaluable model for drug development (Trusheim et 
al. 2011). Corroborating this prediction, Parker et al have shown that the application of Her2 
in the development of anti-breast cancer treatment  reduced the clinical trial risk by 50% 
(Parker et al. 2012). On a global scale, it has been quantitatively demonstrated that 
probability of phase to phase transition is 15 to 19 percent higher for anti-cancer treatments if 
their trials include biomarker programs compared to those without (Hayashi et al. 2013).  All 
these findings indicate that early application of stratified molecular biomarker may 
significantly improve the success of clinical development. As representative picture of 
worldwide clinical trials with stratified biomarker, our analysis on ClinicalTrial.gov shows 
that 21% of the stratified trials are done in the later stages (phase III and IV, Figure 22) with 
significant efforts in post-marketing research. A more comprehensive picture of worldwide 
clinical trials can be drawn by inclusion of proprietary clinical trial registries such as 
Trialtrove and PharmaProjects into our analysis; however the proprietary laws do not allow 
us to publish these results. ClinicalTrials.gov itself has reported issues with the updates, 
consistency and completeness of the data particularly in those trial files collected before the 
database launch (Wadman 2006; Innocenzi et al. 1984). Surely a complete manual curation of 
all 150.000 trial registry files may enhance the accuracy of our analysis however such an 
effort is immensely time consuming involving multiple scientific annotators which is beyond 
the scope of this research. Hence our semi-automatic approach in identifying trials with 
stratified biomarker from the oldest and largest clinical trial registry and successive analysis 
is a representative study of worldwide trend in clinical trials. 
 
According to our analysis (Figure 21), oncology represents more than 75% of all the trials 
with stratified biomarker. So cancer being at the forefront of stratified medicine will dictate 
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the success rate of future clinical trials with stratified biomarker. The analysis also shows 
with 95% confidence interval that less than 5% of all interventional trials are using molecular 
biomarker for patient stratification. Some reasons for slow adoption of biomarker approaches 
in the clinics are summarized as follows: first of all stratification biomarker discovery 
requires an in depth understanding of disease mechanism and drug mode of action. 
Demonstration of clear relationship of biomarker changes and disease progression or 
treatment success requires substantial effort and resources spent early in pre-clinical research. 
In this direction, a number of system biology approaches based on quantitative modelling has 
been suggested to be of use for biomarker prediction reviewed by Kreeger at al (Kreeger & 
Lauffenburger 2009). However, labour-intensive collection of quantitative data as well as 
limitation of current computational power to model complex biological systems containing 
over hundred molecules hinders current use of quantitative modelling for biomarker 
prediction. Qualitative modelling approaches can provide an alternative for prospective 
biomarker prediction. Quite a few qualitative modelling are based on boolean networks and 
able to simulate the dynamics of signalling pathways. It has been employed for the discovery 
of novel oncological biomarkers as well as used to develop robust clinical treatment decisions  
(Sahoo 2012). An example of another type of modelling is integrative model (Figure 44) i.e. 
literature-derived knowledge and OMICS data together, reflecting ‘cause and effect’ 
relationships into an integrated biomarker discovery platform (Martin et al. 2012).  
 
Figure 44: Integrative model driven approach to identifying candidate 
biomarkers (Younesi et al, 2013). 
The figure proposed a model driven approach for the identification of biomarker by integrating omics data and textual 
knowledge.     
A variety of OMICS technologies have been developed in recent years with the aim to 
contribute detailed understanding of disease pathophysiology and drug mode of action. 
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However neither OMICS data nor the knowledge accumulated in the text can be 
automatically translated into clinical advances.  Knowledge capturing technologies combined 
with pathway analytics provide a great framework for OMICS data interpretation. The lack of 
standardized translational algorithms allowing the use of OMICS data along with the 
knowledge derived from the scientific literature hampers biomarker prediction. Hence any 
improvement is concurrent with improvement of knowledge representation standards to 
present dynamic interconnectivity of the molecular pathways aided by strong signal 
integration from experimental data.  
The clinical developmental success of stratified therapy in cancer can also be augmented by a 
fresh approach of selecting new class of biomolecules as candidate biomarker. miRNAs can 
potentially be one such new class of candidate. miRNA plays an important role in 
tumorgenesis by regulating expression of oncogenes and tumor suppressors thus affecting 
cell proliferation, differentiation, apoptosis, invasion and angiogenesis. miRNAs are potential 
biomarkers for diagnosis, prognosis and therapies of different forms of cancer. We have 
developed a novel translational algorithm i.e. SMARTmiR to identify crucial miRNA for the 
efficacy of a targeted therapy. As a use case we have also shown the clinical utility of 
SMARTmiR to identify and rank miRNAs which can predict the efficacy of cetuximab 
therapy in one of the most prevalent cancer in western world i.e. colorectal cancer.    
 
In colorectal cancer, the effects of cetuximab are mediated through various molecular 
pathways, including the Ras-Raf-MAPK, PI3K-AKT, protein kinase C, STAT and SRC 
pathways (Toni M Brand et al. 2011a; Maragkakis et al. 2009). The efficacy of cetuximab in 
responsive CRC patients is mainly manifested through reduction of cell proliferation and 
differentiation, inhibition of angiogenesis, prevention of epithelial to mesenchymal transition 
(metastasis) and induction of apoptosis (Toni M Brand et al. 2011b).  However, cetuximab 
resistance mechanisms by alternative molecular pathways was recently reviewed (Toni M 
Brand et al. 2011b) which demonstrated that the reactivation of pro-angiogenic factors 
(pMAPK, VEGF) leading to increased angiogenesis in CRC is one such resistant mechanism 
(Ciardiello et al. 2004). In agreement with those results, our top-ranked miRNA, i.e., miR-21, 
is a well-known angiogenesis regulator in both in vitro and in vivo models (Sabatel et al. 
2011). Moreover, cetuximab treatment affects the expression of miR-21 in vitro (du Rieu et 
al. 2010). Another group suggested that the cetuximab resistance mechanism is a 
phenomenon caused by an increased rate of EGFR degradation and internalisation; switching 
157 
 
towards alternate pathways for growth and survival of CRC resistant tumor cells (Lu et al. 
2007). In resistant cells, EGFR is localised in the sub-cellular compartments i.e., endosome, 
mitochondria and nucleus. The overexpression of nuclear EGFR is linked to SFKs (SRC-
family kinase) expression, modulating the up regulation of the PI3K/AKT pathway in 
cetuximab resistance (Wheeler et al. 2009). Mutations of KRAS are also connected to the 
increased activation of SFKs, affecting the MAPK, beta-catenin, STAT and PI3K/AKT 
pathways in CRC resistant tumors (Dunn et al. 2011). However, the mechanisms of 
cetuximab resistance in CRC remain poorly understood.  
To address the issue, we attempted to create a comprehensive CRC specific molecular 
network snapshot leading to the four cellular processes of apoptosis, proliferation and 
differentiation, metastasis and angiogenesis, which are crucial for mode of action of 
Cetuximab therapy in CRC. Pathways from Metacore were integrated. The Metacore 
pathway knowledge base was selected because of the high experimental validation of 
molecular interactions in its pathways (Shmelkov et al. 2011b). Of the assembled Integrated 
map, 96% are differentially expressed in published CRC specific RNASeq data (Anon 2012). 
Based on the well-accepted node removal algorithm (Bossi & Lehner 2009; Waldman et al. 
2010; Lopes et al. 2011), that high percentage makes the Integrated map CRC specific. 
miRNA-target interactions have been screened from prediction algorithms (miRanda, Pictar 
and DianaMicroT) and literature based knowledgebase (Tarbase, Pathway Studio). 
TargetScanS, Pictar and miRanda used individually, or in combination, provide a good 
balance between precision and recall (Witkos et al. 2011). However, Maragkakis et al. 
demonstrated that Pictar predictions overlap more than 75% of the predictions obtained from 
TargetsScanS (Maragkakis et al. 2009). Therefore, Pictar, miRanda and DianaMicroT were 
used. Next, a candidate miRNA was ranked based on its relationship to the four cellular 
processes and to CRC. The other ranking parameters were miRNA target’s relation to 
cetuximab; the node degree of the target; and the number of targets for each candidate 
miRNA. A high number of targets of miRNA in a pathway suggests the multi-level 
regulation of that pathway (Uhlmann et al. 2012; Malumbres 2012). miRNAs also 
preferentially regulate network hubs that participate in complex dynamic processes, and their 
expression profile is highly dynamic, thereby requiring tighter regulatory control (Cui, Yu, 
Pan, et al. 2007; Cui, Yu, Purisima, et al. 2007).  
Literature search confirmed that three of our top 10 miRNA in Table 13 i.e. miR-21 (1
st
), 
miR-34a (2
nd
), miR-17 (5th) are published biomarker for cetuximab therapy (du Rieu et al. 
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2010; Schou et al. 2014; Ragusa et al. 2012). Although no relation between miRNA to 
cetuximab was incorporated into the SMARTmiR scoring function. Our methodology has 
successfully predicted possible relationships between a miRNA and cetuximab. In the case of 
three top ranked miRNA i.e. miR-21, miR-34a and miR-17; the relationship has already been 
experimentally validated. This result again demonstrates the novelty and applicability of our 
methodology.   
Genome-wide miRNA and mRNA expression profiles of cetuximab-sensitive and cetuximab-
resistant mCRC patients and PLS regression/Pearson’s correlation of significant differentially 
expressed miRNAs and target mRNAs followed by pathway-centric interpretation could be 
another approach to discover the role of miRNAs in cetuximab resistance mechanisms in 
mCRC. However, due to a lack of such experimental data, the SMARTmiR algorithm utilised 
existing resources to predict crucial miRNAs as therapeutic biomarkers for cetuximab 
treatment in CRC patients.  
The accurate prediction of miRNAs that might serve as potential therapeutic biomarkers 
would be of great importance for patients. Herein, we developed a novel algorithm that 
facilitates the prediction of potential miRNA biomarkers based on the knowledge 
accumulated in the public domain. To our knowledge, there is only one published alternative 
methodology that uses literature-based evidence for drug-associated miRNA predictions. 
Recently, Rukov et al. launched PharmacomiR, a miRNA Pharmacogenomics database that 
uses the triplet sets consisting of a miRNA, a target gene and a drug associated with the gene 
to predict miRNAs that could serve as potential therapeutic biomarkers (Rukov et al. 2013). 
We compared the performance of PharmacomiR to that of our methodology in predicting the 
pharmacogenomics role of miRNAs in cetuximab treatment. PharmacomiR predicted 1102 
unique miRNAs (6975 redundant miRNAs as the initial output). Next, we calculated the 
overlap between the number of predicted miRNAs with the published differentially 
upregulated miRNAs by Mosakhani et al. (Mosakhani et al. 2012) in cetuximab-sensitive and 
cetuximab-resistant CRC patients.  Clearly, our methodology has higher prediction accuracy, 
with 27.1% (51 of 188) compared with 4.44% (49 of 1102) for PharmacomiR, in identifying 
experimentally validated potential miRNAs as therapeutic biomarkers for cetuximab therapy 
in CRC patients. Unlike PharmacomiR, SMARTmiR could also rank each candidate miRNA 
based on a novel disease specific score, making our methodology more advanced in 
prioritising candidate miRNAs for further experimental validation. A methodological 
comparison SMARTmiR and PharmacomiR has been provided in Table 14. 
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Methodology SMARTmiR Pharmaco-miR 
Relation to 
Disease 
Relation to Disease is achieved No relations to disease  
Relation to 
Drug 
Pathway centric relation to Drug Gene Centric relation to Drug 
miRNA 
Prioritization 
Pharmacogenomic role of a 
miRNA to a drug's action in a 
specific disease can be evaluated 
and ranked  
Pharmacogenomic role of a miRNA to 
a drug's action in a specific disease 
cannot be evaluated and ranked  
miRNA 
prediction 
Algorithms 
Pictar, miRanda, DianaMicroT Verse, TargetSCan, miRTarBase, 
miRecords, miRanda,Pita 
Table 14: Methodological comparison between SMARTmiR and Pharmaco-miR 
However, SMARTmiR algorithm has limitations. The inherent issue of pathway map 
building is that its completeness is limited to valid and available data. Therefore, the 
sensitivity and specificity of the translational methodology is a function of completeness of 
the presented interactome. Additionally, the developed pathway maps could not integrate the 
dynamic nature of miRNA regulations. Annotations and encoding of the transcripts of the 
genes in the pathway maps are absent. However, these are outstanding challenges in 
representing dynamic biological systems, and the scientific community must act to solve 
these issues.  
 
Biological data and knowledge is growing exponentially. Efficient management of those 
resources can be invaluable to measure the plausibility of a hypothesis as a prospective 
biomarker before designing the experiment to validate the hypothesis. In that direction, the 
thesis has demonstrated the power of efficiently managing existing data and knowledge in 
oncology to predict the therapeutic biomarker. Finally a prospective plan on future scenario 
of biomarker research during drug development has been drawn in the next section focusing 
to reduce the risk of most expensive phase III drug failures.  
Building a Disease Mechanism: A concrete understanding of the tissue specific targeted 
cancer mechanism is of prime importance. A knowledge map representing the disease 
mechanism has the conceptual benefit to cover the biomolecular space within a tissue where a 
drug treating the cancer has to work. Omics data sets on targeted cancer without any 
therapeutic intervention from GEO and data from ICGC/TCGA projects can be analysed, 
interpreted and further merged with existing knowledge on the targeted cancer from 
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biomedical literature to deliver a knowledge map representing the targeted cancer 
mechanisms.  
Building Drug Mode of Action (MoA): Next deciphering the drug mode of action holds 
the key to understand the consistency of the treatment outcome. The data from preclinical, 
phase I can be analysed, interpreted and represented through a knowledge map. The 
comparison of drug mode of action map with reference to the disease mechanism map can 
detect the potential pitfalls of a drug. If the targeted drug is a small molecule then analysis of 
cancer cell line profiling data (http://www.broadinstitute.org/ctrp/) from Broad Institute can 
potentially provide vital clues on the drug mode of action and molecules that can potentially 
detect therapeutic efficacy. Currently targeted cancer drug falls into one of ten categories that 
have been described in Figure 4 of the thesis. If the drug being investigated falls in one of 
those ten groups then biomedical literature and ongoing clinical trials on same category of 
drugs can provide crucial knowledge on trial designing and applied biomarker.         
Selection of biomarker: Conventional gene centric biomarker is unlikely to ascertain the 
therapeutic efficacy of a treatment as complex as cancer. Cancer is a system disorder 
disrupting the hallmarks of healthy cells (see Figure 3) i.e. severely damaging the normal 
expression of multiple molecular pathways. Hence transcriptomics profiles of a panel of 
biomarkers instead of a single one holds the promise for better stratification benefitting from 
targeted therapy. Especially, a panel of microRNAs which can regulate the expression of 
several genes and are essential for the drug’s mode of action, can be a more potent cancer 
therapeutic biomarker.  
Streamline the biomarker panel: The analysis followed by interpretation of preclinical, 
phase I data along with the literature mining (described in previous steps) can potentially 
generate novel hypothesis on a panel of therapeutic biomarkers. The panel of biomarkers 
from these analyses can be further tested in phase II trials. Supervised modeling can be 
applied first to train and then to test the stratification power of the panel of biomarkers in 
phase II trials. A knowledge based score similar to that produced by SMARTmiR algorithm 
for each of biomarker can be calculated and then applied in the supervised model along with 
expression profiles of the biomarker. This will ensure that statistically significance of 
expression along with parameters important for the drug MoA i.e. biological point views 
have been incorporated in building the model. Ideally this should improve the stratification 
power of the model compared to a model which is only built on the expression signature of 
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the biomarker. If the panel of biomarker shows considerable promise to stratify the patient 
population to predict the therapeutic efficacy of the drug, this panel of biomarker can be 
applied in designing the phase III trials.  
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12. Conclusion 
Our meta-analysis of stratified molecular biomarker trials registered in ClinicalTrials.gov 
database clearly shows that the molecular biomarker trend is rapidly being adopted in clinical 
research with oncology being at the forefront of the personalized medicine. However 
percentage of the trials including patients’ stratification based on molecular differentiation is 
still very low (less than 5%) reflecting all the challenges of biomarker discovery and 
development. A variety of OMICS technologies have been developed in recent years with the 
aim to identify biomarker by detailed understanding of disease pathophysiology and drug 
mode of action. However neither OMICS data nor the knowledge accumulated in the 
scientific literature can be automatically translated into clinical advances for biomarker 
discovery. The lack of standardized translational algorithms allowing the use of OMICS data 
along with the knowledge derived from the scientific literature hampers endeavours to predict 
biomarkers with greater confidence. Thus, any improvement of the current situation depends 
on the improvements in knowledge representation standards enabling to present 
interconnectivity of the molecular pathways supported by integration of strong signal from 
experimental data and enriched granular knowledge. The overall trend indicates that there is a 
drive away from correlative biomarkers towards causative biomarkers. Therefore, the aim of 
next-generation integrative models is to capture causal relationships between the candidate 
biomarker and clinical outcome.  
A new class of stratified biomarker i.e. miRNA is also rapidly emerging in cancer treatment 
with the promise of stratifying the patient population with greater confidence and ease of 
detection. But lack of translational algorithm which can integrate OMICS data and 
knowledge to predict the causal relationship between candidate miRNA and clinical outcome 
of a treatment in a disease condition potentially hamper the discovery of miRNA as stratified 
biomarker. In this direction a novel integrative algorithm i.e. SMARTmiR has been invented 
by combining granular knowledge and available OMICS data. The algorithm is a pathway-
centric methodology that facilitates the prediction of pharmacogenomics role of miRNA. The 
method is generic and can be applied to model the role of miRNA as a therapeutic biomarker 
for targeted therapy in any diseases. We are optimistic that the application of an optimised 
and fully automated version of the algorithm has the potential to be used as clinical decision 
support tool. Moreover this research will also provide a comprehensive and valuable 
knowledge map demonstrating functional bimolecular interactions in colorectal cancer to 
scientific community for future experimental studies in CRC. We have also detected seven 
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miRNA i.e. hsa-miR-145, has-miR-27a, has-miR-155, hsa-miR-182, hsa-miR-15a, hsa-miR-
96 and hsa-miR-106a as top stratified biomarker candidate for cetuximab therapy in CRC 
which were not reported previously. Hence this research had drawn the attention of scientific 
community to investigate the pharmacogenomics role of those seven top ranked miRNA 
when treating CRC patients with cetuximab. In addition the research has identified 188 
miRNA in total thus demonstrating an overall miRNA regulatory mechanism in CRC.  
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